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Abstract 
 
As one of the leading threats to human health, type 2 diabetes (T2D) will continue 
to escalate with 300 million cases worldwide predicted by 2025 [1, 2]. The early 
pathogenesis of metabolic diseases like T2D is associated with skeletal muscle 
insulin resistance [3].   The diminished response to insulin in this tissue, which is 
responsible for the majority of postprandial glucose uptake, contributes to high 
blood glucose levels in T2D patients [3].  Coordinated downregulation of a set of 
metabolic and mitochondrial genes that mediates muscle mitochondrial and 
oxidative dysfunction is associated with the development of muscle insulin 
resistance [4, 5].  Exercise induces phenotypic adaptations in skeletal muscle to 
correct the faulty gene expression, and enhance mitochondrial function and muscle 
metabolism, which could ameliorate muscle insulin resistance [6]. This, in part, is 
mediated by inactivating a class of chromatin remodelling enzymes called as histone 
deacetylases (HDACs), in particular class IIa HDACs, in skeletal muscle during 
exercise. HDACs act as transcriptional repressors by deacetylating histone proteins 
bound to DNA within chromatin and thereby condensing chromatin structure [7]. 
Considering class IIa HDACs as potential targets involved in exercise induced 
signalling and adaptations in skeletal muscle, we propose that pharmacological 
inhibition of class IIa HDACs by HDAC inhibitors (HDIs) could be a promising strategy 
to enhance skeletal muscle metabolic gene expression, mitochondrial function and 
muscle metabolism and thus, could represent a novel therapeutic intervention to 
ameliorate skeletal muscle insulin resistance in metabolic diseases such as obesity 
and T2D. 
   xvii 
In vitro screening of the broad spectrum HDIs - Scriptaid (SCR) and Trichostatin-A 
(TSA) was performed to examine their ability to regulate muscle metabolic 
parameters. Initial analyses showed that both HDIs increased global histone H3 
acetylation in L6 myotubes, a proxy measure of HDI activity. SCR increased the 
expression of various metabolic and mitochondrial genes involved in oxidative 
metabolism over 24 hours in myotubes. Consistent with this, the bioenergetic and 
mitochondrial function analyses in L6 myotubes showed that SCR enhanced basal 
respiration. This was associated with increased ATP turnover, without any 
contributing effect from uncoupled respiration. SCR also increased the maximal 
respiratory capacity of mitochondria. However, despite inducing histone 
acetylation, TSA differentially regulated metabolic and mitochondrial gene 
expression. It did not improve basal respiration and other indices of mitochondrial 
function. Rather it reduced maximal respiratory capacity of mitochondria. Based on 
the ability of SCR to increase muscle metabolic gene expression, mitochondrial 
function and energy expenditure in vitro, it was selected for in vivo efficacy studies 
to examine whether broad spectrum HDI is an effective exercise mimetic that 
enhnaces various skeletal muscle and whole body metabolic parameters. These 
experiments were also conducted in diet-induced obese mice to assess its 
therapeutic potential to treat insulin resistance in metabolic diseases. 
 
In vivo, SCR increased global histone H3 acetylation in both EDL and soleus skeletal 
muscles compared with other tissues. This was associated with increased metabolic 
and mitochondrial gene expression in skeletal muscle. SCR increased the expression 
of genes involved in oxidative phophorylation (OXPHOS genes) in response to high  
   xviii 
fat diet (HFD) feeding. Total skeletal muscle lipid levels were reduced by SCR in vivo. 
SCR normalised muscle GLUT-4 gene expression in vivo and insulin-stimulated 
muscle glucose uptake ex vivo in response to high fat feeding. These results suggest 
that the broad spectrum HDI SCR enhanced oxidative capacity and glucose 
metabolism of skeletal muscle. Furthermore, SCR increased the time to fatigue 
during incremental exercise performance during a forced treadmill test. SCR also 
enhanced energy expenditure, oxygen consumption rate, glucose and lipid 
oxidation and reduced the respiratory quotient, indicative of a relative shift towards 
lipid metabolism. These data suggest that SCR augmented endurance and whole 
body energy expenditure. However, SCR had no effect on body weight, body 
composition, food intake and energy intake in vivo. Furthermore SCR had no effect 
on glucose tolerance and impaired insulin tolerance in vivo. Direct assessment of 
the effect of SCR on hepatic glucose production (HGP) under basal and insulin 
stimulated conditions in cultured hepatocytes showed that SCR impaired the ability 
of insulin to suppress hepatic glucose production in vitro. Collectively, these results 
indicate that the broad spectrum HDI SCR improved muscle metabolic parameters, 
exercise performance and whole body energy expenditure, but impaired whole 
body insulin action. 
 
In an attempt to minimize off target effects associated with broad spectrum HDIs, 
we further determined whether novel class IIa HDIs analogues- MRU 062 (published 
as MC1568), MRU 047, MRU 059 and MRU 066, produced by modulating the 
canonical cap-linker-chelator HDI structure, could regulate skeletal muscle 
metabolic parameters in vitro.  All the four novel class IIa HDIs analogues regulated  
   xix 
global histone H3 acetylation in L6 myotubes. MRU 047, MRU 059 and MRU 066 
had differential impacts on metabolic and mitochondrial gene expression in L6 
myotubes. MRU 047 and MRU 059 increased the maximal respiratory capacity of 
mitochondria, whereas MRU 066 had no effect on mitochondrial function in 
myotubes. MRU 062 downregulated the expression of various metabolic and 
mitochondrial genes in myotubes. In contrast, it induced the maximum 
improvement in basal respiration associated with increased ATP turnover without 
any effect from uncoupled respiration and also increased maximal respiratory 
capacity of mitochondria. IC50 determination against different HDAC isoforms for 
all the four novel class IIa HDIs analogues including MRU 062, which is a published 
class IIa selective HDI, showed that they were not selective against class IIa HDACs. 
 
Collectively, these data suggest that HDAC inhibition (HDACi) could be an effective 
strategy to regulate muscle metabolism. The broad spectrum HDI SCR could be a 
potential therapeutic to improve skeletal muscle metabolic gene expression, 
mitochondrial function, energy expenditure and oxidative metabolism to treat 
skeletal muscle insulin resistance in metabolic diseases such as obesity and T2D. 
Further research will involve designing and synthesising new compounds with class 
IIa specific HDAC inhibitory activity to determine whether compound specificity will 
minimise non-muscle effects on metabolism and is therefore a more effective 
therapeutic strategy for metabolic diseases. 
 1 
 
CHAPTER ONE 
Review of the literature 
 
 
1.1 Introduction 
 
Type 2 diabetes (T2D) is one of the leading threats to human health in the 21st 
century [1]. The global prevalence of diabetes in 1995 was about 135 million, and is 
predicted to rise to 300 million by 2025 [2]. This epidemic is associated with a range 
of pathophysiological complications and premature morbidity and mortality, 
thereby imposing an enormous burden on health systems globally [8]. Genetic 
susceptibility in conjunction with environmental and behavioural factors such as a 
sedentary lifestyle, age and obesity contribute to the development of this disease 
[1]. T2D is defined as a complex, heterogeneous and polygenic disease 
characterized by ŝŶĂĚĞƋƵĂƚĞ ɴ-cell insulin secretion, excessive hepatic glucose 
production (HGP) and insulin resistance, defined as an inability of metabolic tissues 
(such as fat, muscle and liver) to respond normally to insulin hormone [9, 10].  
Under the normal glucose homeostasis when blood glucose level increases (termed 
as hyperglycemia), insulin is secreted by the pancreatic ɴ-cells to promote glucose 
uptake and its utilization by the peripheral tissues such as muscle and fat and to 
suppress endogenous glucose production by the liver (HGP).  This eventually results 
in lowering blood glucose levels. The pathophysiology of T2D is believed to begin 
with insulin resistance in peripheral tissues, which results in reduced glucose uptake 
and utilization by the muscle and the fat tissues and increased glucose production 
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by the liver. The resulting hyperglycemia stimulates the pancreatic ɴ-cells 
consistently to secreate more insulin (hyperinsulinemia) that gradually can no 
longer compensate for the insulin resistant state and ends with a loss of insulin 
secretion due to the pancreatic ɴ-cells failure. This results in the development of 
overt T2D, which is characterized by glucose intolerance and hyperglycemia [10-12] 
(Fig. 1.1). In particular, skeletal muscle insulin resistance represents a major risk 
factor in the pathogenesis of T2D [3]. Impaired use of carbohydrate and lipid fuels 
for energy production by muscle results in the accumulation of these substrates in 
skeletal muscle, which interferes with insulin action [13].  
 
Insulin resistance in skeletal muscle is associated with decreased metabolic and 
mitochondrial gene expression that contributes to mitochondrial dysfunction, 
reduced muscle oxidative capacity and whole body aerobic capacity [4, 5]. Regular 
physical exercise and diet are considered the cornerstone in the improvement of 
insulin sensitivity and treatment of T2D by increasing energy expenditure and 
aerobic capacity in diabetic patients [14]. In this regard, exercise, to some extent, 
induces phenotypic adaptations in skeletal muscle in part by increasing the 
expression of a program of metabolic and mitochondrial genes [6, 15, 16]. This is 
associated with enhanced skeletal muscle mitochondrial function in both normal 
and diabetic individuals [6]. This could contribute to improved substrate turnover 
and skeletal muscle metabolism to make the muscle more responsive to circulating 
insulin [17].  
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Figure 1.1. Pathophysiology of type 2 diabetes. Peripheral insulin resistance in 
muscle, adipose tissue and liver, coupled with inadequate insulin secretion due to 
ƉĂŶĐƌĞĂƚŝĐ ɴ-cell dysfunction contribute to the development of T2D (Reproduced 
from [10]). 
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There is a growing appreciation that epigenetic factors can alter gene expression or 
cellular phenotype through the modulation of chromatin architecture without 
affecting the primary nucleotide sequence [18]. It is thought that many of the 
exercise-induced alterations in skeletal muscle metabolic gene expression involve 
one such class of epigenetic regulators, known as the class IIa histone deacetylases 
(HDACs) [19]. Histone deacetylases are chromatin remodelling enzymes that 
deacetylate the core histones and bring them close to the DNA molecule, resulting 
in a condensed chromatin structure which is transcriptionally silent [19]. It has been 
proposed that exercise results in the inhibition of these transcriptional repressors 
and increases histone acetylation by inducing chromatin remodelling. This is 
mediated by histone acetyltransferases (HATs) that act antagonistically to HDACs, 
relax the chromatin structure and increase the transcriptional activity of MEF2 
transcription factors, which are otherwise suppressed by HDACs  [19]. This results in 
increased expression of various genes essential for substrate transport, oxidation 
and mitochondrial function in skeletal muscle [20] (Fig. 1.2).  
 
Exercise coupled with diet has always been the primary nonpharmacological 
therapy recommended for the reversal of insulin resistance and T2D treatment [14]. 
However, poor adherence to a regular exercise regime has become one of the 
majors concerns in this industrialized world. Furthermore, many patients are not 
able to physically engage in exercise regimes. This highlights the need to develop 
pharmacological compounds that could mimic aspects of the beneficial effects of 
exercise [21].  
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Figure 1.2. Flowchart depicting exercise-induced skeletal muscle metabolic and 
mitochondrial gene expression. 
 
 
Inhibition of class IIa HDACs seems to be one underlying mechanism regulating 
exercise adaptations in skeletal muscle, and they appear to be an attractive target 
to prevent or reverse skeletal muscle insulin resistance in obesity and type 2 
diabetes. Therefore, pharmacological inhibition of class IIa HDAC repressive activity 
by chemical modulators might mimic the aspects of the adaptive response of 
skeletal muscle to exercise. We propose that class IIa HDAC inhibition (class IIa 
HDACi) could be an effective exercise mimetic with potential to treat skeletal 
muscle insulin resistance in metabolic diseases such as obesity and T2D. 
 
Exercise 
Inhibition of class IIa HDACs 
Increased MEF2 transcriptional activity 
Enhanced skeletal muscle metabolic & mitochondrial gene expression 
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1.2 Skeletal muscle insulin resistance and Type 2 diabetes 
 
Skeletal muscle insulin resistance plays a major role in the early pathogenesis of 
metabolic diseases including Type 2 diabetes [22]. This tissue is a key determinant 
of systemic insulin sensitivity, as under insulin-stimulated conditions, approximately 
80% of glucose uptake occurs in skeletal muscle [3]. Therefore, defective skeletal 
muscle response to insulin reduces glucose uptake and impairs whole-body glucose 
metabolism. This culminates in high blood glucose levels (hyperglycemia), the 
defining characteristic of T2D [23]. Moreover, it is also an important site for 
contraction-mediated glucose uptake [24]. In addition, skeletal muscle has large 
mass and high capacity to metabolise energy-bearing substrates like glucose and 
lipids (oxidative capacity). Therefore, skeletal muscle is very important in metabolic 
homeostasis and whole body glucose metabolism [25]. 
 
1.2.1  Skeletal muscle oxidative dysfunction and muscle insulin 
resistance 
 
Several defects have been identified as potential mediators of skeletal muscle 
insulin resistance [26, 27]. However, defects in skeletal muscle oxidative capacity 
may be one component of a multifactorial process associated with the development 
of insulin resistance in this tissue. There is accumulating evidence that impaired 
muscle metabolism contributes to accumulation of energy stores, which play a 
central role in the etiology of muscle insulin resistance in T2D. The mechanisms 
associated with such substrate accumulation are not well understood [25, 28]. It has 
been suggested that the capacity of muscle to metabolize glucose and fatty acids 
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and oxidation of these substrates is impaired in insulin-resistant muscle [29]. T2D 
and obese patients have reduced rates of muscle fat oxidation during 
postabsorptive conditions [30, 31]. Increased plasma free fatty acid levels (FFA) due 
to disturbed lipolysis by insulin resistant adipose tissue is also observed in obese, 
T2D patients [3] and their first-degree relatives [32].  
 
Other risk factors such as overnutrition along with physical inactivity also contribute 
to the increased flux of energy fuel substrates (such as fatty acids) in the body [33]. 
Hence, the increased flux of FFA together with impaired clearance may result in the 
net accumulation of fatty acids as triglycerides (TAGs), diacylglycerides (DAGs) and 
ceramides  in non-adipose tissues including muscle [34]. A number of animal and 
human studies have suggested that lipid accumulation (lipotoxicity) in muscle, i.e. 
intramyocellular lipid (IMCL), act as potential mediators of muscle insulin resistance 
in obese subjects and individuals at high risk of developing T2D [35-39]. 
Intramyocellular lipid metabolites such as fatty acyl-CoA, diacylglycerides (DAGs) 
and ceramides  may antagonize insulin signaling and further worsen both insulin-
mediated glucose uptake in skeletal muscle and glucose-stimulated insulin secretion 
in pancreatic ɴ-cells [40-42]. 
 
However, a positive association between skeletal muscle oxidative enzyme activity 
and insulin sensitivity compared amongst exercise trained, obese and insulin 
resistant subjects, suggests that muscle oxidative capacity as a better predictor of 
insulin sensitivity than muscle lipid status [43]. Furthermore, deterioration in 
muscle mass with increasing age is also associated with a decline in skeletal muscle 
 8 
 
metabolic oxidative capacity and increased incidence of T2D in the elderly, further 
supporting the role of muscle metabolism in T2D susceptibility [14]. Hence, 
understanding the causative factors of impaired skeletal muscle oxidative capacity 
may offer insight into potential therapies for muscle insulin resistance. 
 
1.2.2  Defective metabolic gene expression and mitochondrial function 
in muscle insulin resistance  
 
The molecular mechanisms responsible for skeletal muscle insulin resistance in T2D 
remain poorly understood. Recently, oxidative stress has been identified as a 
common mediator of a diverse set of insults causing peripheral insulin resistance in 
obesity and T2D [44, 45]. In addition, there is growing evidence that high fuel 
substrate availability such as excess fatty acids and glucose can induce oxidative 
stress in skeletal muscle [46, 47]. Oxidative stress due to the overproduction of 
reactive oxygen species (ROS) by the mitochondria interferes with insulin action and 
has been implicated in skeletal muscle insulin resistance [44, 48]. In support of this, 
mitochondrial ROS production is more pronounced in T2D despite the similar basal 
O2 consumption compared with healthy subjects [47]. Excess ROS causes oxidative 
damage to mitochondria, the major site of substrate metabolism in skeletal muscle, 
and results in mitochondrial dysfunction and reduced muscle oxidative capacity in 
obese, T2D patients and their first degree relatives [49-51].  
 
Similar ROS-mediated oxidative damage to mitochondria is also observed with 
increasing age [52]. This is consistent with reduced mitochondrial oxidative 
phosphorylation activity in the elderly and the age-associated decline in muscle 
 9 
 
metabolism which contributes to the high prevalence of skeletal muscle insulin 
resistance and T2D in the elderly [52, 53]. Additionally, studies have found that 
reduced maximal ADP-stimulated respiration by skeletal muscle mitochondria is 
reduced in obese and type 2 diabetic patients [47, 54]. This suggests that impaired 
mitochondrial respiration is associated with the skeletal muscle insulin resistance 
that contributes to the development of T2D [47, 54].   
 
This defect in the functional capacity of skeletal muscle mitochondria is also 
accompanied by changes in skeletal myofibre composition, with an increased 
proportion of glycolytic type IIb fibres in T2D patients [54]. Mitochondrial 
dysfunction in skeletal muscle subsequently results in impaired substrate utilization 
which further exacerbates muscle insulin resistance in T2D [55]. Indeed, insulin 
sensitivity directly correlates muscle oxidative capacity [56] and skeletal muscle 
insulin resistance is associated with impaired mitochondrial oxidative 
phosphorylation [57, 58]. This is supported by several morphological and 
biochemical changes in muscle mitochondria from T2D patients, characteristic of 
impaired mitochondrial function. Electron transport chain capacity [59], oxidative 
enzyme capacity such as citrate synthase activity [60] and dWƐǇŶƚŚĂƐĞɴ-subunit 
content [61] are all reduced in mitochondria from T2D skeletal muscle. This is 
further linked with diminished mitochondrial size [62] and density [63], which could 
be responsible for mitochondrial dysfunction in such insulin resistant subjects.  
 
Various independent DNA microarray studies linked metabolic disturbances in 
skeletal muscle with the coordinated downregulation of nuclear and mitochondrial-
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encoded genes of oxidative metabolism in both insulin resistant (prediabetic) and 
T2D muscle [4, 5]. The expression of peroxisome proliferator activated receptor 
;WWZͿ ŐĂŵŵĂ ĐŽĂĐƚŝǀĂƚŽƌ ϭɲ ;W'-ϭɲ), a transcriptional coactivator and master 
switch of the cluster of genes involved in oxidative phophorylation (referred to as 
OXPHOS genes) and mitochondrial function, was significantly reduced in both non-
diabetic family history positive and T2D subjects [4, 5]. Other studies have also 
shown reduced levels of the genes involved in various metabolic functions such as 
insulin signalling, substrate transport and metabolism, transcription factors, 
intramitochondrial free-radical scavengers and  muscle and mitochondrial 
maintenance in T2D patients [64-66].  
 
Collectively, these findings suggest that defective expression of metabolic and 
mitochondrial genes is an underlying abnormality contributing to impaired muscle 
substrate oxidation in insulin resistance and T2D. Therefore, normalizing metabolic 
gene expression profiles in patients with metabolic diseases and aging individuals 
could be beneficial for improving skeletal muscle insulin sensitivity and treating 
T2D.  
 
1.3  Exercise as a treatment for skeletal muscle insulin resistance 
 
Regular physical exercise, usually endurance training along with other lifestyle 
interventions such as diet, is the most effective therapeutic and preventive strategy 
against muscle insulin resistance and T2D [67]. Optimal exercise programs enhance 
maximum oxygen consumption (VO2max), which is proportional to improvements in 
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skeletal muscle insulin sensitivity and glycaemic control [14]. This is associated with 
enhanced ATP production by increasing carbohydrate and fatty-acid oxidation in 
muscle. Exercise training improves muscle oxidative capacity and whole body 
energy homeostasis [68]. Exercise also improves insulin-independent glucose 
transport in insulin-resistant skeletal muscle [6, 69]. A single bout of prolonged 
aerobic exercise induces translocation of the GLUT-4 glucose transporter, a specific 
component of the glucose transport system responsible, in part, for insulin-
mediated glucose uptake in skeletal muscle, heart, and adipose tissue [69]. In the 
context of enhanced insulin action, exercise acts as a physiological stimulus that 
induces phenotypic adaptations in skeletal muscle to counteract the adverse effects 
of diabetes on muscle metabolism [70]. 
 
At the cellular level, endurance exercise training can not only prevent but reverse 
the diabetic phenotype in part by enhancing mitochondrial density, function and 
the metabolic enzyme profile involved in substrate transport and oxidation in lean, 
aged, obese or T2D skeletal muscle [71, 72]. This is in part attributed to the 
coordinated increase in metabolic and mitochondrial gene expression that favours 
energy expenditure [73, 74]. Additionally, exercise improves whole body glucose 
tolerance by improving insulin-stimulated glucose transport. This is mediated not 
only by inducing the expression of genes involved in glucose transport such as 
GLUT-4 [75, 76], but also through modulating the insulin signalling pathway activity 
by increasing the expression and function of proteins involved in this signal 
transduction in skeletal muscle [77]. Therefore, the cumulative effects of exercise 
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are enhanced substrate oxidative capacity and metabolism of skeletal muscle, 
which ameliorates insulin resistance [78].  
 
Despite that, none of the studies mentioned above clearly defined the molecular 
mechanisms underlying the relationship between skeletal muscle adaptations and 
metabolic gene regulation during exercise. Consequently, further investigations are 
needed to elucidate the specific molecular mechanisms underlying exercise-induced 
gene expression in insulin-resistant mammalian skeletal muscle. 
 
1.4  Molecular mechanisms regulating gene expression 
 
In recent years, chromatin remodelling has emerged as a significant regulator of 
eukaryotic gene expression and metabolic diseases such as T2D [18, 79]. In 
chromatin, ~146 bp of DNA is wrapped around an octamer core of four histones i.e. 
two copies each of H2A, H2B, H3 and H4 via electrostatic interactions to form a 
nucleosome, which is further repeated and folded to assemble higher-order 
chromatin fibres [80] [Fig. 1.3 (A)]. The transcriptional status of the surrounding 
genes is largely influenced by the spatial organization of DNA and histones in 
chromatin. This assembly is transcriptionally silent in resting cells by restricting the 
accessibility and function of the multitudinous factors that act in concert to produce 
appropriate levels of transcription [81].  
 
Hence, over the past two decades, researchers have come to appreciate that the 
activation of many genes requires chromatin disruption and modification [79]. This 
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is controlled, in part, through “post-translational modifications” to histone tails, 
specifically histones 3 and 4 [82]. An immense literature documents the plethora of 
“post-translational modifications” or “epigenetic marks” including acetylation, 
phosphorylation and methylation of amino acid residues, forming the “histone 
code” within the N-terminal basic tail domain of core histones [Fig. 1.3 (B)]. These 
modifications may act alone, sequentially or in conjunction to promote or impede 
gene expression, which is determined by the type of mark and the residue on which 
it occurs. 
 
Additionally, they alter the affinity of histones for DNA and recruit nonhistone 
proteins with enzymatic activities to chromatin for remodelling and modulation of 
DNA based transcription [82, 83]. Amongst all of them, reversible histone 
acetylation has been the most studied and understood. This is finely tuned by the 
competitive activities of histone acetyltransferases (HATs) and histone deacetylases 
(HDACs), a class of epigenetic regulators that control diverse cellular processes [84, 
85] [Fig. 1.3 (B)]. These enzymes combine with other cofactors for various activities 
such as binding to DNA, for the recruitment to their substrates, for chromatin 
remodelling or for corepression and hence appear as high molecular weight 
activator or repressor complexes [86]. 
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Figure 1.3.  (A) Structure of nucleosome core. DNA (red) wrapped around the four 
core histone proteins (blue): H2A (histone 2A), H2B (histone 2B), H3 (histone 3), and 
H4 (histone 4), each present in two copies. (B) Post-translational modifications of 
the amino-terminal tails of core histones: A = acetyl; C = carboxyl terminus; E = 
glutamic acid; K = lysine; M = methyl; N = aminoterminus; P = phosphate; S = serine. 
Lysines (K) in the amino terminal tails of histones are acetylated and deacetylated 
by histone acetyltransferases (HATs) and histone deacetylases (HDACs) respectively. 
Acetylation neutralizes the charge on lysines (Reproduced from [87]).  
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1.4.1  Histone Deacetylases and transcriptional repression 
 
HATs acetylate the core histone proteins by transferring the acetyl moiety from 
acetyl-coenzyme A to the positively charged ɸĂŵŝŶŽŐƌŽƵƉ of a specific lysine (K) 
residue located at the histone N-terminus through amide linkage [Fig. 1.3 (B)]. This 
dynamic process neutralizes the positive charge present on histone tails and 
disrupts their interaction with the negatively charged DNA. This relaxes the 
chromatin and allows the transcriptional initiation complex (TIC) to bind to the 
exposed gene promoter regions which activates transcription (Fig. 1.4). Conversely, 
HDACs deacetylate histone lysine residue side chains via amide hydrolysis, restoring 
their positive charge, which encourages their high-affinity binding with DNA and 
condenses chromatin. This diminishes the accessibility of the TIC to gene promoter 
regions and renders them transcriptionally inactive. Apart from nucleosomal core 
histones, various non-histone proteins such as transcription factors (TFs), 
transcriptional regulators, cytoskeletal proteins, molecular chaperones, signal 
transduction mediators, DNA repair enzymes, nuclear import regulators, structural 
proteins, inflammation mediators and viral proteins also act as HDAC substrates and 
are functionally modulated by HAT and HDAC activities. Acetylation status can 
affect the DNA binding affinity, transcriptional activation, coregulator interaction, 
half-life, and subcellular localization of TFs, and affect protein-protein interactions, 
subcellular localization and protein stability. For instance, deacetylated lysine 
residues are prone to ubiquitination and result in protein degradation. Hence, 
HDACs are transcriptional corepressors that repress gene expression through lysine 
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deacetylation and seem to play an equally important role as HATs in regulating gene 
expression [86, 88, 89]. 
 
 
 
Figure 1.4. Proposed mechanism of action of histone acetylases (HAT) and histone 
deacetylases (HDAC). HAT adds acetyl groups (Ac=acetyl) to the histone tails and 
relaxes the chromatin followed by transcriptional activation. HDAC removes those 
acetyl groups to condense chromatin and repress transcription (Reproduced from 
[7, 87]). 
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1.4.2  Classification of Histone Deactetylases 
 
Eleven distinct human HDACs with a highly conserved deacetylase domain are 
known as the classical HDACs. They are zinc (Zn2+) dependent metallo-enzymes. 
Based on differences in structure, enzymatic function, subcellular localization and 
expression patterns, the members of the HDAC family are categorized into four 
classes: I, IIa, IIb and IV. The class I HDACs consists of HDAC1, 2, 3 and 8. They are 
ubiquitously expressed and localized mainly in the nucleus since they lack a nuclear 
export signal (NES), with an exception of HDAC3 that contains both a nuclear import 
signal (NIS) and NES and hence can also move to the cytoplasm. The class IIa HDACs 
include HDAC 4, 5, 7 and 9. HDAC6 and HDAC10 belong to the class IIb HDAC family. 
The class IV HDAC family contains HDAC11 [90].  
 
1.5  Class IIa Histone Deacetylases 
 
The class IIa HDACs 4, 5 and 7 share highly conserved sequences and form a 
subgroup in the phylogenetic tree that is different from a subgroup formed by splice 
variants of HDAC 9 [91]. Class IIa HDACs exhibit tissue specific patterns of 
expression in humans and mice, indicative of their implication in cellular 
differentiation and development [92]. In response to cellular signals, they can 
shuttle between the nucleus and cytoplasm [91] and are highly expressed in muscle 
cells, neurons and T-cells [93]. Class IIa HDACs are expressed in human skeletal 
muscle, with HDACs 4 and 5 being most abundant (SL McGee and M Hargreaves, 
unpubl. obs., 2007) and play an important role in regulating skeletal muscle 
oxidative metabolism by exerting their repressive influence on MEF2 TFs, which are 
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also predominantly expressed in the same tissue [94]. HDAC 4 and 5 also form 
oligomers, which enhances their repressive influence and responsiveness to various 
signals [95]. Class IIa HDAC members exhibit substantial functional redundancy, 
although they also appear to have isoform specific functions [96, 97]. 
 
1.5.1  Structure of class IIa Histone Deacetylases 
 
Class IIa HDACs have a bipartite structure incorporating two distinct domains: a 
large N- terminal repression domain and a C- terminal deacetylase domain, unlike 
other classical HDACs that have small N- and C-terminal extensions [90] (Fig 1..5). 
The N-terminal adapter domain (~450–600 amino acids) mediates  protein–protein 
interactions with the various factors such as transcriptional corepressor C-terminal-
binding protein (CtBP)  (via a P-X-D-L-R motif), MEF2 TFs, calmodulin (CaM) and 
proteins of the 14-3-3 family [98]. By far the best characterized interaction is with 
the MEF2 TFs, one of the major substrates of the class IIa HDACs, which are 
required for myogenesis of skeletal, cardiac and smooth muscle cells and muscle 
differentiation [99]. These HDACs do not interfere with the DNA binding ability of 
MEF2 since they bind to the carboxy-terminal subregion of MADS/MEF2 domains of 
all MEF2 family members, which are different from the amino-terminal residues 
required for DNA binding in the MADS domain of MEF2 [100]. The CaM binding 
region in the class IIa HDACs  shows overlap with the MEF2 binding region, and CaM 
competes with MEF2 for association with class IIa HDACs [94]. The N-terminal 
region of class II HDACs also harbours a nuclear localization signal (NLS or NIS) [94, 
98]. 
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Figure 1.5. Structure of class IIa HDACs  (Reproduced from [101]) 
All Zn2+ dependent class IIa HDACs have a highly conserved C-terminal domain (~420 
amino acids) that exhibits HDAC catalytic activity in vivo, with the exception of 
HDAC9 (9a & 9b), which has catalytic domain located on the N-terminus like class I 
HDACs  [91, 98]. This catalytic domain contains a structurally conserved deacetylase 
core (the active site), which has zinc-dependent catalytic machinery. The active site 
has three conserved regions. First, a channel opening with a rim that has great 
amino acid sequence diversity. Second, a hydrophobic tunnel for acetyl-lysine 
substrate penetration. Third, a gently curved tubular pocket with a wider bottom 
that makes up the catalytic centre (or internal cavity) [102, 103]. It has a central Zn2+ 
ion at the base of the pocket that facilitates amide hydrolysis in the removal of 
acetyl groups. The Zn2+ ion is surrounded by a tyrosine residue, which is responsible 
for the catalytic proficiency in all HDACs [88, 102, 104, 105]. 
 
However, this tyrosine (Y) residue is substituted by a histidine residue in all 
vertebrate class IIa enzymes and accounts for their diminished intrinsic deacetylase 
activity [106]. A gain of deacetylase function was demonstrated by substituting 
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histidine-976 residue with Y residue in the catalytic domain of HDAC 4 (HDAC 4 cd) 
[106, 107]. Interestingly, studies also reported the presence of an additional 
structural zinc ion motif within the class IIa HDACs catalytic domain that 
distinguishes class IIa HDACs from other HDACs. This highly conserved class IIa-
specific, structural zinc-binding domain is responsible for substrate binding, protein-
protein interactions and may be an activity modulation site [108, 109]. However the 
exact mechanism of class IIa HDAC mediated gene silencing and the role of the 
catalytic domain in this activity remains elusive. Indeed, class IIa HDACs enzymatic 
activity was shown to be due to contaminating endogenous class I HDACs, which 
associate with class IIa HDAC isoforms in vivo  [106, 107].  
 
Accordingly, there is evidence that class IIa HDACs lack intrinsic HDAC activity and 
rather recruit HDAC3 via the SMRT/N-CoR corepresor complex for this function 
[110, 111].  Structural anĂůǇƐŝƐŽĨĐůĂƐƐʳʳĂ,Ɛ catalytic domain (HDAC4cd) found 
that the structural zinc binding domain is involved in associating HDAC4 with N-CoR: 
HDAC3 to form the multiprotein repressor complex [108, 109]. Various other 
studies have indicated that rather than the repressive activity exerted via 
HDAC3/SMRT-associated deacetylase domain that is located in the carboxy-terminal 
part of the class IIa HDACs, these proteins also exert their repressive activity on MEF 
TF through their amino (N) terminal regions [106, 112, 113].  This amino terminal 
region of class IIa HDACs represses MEF transcriptional activity that is independent 
of their deacetylase enzymatic function [114].  Class IIa HDACs repress MEF2 
transcriptional activity through the association of the N-terminal repression domain 
with corepressors such as CtBP and other class-I and -II HDACs [115]. 
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Moreover, MEF2-interacting transcription repressor (MITR), also called HDAC-
related protein (HDRP), is a natural HDAC9 splice variant that despite lacking the 
catalytic domain, exerts full transcriptional repressive functions on MEF2 via its N-
terminal association with transcriptional corepressors such as COOH-terminal-
binding protein (CtBP)  [112, 116]. The N-terminal repressor domain of class IIa 
HDACs also interact with an other transcriptional repressor called heterochromatin 
protein 1 (HP1), an adaptor protein involved in recognizing methylated lysines 
within histone H3 tails, recruiting histone methyltransferase and silencing MEF 
mediated transcription via association with a variety of transcriptional repressors 
[117]. An argument can be made that deacetylase domain-independent repression 
in the case of class IIa HDACs could be because they lack HDAC activity and recruit 
HDAC3-SMRT/N-CoR corepresors complex via their deacetylase domain for this 
function [110]. But recently a study has shown that the deacetylase domain mutant 
class IIa HDAC (HDAC5) was still able to repress the transcriptional activity of the 
GLUT-4 promoter in vitro suggesting that this domain is not required for the 
inhibitory effect on transcription [113].  
 
Class IIa HDACs suppress the activity of transcription factors including MEF2 by 
deacetylating the nuceosomal histones, however whether they affect their 
acetylation status directly is still unknown [118, 119]. Unexpectedly, HDAC3 is 
reported to physically interact and deacetylate both MEF2 and its coactivators with 
intrinsic HAT activity such as p300 and P300/CBP-associated factor (PCAF) [119]. 
Hence the precise molecular mechanisms of class IIa HDAC function have not been 
fully elucidated and require further investigation. The C-terminal domain of class IIa 
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HDACs (except HDAC7) also contain a nuclear export signal (NES) and depending 
upon the various cellular signals they can exclusively shuttle in and out of the 
nucleus [91]. 
 
1.6  Posttranslational regulation of class IIa HDACs 
 
In the nucleus, class IIa HDACs interact with transcription factors and corepressors 
to regulate histone deacetylation and inhibit transcription. Hence, it is important to 
understand the mechanisms that sequester them away from their substrates to 
render them enzymatically inactive and regulate class IIa HDACs activity as 
transcriptional repressors [118]. 
 
1.6.1  Phosphorylation-dependent subcellular compartmentalization  
 
The best understood posttranslational mechanism regulating class IIa HDACs 
function is phosphorylation-dependent nuclear export [118]. Class IIa HDACs are 
phosphorylated at various conserved serine residues located in the N-terminal 
domain [118]. This creates a docking site for the 14-3-3 family of intracellular 
proteins and promotes binding to 14-3-3, which is required for the interruption of 
the MEF2-HDAC complex [118, 120]. This binding masks the NLS, which is flanked by 
the phosphorylated 14-3-3 binding sites in the N-terminal [121] and sequesters 
these transcriptional repressors to the cytoplasm via the nuclear exportin protein 
chromosome region maintenance 1 (CRM1) [122] (Fig. 1.6). Multiple kinases, each 
with multiple isoforms, are reported to act as class IIa HDAC kinases that can alter 
their subcellular localization [118]. Members of the Ca2+/calmodulin-dependent 
 23 
 
protein kinase family (CaMKs) have been shown to phosphorylate class IIa HDACs at 
various conserved serine residues (HDAC4 at Ser-246, Ser-467, Ser-632; HDAC5 at 
Ser-259, Ser-498) and promote their intracellular trafficking. This overrides HDAC-
mediated repression rendering CaMK as a potent HDAC export kinase [123-127]. 
 
 
Figure 1.6. Class IIa HDAC-regulated metabolic gene expression. Class IIa HDAC 
condenses chromatin structure to repress metabolic gene expression. 
Phosphorylation by various kinases exports class IIa HDAC from nucleus to 
cytoplasm. Ubiquitination (Ub) of class IIa HDAC signals them to be degraded by the 
proteasome (Reproduced from [128]). 
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Class IIa HDACs impede hypertrophy of cardiomyocytes but multiple stress induced 
kinases neutralize this repressive effect by phosphorylating the same CaMK 
targeted sites, resulting in HDAC export and fetal cardiac gene activation. The use of 
broad-specificity kinase inhibitors in this study suggests that class IIa HDACs could 
have multiple upstream kinases since the use specific kinase inhibitors fails to block 
their phosphorylation [129]. Indeed, similar 14-3-3 binding sites that can be 
phosphorylated by various kinases are conserved in all the members of class IIa 
HDACs [130].  
 
Recently, AMP-activated protein kinase (AMPK) was also reported to phosphorylate 
HDAC5 (at Ser-259 and Ser-498), which was followed by its association with 14-3-3 
and nucleocytoplasmic shuttling [131]. Protein kinase C (PKC) and its downstream 
effector kinase PKCμ/protein kinase D (PKD) also control the phosphorylation and 
nuclear efflux of class IIa HDACs to promote cardiomyocyte hypertrophy [132, 133]. 
Another recent study in which the use of a PKD inhibitor blunted PKD controlled 
class IIa HDAC phosphorylation and cardiac hypertrophy confirms PKD, a 
serine/threonine kinase of the CaMK superfamily, as a critical HDAC regulator [134]. 
Protein kinase C-related kinases (PRKs) have been shown to stimulate the NLS 
phosphorylation and 14-3-3 binding to the NLS flanking sites in class IIa HDACs that 
impairs their nuclear import and promotes their cytoplasmic sequestration [135]. 
Salt-inducible kinase 1 (SIK1) and two members of the microtubule affinity-
regulating kinase (MARK)/Par-1 family also participate in the phosphorylation 
mediated nuclear export of class IIa HDACs, but the biological relevance of these 
findings in the MEF2-regulated programs remains totally unexplored [136].  
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1.6.2  Ubiquitin-mediated proteasomal degradation of class IIa HDACs  
 
Another post-translational modification that destabilizes class IIa HDAC protein 
levels, rather than affecting their subcellular localization, is ubiquitin directed 
proteasomal degradation [128]. A series of enzymes are activated in the 
ubiquitination cascade culminating in E3 ubiquitin ligase, an enzyme which finally 
marks the protein lysine residues with ubiquitin peptides. This tag signals the 
protein to be shuffled to the proteosomal machinery where it undergoes 
proteolysis by various proteases [137] (Fig. 1.6). Class IIa HDACs are ubiquitinated in 
the nucleus and degraded by the proteosome in slow fibre dominant soleus muscle 
which rescues MEF2 transcriptional activity and regulates muscle remodelling genes 
[96]. Apart from being ubiquitinylated, class IIa HDACs are also sensitive to 
sumoylation at lysine residues by the Small Ubiquitin-like Modifier or SUMO 
proteins which affect their subcellular compartmentalization and repressive or 
deacetylase activity [138]. Another study showed that sumoylation by RANBP2, a 
SUMO E3 ligase, mediates nuclear localization and subsequent proteosomal 
degradation of class IIa HDACs [139]. 
 
Hence, these two well characterized mechanisms differentially suppress HDAC 
activity and enable HATs to acetylate histones around MEF2 targeted promoters 
and activate their transcription. 
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1.7  Physiological roles of class IIa HDACs  
 
Class IIa HDACs are well-known signal responsive transcriptional repressors. They do 
not interact directly with DNA but depend on MEF2 transcription factors for their 
recruitment and targeting the specific genomic regions. Since, they are not 
functional deacetylases, it has been hypothesised that class IIa HDACs act as a 
bridge between the enzymatically active transcriptional repressor (SMRT/N-CoR-
HDAC3) complex and MEF2 TFs to regulate transcription of target genes [110]. 
Using both gain and loss-of-function approaches in mice, many studies have 
suggested that several tissue specific gene programmes are regulated by the 
HDAC:MEF2 axis, such as the onset of apoptosis via activated T-Cell receptor, 
regulation of bone formation, cardiovascular growth and endothelial function and 
myogenesis [90, 140]. 
 
1.7.1  Role of class IIa HDACs:MEF2 and skeletal muscle development 
 
Class IIa HDAC:MEF2 interactions exhibit different functions in skeletal muscle but 
their role in controlling skeletal muscle differentiation (myogenesis) and muscle 
fibre remodelling is widely known [90, 140]. The muscle-enriched MEF2 
transcription factors belong to the MADS-Box family of transcriptional regulators 
and play a critical role in orchestrating muscle development by binding and 
potentiating the muscle inducing activity of myogenic members of the MyoD family 
of basic-helix-loop-helix (bHLH) proteins-MyoD, Myf5, myogenin and MRF4 in vitro 
and in vivo [99]. MEF2 factors remain constitutively bound to their target gene 
promoters in muscle, and may act as activators or repressors depending on the 
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specific recruitment of coactivators and corepressors respectively in response to 
specific signals [99, 141]. For instance, MEF2 regulatory gene promoters turn on 
when MEF2 binds with myogenic regulatory factors which recruit coactivators 
possessing HAT activity [141] whereas they turn off when MEF2 recruits class IIa 
HDACs [142]. 
 
Class IIa HDACs associate with MEF2 via a unique 18-amino acid motif in the N-
terminal, and they act as potent repressors of MEF2 dependent transcription of 
muscle specific genes by blocking MyoD activity during myoblast differentiation and 
simultaneously deacetylating the local chromatin [100, 142] (Fig. 1.7). At the onset 
of muscle growth and differentiation, MEF2 activity can be rescued from this 
repression with the stimulation of various intracellular signalling pathways in 
response to elevated intracellular calcium levels [136, 143]. Activated CaM 
following the  Ca2+ signalling binds to class IIa HDACs directly and overcomes their 
repression of MEF2 [94]. Indirectly, Ca2+/CaM activate CaMK signalling which is one 
of the important factors responsible for preventing the formation of MEF2: HDAC 
complexes and executing the MEF2 dependent muscle differentiation program. 
CaM kinase releases HDAC repression of MEF2 by regulating class IIa HDACs nucear-
cytoplasmic shuttling [142, 144]. Thus, MEF2 activity is crucial but nuclear export of 
HDACs serves as a reinforcing mechanism to ensure maximal activation of MEF2 
target genes. This CaMK dependent release of HDAC repressive activity efficiently 
unmasks MEF2 transcriptional activity and stimulates myogenesis [141].  
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In the nucleus, MEF2 becomes free to associate with MyoD and recruits various 
coactivators with intrinsic HAT activity such as p300 and P300/CBP-associated factor 
(PCAF) to the muscle metabolic gene control regions resulting in enhanced muscle 
specific gene expression. HATs can physically associate with MyoD and also 
compete with HDACs to bind with MADS/MEF2 domains of MEF2 factors [141, 145]. 
Enhanced acetylation status of histones in the regulatory regions of muscle specific 
genes is seen during muscle differentiation [100] (Fig. 1.7). Compelling evidence 
indicates that the differentiation of myoblasts to form myotubes requires the 
translocation of class IIa HDACs from the nucleus to the cytoplasm [144]. Similar 
nucleo-cytoplasmic trafficking of HDACs also regulates skeletal muscle remodelling 
towards a more oxidative phenotype [146-153].  
 
 
Figure 1.7. A model for the roles of HAT and HDAC in the control of muscle gene 
expression. In undifferentiated myoblasts, class IIa HDACs suppress the MyoD and 
MEF2 activity resulting in muscle gene transcriptional suppression. Following 
differentiation, activation of CaMK and possibly other kinases dissociate class IIa 
HDAC from MEF2 and MyoD, which then interact with coactivators like P300 and 
PCAF with HAT activity to activate muscle specific gene expression and myotube 
formation (Reproduced from [141]). 
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1.8  Class IIa histone deacetylases as regulators of skeletal muscle 
exercise adaptations and muscle metabolism 
 
Exercise-induced histone modifications regulate chromatin remodelling to initiate 
transcriptional activation in human skeletal muscle [20]. Various exercise responsive 
metabolic genes such as peroxisome proliferator-activated receptor (PPAR) gamma 
coactivator 1ɲ (PGC-ϭɲ) [154-162], GLUT-4 [163], UCP-3 [164], CPT-1 [165] and 
various cytochrome c oxidase subunits [166] contain conserved MEF2 binding sites 
in their promoter regions. Hence, MEF2 is central to metabolic gene expression and 
oxidative metabolism [167]. Exercise also improves the DNA-binding activity of 
MEF2 transcription factors to modulate metabolic gene expression [168]. MEF2 
activity is regulated by a balance between transcriptional repression by HDACs and 
transcriptional activation by HATs and various kinases [169]. 
 
In the basal state, it has been proposed that class IIa HDACs associate with MEF2 
which are bound to their targeted promoters. This inhibits MEF2 transcriptional 
activity  [170]  (Fig. 1.8). Following exercise, this HDAC:MEF2 association is reduced 
in human skeletal muscle and regulates the expression of one exercise-sensitive 
gene, GLUT-4 [75, 169, 171]. This is associated with decreased nuclear abundance 
of class IIa HDACs and their nuclear export [169, 171]. Several lines of evidence 
suggest that exercise activates multiple class IIa HDAC kinases including AMPK and 
ĂD<ʳʳ [172-176]. These kinases phopshorylate 14-3-3 binding sites in these HDACs 
and trigger their nuclear export during exercise thereby derepressing MEF2 activity 
to regulate gene expression [172, 173, 177] (Fig. 1.8). This is consistent with studies 
suggesting that redundancy exists among the various exercise-induced HDAC 
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kinases and this could maintain compensatory signalling to attenuate class IIa HDAC 
control of MEF2 metabolic transcriptional activity and enhance skeletal muscle 
oxidative and metabolic transcription including PGC-ϭɲ ĂŶĚ '>hd-4 expression 
[173, 178-180]. 
 
Following class IIa HDAC disassociation during exercise, MEF2 interacts with PGC-
ϭɲ, a master transcriptional regulator of metabolic and mitochondrial genes, in the 
nucleus [6, 15, 169, 170, 181-190] (Fig. 1.8). This simultaneously enhances PGC-ϭɲ
transcription [170, 191-193]. This is consistent with the increased MEF2 and PGC-ϭɲ
association observed following exercise [169]. Additionally, exercise-induced 
mitogen-activated kinase MAPK can interact and phosphorylate MEF2 in the 
nucleus, which contributes to increased MEF2 transcriptional activity and exercise-
induced gene expression [194-196]. MAPK also increases nuclear PGC-ϭɲ ĂĐƚivity 
and its transcription followed by its association with MEF2 [197, 198]. Docking with 
MEF2 causes a conformational change in PGC-ϭɲ ƚŽ ƌĞĐƌƵŝƚ ĐŽĂĐƚŝǀĂƚŽƌƐ ǁŝƚŚ
intrinsic HAT activity to MEF2 [199]. This acetylates histones at the GLUT-4 
promoter that contributes to the enhanced GLUT-4 transcription and gene 
expression [170, 200-203]. Increased histone 3 acetylation (at lysine 36) associated 
with enhanced transcription has been observed in muscle following 60 min of 
cycling. This supports that exercise could induce histone modifications, at some 
specific metabolic gene promoters, favouring histone acetylation and transcription. 
Increased ubiquitination of class IIa HDACs without any difference in their 
abundance was also observed in this study [172]. This suggests that ubiquitin-
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mediated proteosomal degradation might play a role in the post-exercise period 
and could mediate adaptations to exercise [96, 172].  
 
 
Figure 1.8. Proposed regulation of myocyte enhancer factor 2 (MEF2) in 
contracting human skeletal muscle. At rest, class IIa HDACs interact with MEF2 to 
suppress its transcriptional activity at the metabolic gene promoter. During 
exercise, activation of various kinases export class IIa HDACs out from the nucleus. 
MEF2 interacts with p38 MAPK and PGC1-ɲƚŽƌĞĐƌƵŝƚĐŽĂĐƚŝǀĂƚŽƌƐǁŝƚŚŝŶƚƌŝŶƐŝĐ,d
activity. This increases histone acetylation around the metabolic gene promoter and 
mediate MEF2 dependent metabolic gene transcription (Reproduced from [170]). 
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As described above, class IIa HDACs regulate GLUT-4 gene expression. This suggests 
a regulatory role for the class IIa HDACs in muscle glucose uptake. Considering the 
role of class IIa HDACs in regulating GLUT-4 gene expression during exercise, it can 
be hypothesised that these HDACs might mediate phenotypic adaptations to 
exercise by regulating a broader set of metabolic genes in skeletal muscle. 
Therefore, it can be postulated that inhibition of class IIa HDACs could be the 
mechanism underlying exercise adaptations in skeletal muscle. This fits with the 
observations of many other studies [96]. Using mouse models with genetically 
altered HDACs or MEF2 in skeletal muscle, it has been discovered that HDACs 
suppress MEF2 activity and contribute to the suppression of slow twitch oxidative 
myofibres. Loss of class IIa HDACs contributes to the formation of oxidative fibres in 
skeletal muscle. Whereas, adaptive skeletal muscle remodelling towards a more 
oxidative phenotype is inhibited in response to four weeks of exercise training when 
HDAC5 is overexpressed [96]. Conversely, their ablation and MEF2 activation 
throughpout development promotes an increase in skeletal muscle oxidative 
capacity, reduced muscle fatigability and increased mitochondrial content via 
enhanced expression of metabolic genes and metabolic transcription factors [96]. 
Furthermore, downregulation of various metabolic and mitochondrial genes such as 
PGC-1ɲ, carnitine palmitoyltransferase 1 (CPT-1), medium chain acyl-CoA 
dehydrogenase (MCAD), hexokinase II (HKII), glycogen phosphorylase, and ATP 
synthase that are required for substrate oxidation and energy production were 
reported following expression of a HDAC5 phosphorylation mutant in the heart 
[191].  
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This leads to the hypothesis that class IIa HDAC inhibition (HDACi) could be an 
effective regulator of skeletal muscle metabolic genes and hence could be a 
potential exercise mimetic to enhance muscle metabolism and treat metabolic 
diseases. 
 
1.9  HDAC inhibition as a potential exercise mimetic and treatment for 
metabolic diseases 
 
Potential molecular targets involved in exercise signalling and executing the 
beneficial effects of exercise could be modulated through pharmacological 
intervention to mimic or potentiate the biochemical responses seen during exercise 
[204]. Various pharmacological exercise mimetics are now emerging as a promising 
hope to combat peripheral insulin resistance and T2D in contemporary society with 
many affected, frail and old individuals unable to engage in exercise [21, 205]. 
Insulin sensitisers such as thiazolidinediones (TZD) and metformin are already used 
in T2D treatment [205]. Other potential candidates that could mimic exercise 
response in skeletal muscle include synthetic AMPK and PPAR agonists [206]. 
Chronic treatments with such agents can regulate genes involved in skeletal muscle 
metabolism, oxidative phenotype, mitochondrial biogenesis and endurance at a 
transcriptional level.  
 
But pharmacological activation of AMPK and PPARs is associated with certain 
limitations and side effects [205, 206]. For example, PPAR agonists alone are 
insufficient to improve the oxidative myofibre proportion and physical 
performance, but can do so in conjunction with exercise [206]. Overexpression of 
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PGC-ϭɲ ŝŶƐŬĞůĞƚĂůŵƵƐĐůĞĂŶĚ ůŝǀĞƌ ŝŶĐƌĞĂƐĞd CD36 expression, a lipid transporter 
responsible for increased fatty acid delivery and re-esterification. Hence this results 
in increased intracellular lipid accumulation which contributes to insulin resistance 
in the tissues [207, 208]. It is also associated with skeletal muscle atrophy in old 
mice suggesting detrimental effects in ageing patients [209]. On the other hand the 
AMPK agonist 5-aminoimidazole-4-carboxamide-1-ɴ-D-ribofuranoside (AICAR) has 
poor oral bioavailability and a short half-life when infused intravenously [21]. 
Additionally, chronic AMPK activation inhibits muscle protein synthesis and results 
in muscle wasting [210, 211] and promotes autophagy [212]. 
 
However, targeting class IIa HDACs preferentially, which are located downstream in 
the metabolic signaling cascade, could bypass some side effects associated with the 
enhanced class IIa HDAC kinase activity. Specific inhibition of class IIa HDACs 
repressive activity on MEF2 is essential for the activation of MEF2 transcriptional 
activity and its targeted metabolic gene expression.  Therefore, the class IIa HDAC 
enzymes appear to be an attractive target for therapy in metabolic diseases like 
T2D. 
 
1.10  HDAC inhibitors- structure and mechanism 
 
Numerous natural or synthetic pharmacological inhibitors have been developed 
that block HDAC repressive activity [103]. These HDAC inhibitors (HDI) belong to 
several structural classes including hydroxamic acids, cyclic peptides, electrophilic 
ketones, short chain fatty acids, and benzamides. They have three common 
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structural characteristics: 1) a zinc binding group (ZBG or chelator or metal binding 
group), that interacts with Zn2+  bound to the catalytic centre of classical HDACs 
active site 2) an opposing hydrophobic cap group, also known as surface recognition 
domain that interacts with the rim of the opening channel of HDACs active site 
cavity to establish an appropriate 3D conformation for presenting the chelator 
properly  and 3) a straight chain alkyl, vinyl or aryl linker connecting the two that 
spans through the hydrophobic tunnel/channel of HDACs [88, 103] (Fig. 1.9). All 
these structures have been shown to exhibit target specificity and hence can be 
manipulated chemically to develop potent and isoform selective HDIs. 
 
 
Figure 1.9. Pharmacophoric summary of the HDAC inhibitor. Zinc binding group 
(ZBG) interacts with the Zn2+ ion in the catalytic centre of HDACs active site cavity. 
Linker spans through the hydrophobic channel of HDACs and cap group interacts 
with the rim of the HDACs active site cavity (Reproduced from [88]).  
 
The mechanism of action of HDIs is quite enigmatic. The structure of HDAC: 
inhibitor complexes indicate that they specifically interact with the zinc-containing 
catalytic core through these functional groups, chelate the zinc ion, abolish HDAC 
enzymatic activity and block substrate access [102]. They may also target 
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HDAC:protein interactions that are independent of HDAC deacetylase activity [103]. 
Inhibition of HDACs results in enhanced acetylation of histones and non-histone 
proteins which mediate gene expression and other biological processes [213, 214].  
In vitro studies have also shown that HDIs do not necessarily result in the 
hyperacetylation of all proteins, and hence appear to be specific against histone and 
non-histone proteins [215]. The idea that HDACi enhances histone acetylation 
across the genome and hence promotes global gene expression is not always 
applicable. Studies have shown that HDAC inhibition not only induces gene 
expression, but can also suppress it, which could be related to the acetylation status 
and thus the function of non-histone proteins, particularly transcription factors 
[114, 216, 217]. Evidence has also shown that the effect of HDIs is not only cell type 
or stimulus specific but also concentration and duration of exposure dependent 
[218, 219]. However, the exact molecular pathways through which HDI work remain 
to be fully elucidated. Classical HDAC inhibitors are non-specific broad spectrum 
inhibitors (or pan inhibitors) that are active and potent against most or all HDAC 
enzymes with nanomolar potency, particularly class I, but have relatively low 
affinity for class IIa HDACs [90, 91, 220, 221]. 
 
1.11  Therapeutic potential of HDAC inhibition and therapeutic action 
of HDAC inhibitors  
 
The role of histone acetylation and deacetylation had been implicated in the 
regulation of various biological processes ranging from developmental physiology to 
tissue homeostasis. Hence, pharmacological non-specific inactivation of HDAC 
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activity by classical HDIs could cause global gene expression alterations that could 
result in nonspecific and catastrophic effects.  Despite this, broad spectrum HDAC 
inhibitors have proven useful in vivo by their selective ability to both block and 
enhance disease associated expression of specific genes [90, 222]. Additionally, they 
are generally well tolerated in humans and thus some of them are Federal Drug 
Administration (FDA) approved for clinical use in oncology, while others are 
currently in clinical trials [223].  
 
HDIs as monotherapy and combination therapy are promising anti-cancer agents. 
They enhance the acetylation of various histone and non-histone proteins that 
participate in the regulation of various cellular processes and in turn alter their 
structure and function [213, 214]. Consequently, HDIs selectively induce different 
phenotypes in transformed cells and cause tumour cell growth suppression [88, 
214, 224]. Such multiple biological effects involve the inhibition of ĐůĂƐƐ ʳ ,Ɛ
ǁŝƚŚůŝƚƚůĞĐŽƌƌĞůĂƚŝŽŶŬŶŽǁŶďĞƚǁĞĞŶĐůĂƐƐʳʳ,ƐĂŶĚĐĂŶĐĞƌĚĞǀĞůŽƉŵĞŶƚ[221, 
225-227]. This is associated with enhanced sensitivity to ionizing radiation which 
provides therapeutic benefits in the treatment of some cancers [226, 228]. HDIs are 
also anti-inflammatory agents and modulators of immune responses that contribute 
to their anticancer effects [218, 220, 229, 230].  Many human and in vivo studies 
have shown the therapeutic effect of systemic HDACi in diverse disease states 
including the positive impact on lifespan extension, and control of pathological 
cardiac remodelling by the use of broad spectrum HDIs [222, 231-233]. In addition, 
systemic HDACs inhibition can also regulate various physiological processes similar 
to exercise in tissues other than skeletal muscle and provide a therapeutic benefit in 
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other disease states. In vitro and in vivo, HDACi reduced lipid accumulation in 
adipocytes, arrested adipogenesis, reduced adiposity and body weight due to 
increased oxygen consumption and energy expenditure and hence, increased 
insulin sensitivity and obesity resistance [234-237]. HDACi has been shown to 
enhance a general protection against resistance to oxidative stress [227]. Since class 
IIa HDACs are known to be the mediators of skeletal muscle metabolic adaptations 
in response to exercise, therefore, it can be hypothesized that class IIa HDACi could 
be a specific and effective exercise mimetic and treatment strategy to reverse 
skeletal muscle insulin resistance in obesity and type 2 diabetes. 
 
1.12  Therapeutic potential of HDAC inhibition in metabolic diseases 
 
Protein lysine acetylation has been exclusively shown to play a key role in the 
regulation of chromatin remodelling mediated gene expression via histone 
modification so far [84]. It has now emerged as a key posttranslational modification 
to numerous non-histone proteins that regulates diverse biological and cellular 
processes. Therefore, HATs and HDACs are actively also called as lysine acetylases 
(KATs) and lysine deacetylases (KDACs) as they mediate acetylation and 
deacetylation of various substrates ranging from nuclear proteins such as histones 
and transcription factors to non-nuclear proteins, such as cytoplasmic and 
metabolic proteins or enzymes [215, 238]. The majority of the enzymes 
participating in intermediary cellular metabolic pathways such as glycolysis, 
tricarboxylic acid and urea cycles, fatty acid and glycogen metabolism can be 
reversibly acetylated. Acetylation can affect the activity or stability of these 
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metabolic enzymes. The effects of acetylation on an enzyme’s activity and stability 
vary widely among the various metabolic enzymes and proteins. Also, the 
extracellular nutrient flux can affect the acetylation status of metabolic enzymes 
[239, 240]. These studies suggest that lysine acetylation of proteins plays a pivotal 
role in metabolic regulation and HDACs, along with another class of deacetylases 
called as Sirtuins, also exert their activity in the cytoplasm and mitochondria by 
governing the acetylation of metabolic enzymes [241]. Therefore, dysregulation of 
metabolism could be linked to the changes in the protein acetylation levels in the 
pathogenesis of metabolic diseases. 
 
Lysine acetylation of histones and non-histone proteins occurs in almost all 
metabolically active tissues such as brain, immune cells, skeletal muscle, adipose 
tissue, pancreas and liver to maintain immune function and energy homeostasis 
[242]. This suggests that HDACs might control the various metabolic processes in 
these tissues and contribute to the tissue-specific metabolic dysfunction during 
obesity and associated metabolic diseases. Studies have already linked HDACs with 
genetic and environmental factors associated with the etiology of diabetes [243]. It 
has also been demonstrated in pancreatic ɴ-cells that high glucose concentrations 
increase insulin gene expression by inducing histone hyperacetylation at the 
insulin promoter through the recruitment of HATs by transcription factors, and at 
low glucose concentration HDACs are recruited to the insulin gene promoter and 
abolish histone acetylation and decrease insulin expression, suggesting an 
important role for HATs and HDACs in the regulation of insulin gene expression 
[244-247]. This suggests a regulatory role for HDACs in metabolic tissues that could 
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be manipulated by the use of HDIs to have therapeutic benefits in metabolic 
diseases such as insulin resistance and T2D.  
 
1.12.1  Role of HDACs in skeletal muscle and metabolic diseases 
Skeletal muscle plays an important role in maintaining glucose homeostasis. It is a 
key site for majority of glucose uptake under insulin-stimulated conditions [3, 22]. 
Therefore, skeletal muscle oxidative and metabolic dysfunction contributes to the 
pathogenesis of metabolic diseases. Class IIa HDACs are well known transcriptional 
repressors of metabolic and mitochondrial genes in skeletal muscle [7]. The 
regulatory role of class IIa HDACs in muscle development, metabolism and 
adaptation in response to exercise has been deeply studied (as detailed in section 
1.8), still very little is known about the therapeutic impact of HDIs to treat muscle 
metabolic dysfunction. 
 
In skeletal muscle, in vitro studies have shown that broad spectrum HDI enhances 
GLUT-4 gene expression and GLUT-4 translocation to the plasma membrane 
resulting in improved basal and insulin-stimulated glucose uptake [131, 248]. HDI 
can also increase PGC1-ɲĞǆƉƌĞƐƐŝŽŶĂŶĚW'ϭ-ɲĚĞƉĞŶĚĞŶƚŵƵƐĐůĞŵŝƚŽĐŚŽŶĚƌŝĂů
gene expression and function, thereby normalizing muscle cell insulin resistance 
following long chain saturated fatty acid exposure [249]. These observations 
suggest the role of HDIs as an exercise mimetic in normalizing metabolic gene 
expression and skeletal muscle metabolism in diseased conditions. Gao et al. have 
shown that the natural dietary compound sodium butyrate, that can inhibit both 
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class I and class II HDACs, when supplemented with high fat diet prevented diet-
induced obesity [250]. It improved metabolic dysfunction in diet-induced obese 
mice via increased energy expenditure, fatty acid oxidation, insulin sensitivity, 
reduced adiposity, enhanced thermogenic function, reduced fat accumulation and 
size of brown adipocytes [250]. It was associated with increased mitochondrial 
function and biogenesis with enhanced PGC-ϭɲ ŐĞŶĞ ĂŶĚ ƉƌŽƚĞŝŶ ĞǆƉƌĞƐƐŝŽŶ ŝŶ
skeletal muscle and brown fat. Butyrate also increased the number of oxidative 
;ƚǇƉĞ ϭͿ ĮďĞƌƐ ŝŶ ƐŬĞůĞƚĂů ŵƵƐĐůĞƐ in vivo [250]. Further studies are needed to 
characterize the therapeutic benefits of HDACi, preferably class IIa specific HDACi, 
to reverse skeletal muscle insulin resistance and impaired metabolism in obesity 
and T2D. 
 
1.12.2  Role of HDACs in adipose tissue and metabolic diseases 
Insulin resistance and metabolic dysfunction in adipose tissue is associated with the 
pathogenesis of metabolic diseases such as obesity and T2D [251]. Adipogenesis, a 
process in which preadipocytes differentiate into adipocytes, has recently been 
shown to be regulated by HDACs. Class I HDACs play redundant roles as positive 
regulators of adipogenesis. Class I HDAC (HDAC 1 and 2) inhibition can inhibit lipid 
accumulation and block adipocyte differentiation [235]. Various broad spectrum 
and class I selective HDIs have shown to exhibit anti-adipogenic effects by inhibiting 
the adipose conversion at the beginning of the differentiation program. This ability 
of HDIs to arrest adipogenesis was shown to be reversible [236, 237]. Recently, class 
IIa HDACs have been shown to be negative regulators of differentiation-dependent 
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expression of metabolic genes such as GLUT-4 in preadipocytes. Class IIa HDACs 
regulate the expression of the insulin-responsive GLUT-4 gene in adipocytes. In 
preadipocytes, nuclear class IIa HDACs repress MEF-2 dependent GLUT-4 
transcription, whereas during differentiation, the reduction in nuclear class IIa 
HDACs due to cytosolic translocation results in increased GLUT-4 transcription 
[113]. This provides insights into the molecular mechanisms for regulated GLUT-4 
expression by class IIa HDACs under pathological conditions which could be 
modulated by using class IIa selective HDIs to upregulate GLUT-4 expression and 
restore glucose homeostasis in obesity and T2D. 
 
1.12.3  Role of HDACs in liver and metabolic diseases 
The class I HDACs have been implicated in regulating hepatic gluconeogenesis and 
HDAC3 has been implicated in controlling hepatic lipid metabolism [252, 253]. A 
ŶŽǀĞů ĐůĂƐƐ ʳ ,/ ŚĂƐ been shown to inhibit phopshoenolpyruvate carboxykinase 
(PEPCK) expression, a rate controlling gluconeogenic enzyme involved in the de 
novo synthesis of glucose (i.e. gluconeogenesis) and hepatic glucose production 
[252]. Recent studies have identified a novel role of class IIa HDACs in regulating 
glucose production by the liver [254, 255]. In the liver, gluconeogenesis is regulated 
by two nutrient sensitive hormones, glucagon and insulin, that differentially 
regulates a signalling pathway pathway that involves the cAMP-dependent Protein 
Kinase A (PKA), LKB1-dependent kinases such as AMPK, salt-inducible kinase 1/2 
(SIK1/2) and Akt kinase [254-256]. 
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Mihaylova et. al. showed that in the liver, class IIa HDACs are phosphorylated by 
LKB1-dependent activation of kinases such as AMPK, resulting in their nuclear 
exclusion and inhibition [254]. Genetic deletion of the LKBI gene in mouse liver 
reduced class IIa HDACs phosphorylation, which was restored following exposure to 
the antidiabetic compound metformin, which acts as an AMPK agonist. They 
demonstrated that glucagon, secreted by the pancreas in response to fasting, 
results in the decreased class IIa HDACs phosphorylation and their accumulation in 
the nucleus. This happens through the cAMP-dependent PKA that inhibits AMPK 
and SIK1/2. Once in the nucleus, they associate with the gluconeogenic 
transcription factor FOXO and recruit HDAC3 (class I HDAC) to deacetylate them. 
This deacetylation results in the activation of FOXO, increasing their association 
with gluconeogenic gene promoters such as glucose-6-phophatase (G6Pase) and 
PEPCK and increasing gluconeogenic gene transcription. The loss of class IIa HDACs 
in mouse hepatocytes and liver resulted in FOXO hyperacetylation, the loss of FOXO 
activity and inhibition of gluconeogenic gene expression. This lowers blood glucose 
levels and increases glycogen storage [254-257].  
 
In various mouse models of diabetes, suppression of class IIa HDACs decreased 
fasting blood glucose levels and enhanced glucose tolerance. This suggested that 
class IIa HDACs contribute to hyperglycemia in diabetes and regulate hepatic 
glucose production [254]. These studies have identified the role of class IIa HDACs in 
hepatic glucose metabolism and the potential of class selective HDIs to ameliorate 
hyperglycaemia and metabolic dysfunction in diabetes. 
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Together these data provide strong evidence that the class IIa HDACs play a role in 
regulating metabolic homeostasis and thus, provide a strong rationale for the major 
aim of this project, which is to determine the therapeutic utility of class IIa selective 
HDIs in the treatment of metabolic diseases. 
 
1.12.4  Role of HDACs in pancreas and metabolic diseases 
Type 2 diabetes is associated with peripheral insulin resistance and inadequate 
insulin secretioŶ ĚƵĞ ƚŽ ƉĂŶĐƌĞĂƚŝĐ ɴ-cell dysfunction that results in impaired 
glucose homeostasis. Glucolipotoxicity induces inflammatory mediators, or 
cytokines such as interleukin (IL)-ϭɴ, ŝŶ ƉĂŶĐƌĞĂƚŝĐ ŝƐůĞƚƐ ƚŚĂƚ ƌĞƐƵůƚƐ ŝŶ ɴ-cell 
apoptosis and dysfunction [219]. All classical HDACs are known to be expressed in 
pancreatic ɴ-cell and differentially regulated by proinflammatory cytokines [219]. In 
vitro, HDIs have inhibited HDAC activity and increased histone acetylation in 
pancreatic ɴ-cells without any effects on cell viability [258]. /ŶĐǇƚŽŬŝŶĞŝŶĚƵĐĞĚɴ-
cell dysfunction, HDIs protected against IL-ϭɴ induced apoptosis and inhibited 
cytokine induced NF-ʃ ƚƌĂŶƐĐƌŝƉƚŝŽŶĂů activity and therefore, further suppressed 
NF-ʃ-dependent gene expression [258-260]. These data suggest that HDIs could 
ƉƌĞǀĞŶƚƉĂŶĐƌĞĂƚŝĐɴ-cell apoptosis and dysfunction caused by immune stimuli and 
lipotoxicity.   
 
The use of various HDIs in animal models of diabetes and insulin resistance 
enhanced ɴ-cell function, development, proliferation and differentiation, and 
increased insulin secretion [219, 261]. An increase in insulin gene transcription, 
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associated with enhanced histone acetylation, was also observed following 
treatment with a broad spectrum HDI in vitro [246, 262]. There is also potential to 
stimulate early pancreatic development by differentiating embryonic stem cells into 
insulin producing cells with the use of HDIs, wŚŝĐŚ ĐŽƵůĚ ďĞ ƵƐĞĨƵů ĨŽƌ ɴ-cell 
replacement therapy [263-266]. Haumaitre et. al. showed that the timing and 
determination of pancreatic cell fate could be regulated by different selective HDIs 
and therefore it is a powerful strategy to modify pancreatic endocrine cell lineages 
and enhance specific cellular subtypes with the potential to treat diabetes. They 
discovered that HDACs contribute to the pancreatic endocrine cell development 
without modifying the proliferation/apoptosis balance with ƐƉĞĐŝĮĐƌŽůĞƐŽĨĐůĂƐƐ /
and class II HDACs in endocrine cell subtype development [267]. 
 
It was further characterized that class IIa HDACs have a restricted pattern of 
ĞǆƉƌĞƐƐŝŽŶ ŝŶĞŶĚŽĐƌŝŶĞɴĂŶĚɷĐĞůůƐ ŝŶ the pancreas, ĂŶĚŚĞŶĐĞĐŽƵůĚƌĞŐƵůĂƚĞɴ
ĂŶĚɷĐĞůůƐŵĂƐƐĂŶĚƚŚĞƌĞďǇ ŝŶƐƵůŝŶĂŶĚƐŽŵĂƚŽƐƚĂƚŝŶƉƌŽĚƵĐƚŝŽŶ͕ ƌĞƐƉĞĐƚŝǀĞůǇ͘ /ƚ
was found that overexpression of class IIa HDACs in pancreatic explants can 
suppƌĞƐƐ ƚŚĞ ŝŶƐƵůŝŶ ƉƌŽĚƵĐŝŶŐ ɴ-celůƐ ĂŶĚ ƐŽŵĂƚŽƐƚĂƚŝŶ ƉƌŽĚƵĐŝŶŐ ɷ-cells mass, 
which could possibly be due to MEF-2 activity repression. In contrast, class IIa 
,ƐŬŶŽĐŬŽƵƚŵŝĐĞŚĂĚƵƉƌĞŐƵůĂƚĞĚɴĂŶĚɷĐĞůůƐŵĂƐƐ͘dŚŝƐǁĂƐĐŽŶƐŝƐƚĞŶƚǁŝƚŚ
the increased pool ŽĨɴĂŶĚɷĐĞůůƐďĞĐĂƵƐĞŽĨ ŝŶĐƌĞĂƐĞĚWĂǆϰƚƌĂŶƐĐƌŝƉƚŝŽŶ ĨĂĐƚŽƌ
expression following the treatment of pancreatic explants with class IIa HDAC 
inhibitor [268]. This generates new hope for the use of class IIa selective HDIs in cell 
therapies to treat diabetes. 
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1.12.5  Role of HDACs in brain and metabolic diseases 
The brain is an important tissue that regulates feeding behaviour, energy balance, 
glucose homeostasis and the aging process via its nutrient sensing 
neurons/neurocircuits in the hypothalamus [269]. Regulation of energy homeostasis 
by brain neurocircuits also affects sensitivity of insulin responsive tissues, such as 
the liver and other peripheral tissues [270]. Furthermore, impairment of brain-
regulated glucose homeostasis contributes to metabolic disease states [271]. The 
role of histone acetylation has recently been implicated in learning, memory and 
normal cognitive functions. And thus, the alterated histone acetylation mediated 
ĚŝƐƚƵƌďĂŶĐĞƐŝŶŐĞŶĞĞǆƉƌĞƐƐŝŽŶŝŶďƌĂŝŶŚĂƐďĞĞŶĂƐƐŽĐŝĂƚĞĚǁŝƚŚĐŽŐŶŝƚŝǀĞĚĞĮĐŝƚƐ
related to aging and neurodegenerative disease.  
 
Both class I and II HDACs are expressed in brain [272]. Interestingly, both class IIa 
HDACs and MEF2 are highly expressed in the brain suggesting a specific role for 
these proteins in the CNS [273]. Class IIa HDACs are known to inactivate MEF2 and 
could inhibit MEF2 target gene expression required for neuronal growth and 
neuronal synaptic development [274, 275]. HDIs have shown therapeutic benefits in 
restoration of memory, enhancement of cognitive function, neuroprotection and 
neuroregeneration in the treatment of central nervous system disorders [273, 276-
278]. In brain, the expression of HDACs has been found to change in response to 
nutritional stimuli such as fasting and high-fat diet-induced obesity [272, 279]. 
Further studies are needed to characterize the role of HDACs and lysine acetylation 
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in regulating eating habits and neuropeptide gene expression under different 
metabolic conditions in the brain. 
 
1.12.6  Role of HDACs in immune system and metabolic diseases 
Metabolism is closely interlinked with the immune system because of the many 
molecules and signalling agents playing roles in both immunity and metabolism (or 
immunometabolism). Chronic inflammation contributes to the pathogenesis of 
metabolic diseases such as obesity and type 2 diabetes [242]. HDACs are known to 
regulate inflammatory pathways via toll-like receptor (TLR) and interferon (IFN) 
signalling [280, 281]. Studies have shown that HDIs have therapeutic potential as 
anti-inflammatory agents against various inflammatory diseases [220, 282-284]. 
However, the impact of HDAC inhibition on inflammation in diabetes is not clear. 
Histones at proinflammatory cytokine gene promoters in monocytes isolated from 
diabetic patients were found to be hyperacetylated, suggesting a potential role for 
HATs and HDACs activity on their expression in diabetes [285]. Therefore, studies 
have indicated that broad spectrum HDIs could reduce cytokine production in 
diabetes by inducing hyperacetylation. But different observations from various 
studies have indicated that HDIs could have differential effects on inflammatory 
gene expression, which could be dependent on cell type, stimulus or the 
concentration of HDI [286, 287]. Broad spectrum HDIs have shown both positive 
and negative effects in inflammatory diseases. But the effect of class II selective 
HDACi in these pathways remains to be determined. 
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1.13 Therapeutic potential of class IIa specific HDAC inhibition in 
metabolic diseases 
 
The majority of the studies documented in the previous section have shown the 
potential of the classical broad spectrum HDI to treat metabolic diseases. However, 
the complicated phenotypes and undesirable side effects in clinical applications 
resulting from the inhibition of various HDAC isoforms, required in various cellular 
or tissue responses, by broad spectrum HDIs cannot be precluded [253]. 
  
Studies have reported negative effects on liver and heart metabolism with class I 
HDAC inhibition. Individual studies have shown that HDAC3 knock out resulted in 
altered metabolic gene expression resulting in mitochondrial and metabolic 
dysfunction and disrupted lipid homeostasis in the liver and heart. This was 
associated with liver and cardiac hypertrophy, lipogenesis, lipid accumulation, 
hepatic steatosis, hepatic insulin resistance, hepatocellular carcinoma and cardiac 
dysfunction [208, 288, 289]. This is consistent with other findings, showing that 
HDAC3 is required for normal circadian rhythm and gene expression and normal 
hepatic lipid homeostasis [290]. Inactivation of HDAC3 deacetylase activity also 
affected normal circadian regulation of metabolic genes in vivo [234]. Additionally, 
broad spectrum HDACi is dose limiting because they exhibit side effects like fatigue, 
nausea, dehydration and diarrhea [103, 223]. These findings sƵŐŐĞƐƚ ƚŚĂƚ ĐůĂƐƐ ʳ
HDACs (particularly HDAC3) are required for normal hepatic metabolism and cardiac 
function and hence, could preclude the potential use of broad spectrum HDIs as 
therapeutic agents. 
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Considering all these findings it can be argued that class IIa specific HDACi might be 
more effective exercise mimetic and more efficient in normalizing skeletal muscle 
metabolic gene expression by minimizing off-target effects. As discussed earlier, 
class IIa HDACs regulate PGC1-ɲĞǆƉƌĞƐƐŝŽŶ͕ďƵƚĚŽŶŽƚĂĨĨĞct CD36 expression in 
skeletal muscle [191]. This suggests that class IIa HDACs could be an ideal 
therapeutic target since class IIa HDACi might favour lipid oxidation rather than lipid 
re-esterification. This could contribute to improved muscle oxidative capacity and 
insulin sensitivity. Therefore, it can be postulated that class IIa specific HDACi may 
improve therapeutic efficacy and could be a promising strategy to reverse muscle 
insulin resistance and treat T2D.  
 
As mentioned previously, classical broad spectrum HDIs have high affinity for all 
isoforms, particularly class I, but exhibit low affinity for class IIa HDACs [90, 104, 
220, 221]. Recent studies have also highlighted that the existing HDIs lack inhibitory 
activity against class IIa enzymes. It is because these HDIs target the zinc-containing 
catalytic domain/catalytic activity, which is ineffective in this class due to the 
structural differences from other HDAC classes [291, 292]. This generates the need 
to develop class IIa selective inhibitors. Also, the role of different HDAC isoforms 
varies in development and disease and inhibition of individual isoforms results in 
specific phenotypes. Hence, it seems plausible that improved therapeutic efficacy 
and safety could be achieved through isoform-selective or class-selective inhibitors 
[88, 90]. A recent study showed that a novel isoform selective inhibitor inhibited 
proinflammatory cytokine production only by rheumatoid arthritic (RA) peripheral 
blood mononuclear cells (PBMC) but not by healthy PBMC. This contrasts the effect 
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showed by the non-selective HDI Trichostatin-A (TSA), which prevented the 
inflammatory response in both RA and healthy PBMC [282]. Hence, the effect of 
class-selective and non-selective HDIs (broad spectrum) is cell type, concentration 
and compound specific. Furthermore, the isoform selective HDIs may improve 
therapeutic efficacy by minimizing off target effects.  
 
Novel isoform-selective HDIs have lower toxicity in comparison to ‘pan-HDAC’ 
inhibitors [258]. Mai et al. were the first group to chemically synthesize novel 
(aryloxopropenyl)-pyrrolyl hydroxyamides as class IIa selective HDIs [293]. Recent 
mechanistic insights into the class IIa HDACs structure have led to the design of 
other inhibitors such as trifluoromethylketone (TFMK), which inhibits class IIa 
HDACs in the nanomolar range [106]. These findings further led to the development 
of a series of 5-(trifluoroacetyl) thiophene-2-carboxamides which are novel, potent 
compounds inhibiting both class IIa and IIb HDACs. These HDIs are probably active 
site inhibitors chelating the zinc ion in the active/catalytic domain of these class II 
HDACs [294, 295]. But they lack cell-based activity and did not inhibit either histone 
,ϯ Žƌ ɲ-tubulin deacetylation due to their metabolic instability. The replacement 
for the carboxamide group in these compounds with oxadiazole led to the 
production of 2- dƌŝŇƵŽƌŽĂĐĞƚǇůƚŚŝŽƉŚĞŶĞŽǆĂĚŝĂǌŽůĞƐĚĞƌŝǀĂƚŝǀĞƐǁŚŝĐŚǁĞƌĞĂŐĂŝŶ
class II selective HDIs and moderately stable in vitro [296].   
 
Class IIa HDACs are also known to repress MEF2 activity through their N-terminal 
domain mediated interactions with other corepressors (HDAC-independent 
mechanism) [112-115]. Alternatively, new compounds such as N-(2-aminophenyl)-
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N’-phenyloctanediamide, commercially available as BML-210, and its analogues 
have been developed and shown to directly target MEF2 activity by inhibiting class 
IIa HDAC:MEF2 interaction and thus block class IIa HDAC recruitment to MEF2 
targetted gene promoters in vitro [93].  But the ZBGs of these compounds have an 
unexpected degree of selectivity for the HDAC3-NCoR complex, whose function is 
otherwise important for normal physiological functions in other tissues such as the 
liver and the heart [292]. No other compounds have been developed yet that could 
directly target MEF2 activity by blocking its interaction with class IIa HDACs, without 
affecting HDAC3 corepressor function. 
 
Therefore, considerable effort is needed to produce more stable and efficient class 
IIa selective HDI. In addition, whether class IIa specific HDACi is a potential exercise 
mimetic and a better therapeutic approach to treat muscle insulin resistance and 
T2D remains to be addressed.  
 
1.14  Summary 
 
Type 2 diabetes is one of the leading threats to human health [1, 2]. The early 
pathogenesis of metabolic diseases like T2D and obesity is associated with skeletal 
muscle insulin resistance [11, 13, 22]. Coordinated downregulation of the 
expression of a set of metabolic and mitochondrial genes that mediates muscle 
mitochondrial and oxidative dysfunction is thought to contribute to the 
development of insulin resistance [4, 5]. Exercise coupled with diet is considered a 
cornerstone in the treatment of obesity and T2D [67]. It induces phenotypic 
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adaptations in skeletal muscle that correct this faulty gene expression, normalize 
mitochondrial function and muscle metabolism, and can ameliorate muscle insulin 
resistance [21, 73, 74]. Previous studies have found that class IIa HDACs are 
inactivated in skeletal muscle during exercise and this is associated with the 
enhanced expression of various metabolic genes favouring oxidative metabolism in 
skeletal muscle [20]. In considering the class IIa HDACs as potential targets involved 
in exercise signalling and adaptations, it can be proposed that pharmacological 
inhibition of class IIa HDACs could be an effective exercise mimetic and a valuable 
treatment strategy to combat muscle insulin resistance in T2D. 
 
1.15       Research Objectives 
 
1.15.1   Major Aim and Hypothesis  
 
The major aim of this project is to investigate whether HDIs mimic aspects of 
exercise by regulating skeletal muscle and whole body metabolic parameters with 
therapeutic potential to treat skeletal muscle insulin resistance in metabolic 
diseases such as obesity and T2D. The major hypothesis of this project is that HDIs 
could enhance skeletal muscle oxidative capacity and metabolism and therefore, 
have therapeutic potential to enhance muscle insulin sensitivity in metabolic 
diseases, which would be maximised by class IIa HDIs analogues. 
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1.15.2   Specific Aims and Hypotheses 
 
The major hypothesis and aim of this project are divided into the following specific 
aims and hypotheses. 
Aim 1: To establish an effective HDACi strategy by screening for broad spectrum 
HDIs that regulate skeletal muscle metabolic gene expression, mitochondrial 
function and metabolism in L6 myotubes. 
Hypothesis 1: Broad spectrum HDIs will enhance skeletal muscle oxidative 
metabolism in vitro, and screening will identify a broad spectrum HDI that induces 
the largest improvement in metabolic parameters in vitro, to examine their efficacy 
in in vivo experiments. 
 
Aim 2: To investigate the effect of broad spectrum HDI on  
a) skeletal muscle metabolic parameters such as histone acetylation, metabolic 
and mitochondrial gene expression, lipid levels and glucose metabolism in 
diet-induced obese C57Bl6 mice;  
b) whole body metabolic parameters such as the time to fatigue during 
incremental exercise performance, body composition, energy expenditure 
and whole body insulin action and glucose metabolism in diet-induced obese 
C57Bl6 mice. 
Hypothesis 2: Broad spectrum HDI will act as an effective exercise mimetic to 
enhance skeletal muscle metabolic adaptations, and normalize whole body 
metabolism in response to high fat feeding induced insulin resistance in vivo. 
 54 
 
Aim 3: To determine whether a class IIa specific HDI regulates skeletal muscle 
metabolic gene expression, mitochondrial function and metabolism in L6 myotubes 
and to establish what key components of the canonical cap-linker-chelator HDI 
structure are important for this response.  
Hypothesis 3:  Novel class IIa HDI analogues will enhance skeletal muscle oxidative 
metabolism in vitro. 
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CHAPTER TWO 
The effect of broad spectrum HDAC inhibitors on metabolic 
parameters in vitro 
 
2.1 Introduction 
 
Class IIa HDACs have been found to contribute to the regulation of skeletal muscle 
adaptations to exercise, by repressing the MEF2 transcription factor [172], as 
detailed in Section 1.8. The MEF2 transcription factor, which is highly expressed in 
oxidative tissues including skeletal muscle, contains a conserved binding region for 
the promoters of various exercise responsive metabolic genes such as PGC-ϭɲ [154], 
GLUT-4 [163], UCP-3 [164], CPT-1 [165] and various cytochrome c oxidase subunits 
[166], and appears to be essential for the transcription of metabolic genes. 
 
In the basal state, class IIa HDACs physically interact with the MEF2 transcription 
factor and regulate chromatin structure via deacetylation of lysine residues within 
the chromatin-forming histone proteins found around metabolic gene promoters, 
which restricts the access of transcriptional activators to DNA. This inhibits MEF2-
dependent transcription of metabolic genes [20, 128]. During exercise, various class 
IIa HDAC ŬŝŶĂƐĞƐŝŶĐůƵĚŝŶŐDW<ĂŶĚĂD<ʳʳĂƌĞĂĐƚŝǀĂƚĞĚĂŶĚƉŚŽƉƐŚŽƌǇůĂƚĞϭϰ-3-
3 binding sites in these HDACs to trigger their nuclear export [172]. Following class 
IIa HDACs dissociation, MEF2 interacts with PGC-ϭɲ͕ Ă ŵĂƐƚĞƌ ƚƌĂŶƐĐƌŝƉƚŝŽŶĂů
regulator of metabolic and mitochondrial genes, to recruit coactivators with 
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intrinsic HAT activity. This acetylates histones surrounding MEF2 binding sites at 
metabolic gene promoter regions and enhances MEF2-mediated transcription of 
metabolic genes [170]. Emerging evidence has shown that class IIa HDACs 
contribute to the regulation of various metabolic genes involved in adaptive skeletal 
muscle remodelling towards a more oxidative phenotype in response to exercise, 
ƐƵďƐƚƌĂƚĞ ŽǆŝĚĂƚŝŽŶ ĂŶĚ ĞŶĞƌŐǇ ƉƌŽĚƵĐƚŝŽŶ ŝŶ ŚĞĂƌƚ ;ƐƵĐŚ ĂƐ W'ϭɲ͕ carnitine 
palmitoyltransferase 1 (CPT-1), medium chain acyl-CoA dehydrogenase (MCAD), 
hexokinase II (HKII), glycogen phosphorylase, and ATP synthase), hepatic glucose 
ƉƌŽĚƵĐƚŝŽŶ ĂŶĚ ƉĂŶĐƌĞĂƚŝĐ ɴ-cell development [96, 170, 254, 268]. Therefore, we 
hypothesize that HDAC inhibition (HDACi) could be a potential exercise mimetic and 
treatment for metabolic diseases.  
 
A number of HDIs, belonging to different structural classes, are now currently 
available. A large number of broad spectrum HDIs are undergoing clinical trials and 
some are FDA approved anti-cancer agents [223]. The majority of the currently used 
HDIs abolish HDAC enzymatic activity by interacting with the zinc-containing 
catalytic core, chelating its zinc ion and hindering the access to the HDAC active site. 
They may also target HDAC:protein interactions that are independent of HDAC 
deacetylase activity [103]. Classical broad spectrum HDIs have high affinity for all 
isoforms, particularly class I, but exhibit relatively low affinity for class IIa HDACs 
[90]. All HDACs are the part of large multiprotein transcriptional repressor 
complexes. The role of different HDAC isoforms varies in development and 
metabolism of various tissues and thus, inhibition of individual isoforms results in 
specific phenotypes. Hence, systemic inhibition of HDACs by the use of non-
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selective broad spectrum HDIs, targeting all HDAC isoforms, could alter large gene 
expression subsets, which could be associated with non-specific and unwanted side-
effects [90]. Despite this, broad spectrum HDIs have proven useful in vivo by their 
selective ability to both block and enhance disease associated expression of specific 
genes [90, 222].  
 
A wide range of studies have established that HDACi by broad spectrum HDIs can 
regulate various physiological processes similar to exercise including reduced 
adiposity due to increased oxygen consumption and  energy expenditure, increased 
insulin sensitivity, obesity-resistance and a general protection against resistance to 
oxidative stress [227, 234-237]. Additionally, HDACi is promising in lifespan 
extension, the restoration of memory, the enhancement of cognitive function, the 
treatment of central nervous system disorders and the control of pathological 
cardiac remodelling and inflammatory diseases [218, 220, 232-234, 273]. Growing 
evidence has highlighted the potential therapeutic impact of HDIs in metabolic 
diseases such as insulin resistance and type 2 diabetes by enhancing ɴ-cell 
development, function and enhanced insulin secretion [219, 258]. 
 
Very little is known about the therapeutic impact of HDIs to treat muscle metabolic 
dysfunction. Studies have shown that hydroxamic acid based broad spectrum HDIs 
could modulate glucose metabolism in vitro by inducing GLUT-4 gene expression 
and translocation to the plasma membrane, thereby improving basal and insulin-
stimulated glucose uptake [131, 248]. Broad spectrum HDIs also restored PGC1-ɲ
expression in vitro, a key regulator of mitochondrial biogenesis and function, 
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following long chain saturated fatty acid exposure [249]. Thus HDACi could increase 
the expression of PGC1-ɲƚĂƌŐeted muscle mitochondrial genes, with the potential 
to normalize muscle insulin resistance in obesity and T2D. The role of HDIs as 
modulators of energy metabolism and thus their therapeutic impact in metabolic 
diseases is yet to be explored. 
 
Further studies are needed to characterize the remedial effect of broad spectrum 
HDIs in improving impaired muscle metabolism in metabolic diseases such as insulin 
resistance and type 2 diabetes (T2D). Therefore, the aim of this study was to 
establish an effective HDACi strategy by screening for broad spectrum HDIs that 
regulate skeletal muscle metabolic gene expression, mitochondrial function and 
metabolism in L6 myotubes. In this study we used the commercially available broad 
spectrum HDIs, Scriptaid (SCR) and Trichostatin-A (TSA) (Fig 2.1). They belong to the 
hydroxamic acid class of derivatives that have a five-carbon linker, a bulky cap 
region on one side and hydroxamic acid, zinc binding group (ZBG) or chelator, on 
the other side [291]. SCR inhibits both class I and class II HDACs with similar 
potency, whereas TSA exhibits greater potency towards class I HDACs [291]. 
Considering in vitro findings showing that SCR has the capacity to modulate glucose 
metabolism by increasing GLUT-4 expression and TSA can enhance muscle PGC1-ɲ
expression that could induce muscle mitochondrial gene expression and function, 
we hypothesized that broad spectrum HDIs may enhance skeletal muscle oxidative 
metabolism via improved metabolic gene expression, mitochondrial function, and 
oxidative capacity in vitro, and screening these parameters will identify a broad 
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spectrum HDI that induces the largest improvement in metabolic parameters in 
vitro. 
 
Commercial Broad Spectrum 
HDAC inhibitors 
Structure 
 
Scriptaid (SCR) 
 
Molecular Formula:   C18H18N2O4 
Chemical Name:   6-(1,3-Dioxo-
1H,3H-benzo[de]isoquinolin-2-yl)- 
N-hydroxyhexanamide 
 
 
Trichostatin A  (TSA) 
 
Molecular Formula:   C17H22N2O3  
Chemical Name:   7-[4- 
(dimethylamino)phenyl]-N-
hydroxy-4,6R-dimethyl-7-oxo-2E, 
4E-heptadienamide  
 
 
 
Fig 2.1: Broad spectrum HDIs used in vitro 
 
ZBG Linker Cap 
ZBG LinkerCap 
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2.2  Methods 
 
2.2.1  Cell culture - L6 myoblast culture and differentiation 
L6 myoblasts, a rat (Rattus norvegicus deposited as Rattus sp.) myoblast cell line, 
were maintained as a sub-confluent culture in growth media (GM)-Alpha Minimum 
ƐƐĞŶƚŝĂůDĞĚŝƵŵ ;ɲDDͿ ;/ŶǀŝƚƌŽŐĞŶͿ ƐƵƉƉůĞŵĞŶƚĞĚǁŝƚŚϭϬй ;ǀͬǀͿ ĨĞƚĂů ďŽǀŝŶĞ
serum (FBS; Invitrogen) and 1% antibiotic-antimycotic (Invitrogen) at 37°C in a 
humidified 5% CO2 incubator. Following the attainment of 80-90% confluence, 
myoblasts were washed twice with phosphate buffered saline (PBS), pH 7.4 (Sigma) 
and detached by the subsequent addition of trypsin-EDTA-PBS (TEP) (Invitrogen) 
and incubation for 2 minutes. Normal growth media was added to stop trypsin 
reaction and cells were centrifuged at 10,000 RPM for 5 minutes.  
 
The pellet was gently resuspended in growth media before being seeded in either 
24-well XF24 Seahorse cell-culture plates (Seahorse Bioscience) (for seahorse 
assay), 6-well plate (for immunoblotting or gene expression analysis) or further 
passaged at a ratio of 1:20 (to maintain sub-culture). Myoblasts were grown to 
confluence prior to differentiation. 
 
Differentiation of L6 myoblasts was induced by the addition of differentiation media 
(DM)-ůƉŚĂDŝŶŝŵƵŵƐƐĞŶƚŝĂůDĞĚŝƵŵ;ɲDEM) supplemented with 2% (v/v) horse 
serum (HS; Invitrogen) and 1% antibiotic-antimycotic (Invitrogen). This media was 
replenished every 2 days. Spontaneous fusion of myoblasts to form multinucleated 
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myotubes was observed after two days incubation in differentiation media. 
Experiments were carried out with 3-5 days post differentiated myotubes. 
 
2.2.2  Cell culture treatment with HDAC inhibitors (HDIs) for histone acetylation 
activity (Immunoblotting) 
 
Concentration-dependent regulation of histone (H3) acetylation by HDIs was 
determined by administering each compound over a concentration range of 0.1 to 
10 μM. Histone (H3) acetylation is a proxy measure of HDI activity.  L6 myoblasts 
were cultured in 6-well plates for this experiment as mentioned in section 2.1. Five 
days post differentiated L6 myotubes were treated with 0 [vehicle (VEH)], 0.1, 1, 10 
μM concentrations of broad spectrum HDIs either SCR (Santa Cruz Biotechnology, 
California) or Trichostatin-A (TSA, Sigma Life Sciences) for 1 hour. Differentiation 
media was refreshed 2 hours before starting the treatments. HDIs stocks were 
prepared as 1mM concentration in 100% DMSO (VEH). All treatments were made to 
a constant volume in VEH and differentiation media for each dose. 
 
2.2.3  Protein extraction for immunoblotting studies 
After the HDI treatment, cells were harvested immediately for protein extraction. 
Cells were washed with cold PBS and solubilised in 250 μl cold protein lysis buffer 
(50mM Tris pH 7.5, 1mM EDTA, 1mM EGTA, 10% glycerol, 1% Triton X-100, 50mM 
NaF, 5mM sodium pyrophosphate, 1mM Na3VO4; 1mM DTT, 1X protease inhibitor 
cocktail (Sigma, St Louis, MD, USA); H2O) on ice and rapidly frozen in liquid nitrogen. 
Later, thawed cell lysates were homogenised by using hand-held homogenizer and 
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spun in a centrifuge at 12000 RPM for 10 minutes at 4°C to remove cellular debris. 
The extracted supernatant was stored for later analysis at -80°C. The total protein 
concentration in the lysates was determined using the bicinchoninic acid (BCA) total 
protein kit as per manufacturer’s instructions (Pierce). 
 
2.2.4  Immunoblotting 
Fifty micrograms of protein lysates were prepared in lysis buffer with 4X loading 
buffer (4X SDS reducing buffer, Table 1) keeping the final volume and final 
concentration constant for each sample. Protein samples were incubated at 37°C 
for 5 min before being loaded onto a 12.5% (w/v) acrylamide gel and separated 
using SDS-PAGE (180 V, ~45 min) (Table 2.1). Eight microlitres of molecular weight 
marker (PageRuler™ Prestained Protein Ladder; Fermentas) was run alongside the 
protein samples. Proteins were transferred onto polyvinylidine diflouride (PVDF) 
membranes using 1 × Transfer buffer (Table 2.1) at 4°C, 100 V for 100 min. PVDF 
membranes were blocked for 1 hr in blocking buffer (Table 2.1) on a rocking 
platform at room temperature (RT). The membranes were then exposed to the 
primary antibodies for histone 3 (H3) when acetylated at lysine 9 (aH3K9) (Sigma-
Aldrich) (1 in 500 dilution) and ɲ-Tubulin (Sigma-Aldrich) (1 in 1000 dilution as a 
loading control) diluted in 5 mL of 1xTBST and 0.2% Sodium azide (NaN3)  overnight 
at 4°C on a continuous rotator. Membranes were washed with 1X TBST buffer (4 x 5 
minutes) at RT and exposed to appropriate anti-species horseradish peroxidase 
(HRP) conjugated secondary antibodies at a concentration of 1 in 10,000 in 1×TBST, 
for 1 hr at RT, before final washes. Protein bands were detected using ECL 
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Chemiluminescent Substrate Reagent Kit (Invitrogen) and visualized on a Chemidoc 
XRS System and Analysis Software (Bio-Rad Laboratories, Inc.).  
 
 
Table 2.1: Buffer recipes used in immunoblotting 
Blocking buffer 1% (w/v) bovine serum albumin (BSA) in 1x Tris-
buffered saline and 0.05% Tween (TBST) 
1X Tris-buffered saline and 
0.05% Tween (TBST) buffer 
10 mM Tris pH 7.4; 50 mM NaCl; 0.05% (v/v) 
Tween dissolved in milli Q H2O 
1X SDS PAGE running buffer 24.8 mM Tris (Invitrogen); 0.2 M Glycine (MP 
Biochemicals); 3.5 M SDS (Invitrogen) 
1X Transfer buffer  25 M Tris; 1.92 M Glycine; 20 % (v/v) Methanol  
For 100 ml of 4X SDS reducing 
buffer 
249.3 mM Tris (pH to 6.8); 277.4 mM SDS; 33.3% 
glycerol; 3.6 M bromophenol blue; 408.4 mM 
DTT  
 
 
2.2.5  Cell culture treatment for time course gene expression analysis 
The time course effect of broad spectrum HDIs on the expression of various 
metabolic and mitochondrial genes was investigated for this experiment. L6 cells 
were cultured in 6-well plates as mentioned in section 2.2.1. Five days post 
differentiated myotubes were treated with 1 μM concentration of broad spectrum 
HDIs – SCR or TSA for 1 hour. Following 1 hour treatment period, media was 
replaced by normal differentiation media before mRNA was being extracted at 
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various time points post treatment (0 hr, 1hr, 2hrs, 4hrs, 8hrs, 16hrs and 24 hrs). 
Control cells were incubated with an equivalent volume of the VEH. HDIs stocks 
were prepared as 1mM concentration in 100% DMSO. 
 
2.2.6  mRNA extraction  
After 1 hour of treatment, total mRNA was extracted at various time points (0 hr, 
1hr, 2hrs, 4hrs, 8hrs, 16hrs and 24 hrs). Cells were washed with PBS, harvested for 
total mRNA extraction using the RNeasy® Mini Kit (Qiagen). Briefly, cells in each well 
were disrupted by adding 350 ʅůŽĨZ>dďƵĨĨĞƌ ĨŽůůŽǁĞĚďǇƐĐƌĂƉŝŶŐĂŶĚƉŝƉĞƚƚŝŶŐ
the lysate into a microcentrifuge tube. Lysates were either stored at -80 ºC until 
analysis or further proceeded by vortexing. An equal volume (350 ʅů) of 70% 
ethanol was added and mixed by pipetting before transferring the sample to an 
RNeasy spin column and centrifuging for 15 sĞĐĂƚчϭϬ͕ϬϬϬƌƉŵ͘dŚĞĨůŽǁ-through 
ǁĂƐ ĚŝƐĐĂƌĚĞĚ͘ ϳϬϬ ʅů ŽĨ ďƵĨĨĞƌ ZtϭǁĂƐ ĂĚĚĞĚ ĂŶĚ ĐĞŶƚƌŝĨƵŐĞĚ ĨŽƌ ϭϱ ƐĞĐ Ăƚ ч
ϭϬ͕ϬϬϬ ƌƉŵ ƚŽǁĂƐŚ ƚŚĞ ƐƉŝŶ ĐŽůƵŵŶŵĞŵďƌĂŶĞ͘ dŚĞŶ ϱϬϬ ʅů ŽĨ ďƵĨĨĞƌ ZWǁĂƐ
ĂĚĚĞĚ ĂŶĚ ĐĞŶƚƌŝĨƵŐĞĚ ĨŽƌ ϭϱ ƐĞĐ Ăƚ ч ϭϬ͕ϬϬϬ ƌƉŵ͘ dŚŝƐ ƐƚĞƉǁĂƐ ƌĞpeated again 
ǁŝƚŚĐĞŶƚƌŝĨƵŐŝŶŐĨŽƌϮŵŝŶĂƚчϭϬ͕ϬϬϬƌƉŵ͘dŚĞĨůŽǁ-through was discarded at each 
step. Finally, the RNeasy spin column was placed in a new microcentrifuge tube and 
RNA was eluted by adding 30-ϱϬʅůŽĨZEĂƐĞ-free water and centrifuging for 1 min 
ĂƚчϭϬ͕ϬϬϬƌƉŵ͘ 
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2.2.7  cDNA synthesis and quantitation 
Complementary DNA (cDNA) was synthesised using the SuperScript™ III 
transcription system (Invitrogen). ϭϮʅůƌĞĂĐƚŝŽŶŵŝǆƚƵƌĞǁĂƐƉƌĞƉĂƌĞĚĐŽŶƚĂŝŶŝŶŐ
~0.2-ϭ͘ϱʅŐŽĨZE͕Ϭ͘ϱʅŐKůŝŐŽ;ĚdͿĂŶĚ0.83 mM dNTP and incubated at 65ºC for 5 
min in a thermocycler (GeneAmp® PCR System 9700; Perkin Elmer (PE) Applied 
BiosystemsͿĂŶĚƚŚĞŶƉůĂĐĞĚŽŶ ŝĐĞĨŽƌΕϮŵŝŶ͘&ŽůůŽǁŝŶŐƚŚŝƐƐƚĞƉ͕ϴʅůŽĨŵĂƐƚĞƌ
mix containing 4 ʅůŽĨ5X RT buffer, 10 mM DTT, 40 U RNaseOUT, 50 U Superscript 
III Reverse Transcriptase and 0.75 ʅůNuclease free water (NFW) was added to the 
ƌĞĂĐƚŝŽŶŵŝǆƚƵƌĞǁŝƚŚƚŚĞĨŝŶĂůǀŽůƵŵĞŽĨϮϬʅůĂŶĚ ŝŶĐƵďĂƚĞĚĂƚϱϬΣĨŽƌϱϬŵŝŶ͕
85°C for 5 min and 4°C for 5 min using a thermocycler. Samples were stored at -
20oC and diluted at a ratio of 1:10 with NFW prior to cDNA quantitation and real-
time PCR. 
 
 cDNA was quantified by OliGreen assay (Quant-iTTM  OliGreen® ssDNA Assay Kit; 
Invitrogen) as per manufacturer’s instructions. Briefly, 20 ʅůŽĨĞĂĐŚoligo standard 
(30, 15, 12.5, 10, 7.5, 5, 1.25, 0 ʅŐͬŵůͿƉĞƌƉůĂƚĞǁĂƐƉƌĞƉĂƌĞĚŝŶϭǆd͘ϱʅůŽĨĞĂĐŚ
ƐƚĂŶĚĂƌĚĂŶĚƐĂŵƉůĞǁĂƐůŽĂĚĞĚŝŶƚƌŝƉůŝĐĂƚĞƚŽĂďůĂĐŬ͕ϵϲǁĞůůĨůƵŽƌŽƉůĂƚĞ͘ϵϱʅůŽĨ
ϭǆd ǁĂƐ ƚŚĞŶ ĂĚĚĞĚ ƚŽ ĞĂĐŚ ǁĞůů ĨŽůůŽǁĞĚ ďǇ ƚŚĞ ĂĚĚŝƚŝŽŶ ŽĨ ϭϬϬ ʅů ϭǆ ssDNA 
reagent to each well and incubation for 5 min at RT (away from light). Fluorescence 
intensity was measured (excitation 485 nm, emission 538 nm) on a FlexStation II384 
machine (Molecular Devices). 
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2.2.8  Quantitation of gene expression by SYBR Green Real-time PCR 
Expression levels of various metabolic and mitochondrial genes were quantified 
using the FastStart Universal SYBR Green Master (ROX; Roche Applied-Science) on 
the MX3005P™ Multiplex Quantitative PCR (QPCR) system (Stratagene). The total 
reaĐƚŝŽŶǀŽůƵŵĞŽĨϮϱʅůĐŽŶƐŝƐƚĞĚŽĨϭϮ͘ϱʅůZKyŵĂƐƚĞƌŵŝǆ͕Ϯ͘ϱʅůĞĂĐŚŽĨϭʅD
ĨŽƌǁĂƌĚĂŶĚƌĞǀĞƌƐĞƉƌŝŵĞƌĨŽƌŽŶĞŐĞŶĞ͕ϮʅůŽĨϭ͗ϭϬĚŝůƵƚĞĚĐEƚĞŵƉůĂƚĞĂŶĚ
ϱ͘ϱʅůE&t͘dŚĞƋWZƚŚĞƌŵŽĐǇĐůĞƌĐŽŶĚŝƚŝŽŶƐǁĞƌĞϭϬŵŝŶĂƚϵϱΣĨŽƌϭĐǇĐůĞĂŶĚ
then 30 sec at 95°C followed by 1 min at 60°C for 40 cycles. The gene expression 
levels of each sample were analysed in duplicate and the average gene expression 
for each sample was normalised to its cDNA concentration. Data is represented as 
the percentage of VEH taking VEH as 100%. Due to the high variation in the first 
hour of gene expression, data after the first hour of time course was considered for 
statistical interpretation. The metabolic and mitochondrial genes analysed in vitro 
and their functions are listed in appendix Table A2.1. The primer sets employed 
during the real-time PCR studies are listed in Table 2.2. 
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Table 2.2: Real-time PCR rat primer sequences  
Rat CPT-ϭɴ Forward Primer 5'- TCA TGT ATC GCC GCA AAC T -3’ 
 
Reverse Primer 5'- CGT GCT TCT GCC CAC TCT A -3’ 
 
Rat HSL  Forward Primer 5'- TCA GAC CAG AAG GCA TTG -3’ 
 
Reverse Primer 5'- CGC ATA GAC TCC GTA AGG -3’ 
 
Rat Myogenin Forward Primer 5'- AGC CGG TGG TAC CCA GTG A -3’ 
 
Reverse Primer 5'- GAC CAA ACT CCA GTG CAT TGC -3’ 
 
Rat PGC-ϭɲ Forward Primer 5'- ATA CAC AAC CGC AGT CGC AAC -3’ 
 
Reverse Primer 5'- GCA GTT CCA GAG AGT TCC ACA C -3’ 
 
ZĂƚWWZɷ
(delta) 
Forward Primer 5'- CTC AGG CTT CCA CTA CGG -3’ 
 
Reverse Primer 5'- ACT TGT TGC GGT TCT TCT TC -3’ 
 
Rat SCD 1  Forward Primer 5'- ACA TGC TCC AAG AGA TCT CCA G -3’ 
 
Reverse Primer 5'- GTA CTC CAG CTT GGG CGG -3’ 
 
Rat TFAM Forward Primer 5'- GAA ACG CCT AAA GAA GAA AGC -3’ 
 
Reverse Primer 5'- TCC AAG CCT GAT TTA CAA GC -3’ 
 
Rat PPAR-alpha Forward Primer 5'- CGG GTC ATA CTC GCA GGA AAG -3’ 
 
Reverse Primer 5'- TGG CAG CAG TGG AAG AAT CG -3’ 
 
Rat SDH-b Forward Primer 5'- CTA CCG CTG CCA CAC CAT C -3’ 
 
Reverse Primer 5'- GCC AAT GCC CGC TTC TCC -3’ 
 
Rat ATP-5d Forward Primer 5'- ATG TGC CTA CGC TGA CTG -3’ 
 
Reverse Primer 5'- GTT GTG GTG CCA TCT TCC -3’ 
 
Rat COX-7a 
 
Forward Primer 5'- CTCTTCCAGGCAGACAAC -3’ 
 
Reverse Primer 5'- CCAAGCAGTATAAACAGTAGG -3’ 
 
 
All primers were designed in-house using the Beacon Primer Designer program 
software and synthesised by Gene Works (Adelaide, Australia). Some primers were 
already optimized before and were already in use in the laboratory. The ones which 
were specifically designed and ordered were optimized for their efficiency before 
use (Appendix Fig. A2.1) 
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2.2.9  Cellular bioenergetics and mitochondrial function assays (Seahorse XF-24 
analyser) 
Cellular bioenergetics and mitochondrial function analyses were performed using 
the Seahorse XF24 Extracellular Flux Analyser (Seahorse Bioscience, Billerica, USA). 
Cellular mitochondria consume oxygen to generate ATP, heat and other metabolic 
end products into the extracellular environment. This is known as oxidative 
metabolism or aerobic respiration, one of the major energy yielding pathways of 
the cell. The XF analyser rapidly measures, in real time, the extracellular flux 
changes of oxygen in the media surrounding adherent cells as oxygen consumption 
rate (OCR), an indicator of mitochondrial respiration. This is based upon the 
excitation of a fluorophore (fluorescent biosensors) for O2 embedded in a sensor 
cartridge that lowers down to create transient micro-chamber in specialized 
microplates while in the measurement position during each cycle. After each cycle, 
the sensor cartridge rises allowing the cell medium to re-oxygenate through 
mechanical mixing. This restores the media oxygenation to baseline and enables 
repeated measurements of OCR by cells over time. 
 
2.2.9.1  Cell seeding and Cell culture treatment for mitochondrial function assay 
A 7-day protocol was developed for the in vitro assessment of HDIs effect on 
mitochondrial function. On day 1, L6 myoblasts were seeded into 24 well Seahorse 
V7 plates at a density of 25K cells/well in 100ul of growth media (as mentioned in 
section 2.1), leaving the temperature correction wells empty (Fig. 2.2) Then the 
plate was incubated and cells were allowed to adhere for 1 hour. After which 400 μl 
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of growth media was slowly added to each well, bringing the total volume of media 
to 500 μl per well. 
 
 
Figure 2.2: 24-well Seahorse V7 Cell Culture Microplate.  
Black shaded wells: temperature correction wells 
 
 
On day 2, growth media was replaced with the differentiation media and L6 
myoblasts were differentiated to myotubes for five days (day 2 to day 6). On day 5 
and 6, myotubes were treated with 0 μM (VEH), 0.1μM, 1μM concentrations of 
broad spectrum HDIs - SCR or TSA, twice per day, for 1 hour. This was designed to 
replicate the pulsative nature of repeated bouts of exercise. HDIs stocks were 
prepared as 1mM concentration in 100% DMSO. The following day (day 7), 16 hours 
after the final treatment, myotubes were assayed for the mitochondrial functional 
analyses.  
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2.2.9.2  Preparation of the sensor cartridge, XF24 instrument and the running 
media a day prior to the mitochondrial function assay 
 
To equilibrate a Seahorse sensor cartridge, 1ml of Seahorse Bioscience XF24 
Calibrant (pH 7.4) was added to each well of the sensor cartridge including the 
temperature control wells. The cartridge was placed in non-CO2 incubator at 370 
overnight. The Seahorse machine was left on for overnight to allow the instrument 
temperature to stabilize at 37 oC.  
 
To prepare the unbuffered DMEM used in the preparation of running media, 
Dulbecco’s Modified Eagle’s Medium Base (DMEM base, 8.3g/L, Sigma D5030-1L) 
was dissolved in 500 mL dH2O. Separately, 1.85g NaCl (Sigma S3014) was dissolved 
in 500 mL dH2O. Both NaCl solution and DMEM Base solution were combined and 
15mg of Phenol Red was added. The resulting unbuffered DMEM was filter 
sterilized and stored at 4 oC.  
 
Running media was prepared by mixing with 50 ml of unbuffered DMEM with 500μl 
of 2.5M glucose (45% glucose, Sigma G8270), 500μl of 100X (100mM) Glutamax-1 
(Gibco 35050-61) and 500μl 100mM of Sodium Pyruvate (Sigma S8636). Media was 
warmed to 37 oC and pH was adjusted to 7.4 by adding ~12 μl of 5M NaOH to the 
50ml of running media. After filter sterilizing, the media was stored overnight at 4 
oC. 
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2.2.9.3  Cell plate preparation for mitochondrial function assay 
Prior to assay, cells were equilibrated with running media warmed at 37 oC. This 
involved washing the cells twice with 500 μl of assay running media, before the final 
addition of 600 μl of running media. While aspirating the media from each well 
during the washing, ~50-75 μl of media was left behind so as to avoid disturbing the 
cell layer. And this led to the final volume of ~675 μl in each well. Then the cell plate 
was placed in non-CO2 incubator at 37 0C for 60 min until ready to be loaded in 
XF24 instrument. 
 
2.2.9.4  Loading the sensor cartridge with compounds 
Each sensor cartridge is equipped with four compound delivery ports (designated as 
Port A, Port B, Port C and Port D) per well for injecting testing compounds into wells 
during an assay. The ports (A, B & C) of each well (including the temperature control 
wells) were loaded with 75 μl of the compounds (or mitochondrial inhibitors), 
known to modulate the mitochondrial function (Fig 2.3), prior to the calibration of 
the sensor cartridge. These compounds were ATP synthase inhibitor oligomycin, the 
proton ionophore carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP) and 
the complex III inhibitor antimycin A respectively. 
 
2.2.9.5  Mitochondrial function assay 
The assay protocol consisted of repeated cycles of 4 min mix, 2min wait and 2 min 
measurement periods, with oxygen consumption rate (OCR) measured through 
each measurement period by excitation of fluorophores for O2. OCR was reported 
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in the unit of pico-moles per minute (pmoles/minute). The sensor cartridge and 
calibration plate were first loaded for calibration. Following completion of the 
calibration, the calibration plate was replaced with the cell culture plate (that had 
been placed in non-CO2 incubator at 37 0C). Three baseline (basal) rates of OCR 
were measured after three cycles before the sequential injection of the oligomycin, 
&WĂŶĚĂŶƚŝŵǇĐŝŶ͕ĂůůƚŽĂĨŝŶĂůĐŽŶĐĞŶƚƌĂƚŝŽŶŽĨϭʅD͕ďǇƚŚĞ^ĞĂŚŽƌƐĞŝŶũĞĐƚŝŽŶ
system. Three mix, wait and measurement cycles separated each compound 
injection.  
 
Using these modulators of mitochondrial function, we measured the responses of 
HDIs on OCR during the different bioenergetic and mitochondrial parameters, 
including basal level of oxygen consumption (basal respiration), the amount of 
oxygen consumption linked to ATP turnover rate (ATP-coupled respiration), non-
ATP-linked oxygen consumption i.e. proton leak (uncoupled respiration), maximal 
and spare respiratory capacity and the non-mitochondrial oxygen (O2) consumption 
(Fig 2.3). All treatment conditions were analysed as six to seven replicates, over at 
least one or two independent experiments and data was pooled to give average 
values for each treatment. Data is represented as the percentage of VEH where VEH 
as 100%. 
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Figure 2.3: (A) Effect of mitochondrial modulators, used during mitochondrial 
function assays, on the Electron Transport chain (ETC) and (B) Graphical 
representation of oxygen consumption rate (OCR) measured throughout 
mitochondrial function assays, as measured using the Seahorse analyzer. The 
mitochondrial compounds used for mitochondrial function analysis affect the ETC in 
specific areas and enable to detect several parameters of mitochondrial function; 
Oligomycin inhibits ATP synthase (complex V) and prevents the high proton gradient 
build up to flow back through the inner mitochondrial membrane to produce ATP. 
This stops the electron flow through the ETC and stops the cellular oxygen 
consumption resulting in concomitant decrease in OCR and increased proton leak. 
Thus, measures ATP-linked respiration and is able to differentiate it from the proton 
leak (uncoupled respiration). FCCP, a protonphore, removes the proton gradient 
from the electron transport chain (ETC) by transporting H+ across the inner 
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mitochondrial membrane and allows the continuous flow of electrons through 
complex IV and hence cellular oxygen consumption resumption. Thus, maximal 
respiratory capacity can be measured as the proton gradient is no longer a limiting 
factor of respiration. Antimycin inhibits electron transfer through the cytochrome b-
c1 complex of ETC (complex III) and thus prevents oxygen consumption at 
cytochrome c oxidase and mitochondrial respiration. However, antimycin, Q-cycle 
inhibitor, binds at the Qi site of complex III and blocks the electron transfer from 
semiquinone at QO-site of complex III resulting in electron accumulation. Thich 
increases the probability of its reaction with molecular oxygen (premature electron 
leakage to oxygen) to generate ROS. The remaining Oxygen consumption measured 
by antimycin represents primarily the non-mitochondrial O2 consumption due to 
cytosolic oxidase enzymes and O2 consumed by the QO -site of complex III, in other 
words, the capacity for ROS production.  
 
(B) Following the basal respiration rate measurement of cells, the effect on OCR 
after oligomycin, FCCP and antimycin addition was recorded and various other 
mitochondrial function parameters were calculated such as: proton leak (uncoupled 
respiration), ATP turnover (basal respiration minus proton leak), maximal 
respiratory capacity, spare respiratory capacity (maximal respiratory capacity minus 
basal respiration), true basal respiration (basal respiration minus non-mitochondrial 
O2 consumption), true uncoupled respiration (uncoupled respiration minus non-
mitochondrial O2 consumption) etc. (Figure provided by Dr Sean McGee, Metabolic 
Research Unit). 
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2.2.10  Statistical analysis 
Data is reported as mean ± standard error of the mean. Statistical analysis was 
performed using software package SPSS (PASW Statistics 18) and Minitab. Normal 
distribution of data across the groups was checked using Kolmogorov-Smirnov test 
(KS-test). Analysis of variance between groups (or testing for mean differences 
between groups) for normally distributed data was performed by using appropriate 
parametric tests such as independent samples T-test (including Levene’s Test for 
Equality of Variance), one way ANOVA with appropriate post hoc tests, two way 
ANOVA and two way ANOVA with repeated measurements with a Tukey Post hoc 
test. Analysis of variance between groups (or testing for mean differences between 
groups) for data not normally distributed was performed by using appropriate 
nonparametric tests such as independent samples Kruskal-Wallis Test and Mann-
Whitney U test. The p-value less than 0.05 denoted the presence of a statistically 
significant difference. 
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2.3  Results 
 
2.3.1  SCR and TSA increased global H3 (K9) acetylation in L6 myotubes in vitro 
 
HDIs are known to regulate HDACs enzymatic activity and regulate histone 
acetylation levels [297]. Therefore, we first determined the concentrations of broad 
spectrum HDIs - SCR & TSA, that can induce global histone acetylation i.e. 
acetylation of lysine 9 on histone 3 (K9 H3), in vitro. Following 1 hr of exposure, 
both SCR and TSA increased global H3 (K9) acetylation at 0.1 μM and 1 μM, with no 
further increase at 10 μM in L6 myotubes (Fig. 2.4). This confirms that these 
commercially available HDIs can induce chromatin remodelling by regulating the 
acetylation status of histones and result in the increased global H3 (K9) acetylation. 
 
 
 
Figure 2.4: Representative immunoblots of Histone 3-lysine 9 (K9 H3) acetylation 
at 0, 0.1, 1 and 10 μM concentrations of SCR and TSA in L6 myotubes. 
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2.3.2  TSA and SCR increased metabolic and mitochondrial gene expression in L6 
myotubes 
 
Alterations in the global histone 3 acetylation levels are associated with  
transcriptional regulation and induction of gene expression [86]. Therefore, we 
examined whether the increase in histone (H3 K9) acetylation following HDIs 
treatment was associated with increased expression of metabolic and mitochondrial 
genes in vitro. L6 myotubes were treated with 1μM of SCR or TSA for 1 hour 
followed by gene expression analysis at the various time points over 24 hours. Both 
SCR and TSA regulated metabolic and mitochondrial gene expression differentially 
as summarized in heat maps (Fig. 2.5). SCR increased the expression of many genes 
involved in lipid metabolism, mitochondrial biogenesis and mitochondrial function 
whereas TSA both increased and decreased their expression (Table 2.3). 
 
Full details are given in appendix Fig. A2.2. Over the time course, the peak change 
compared to VEH (100%) demonstrated that SCR regulated the expression of 
various genes involved in lipid metabolism such as HSL (increased by 335%), PPAR-ɲ
(increased by 146%), PPAR-ɷ ;increased by 144%) (Fig.A2.2a), mitochondrial 
biogenesis such PGC-1ɲ ;increased by 31%) and TFAM (increased by 98%) (Fig. 
A2.2b), mitochondrial function such as ATP-5d (increased by 132%), COX-7a 
(decreased by 55%) (Fig. A2.2c) and skeletal muscle development such as myogenin 
(decreased by 98%) (Fig. A2.2d, p < 0.05, HDI vs. VEH). TSA also had differential 
effects on the expression of genes involved in lipid metabolism such as HSL 
(increased by 913%), PPAR-ɲ ;increased by 440%), PPAR-ɷ ;increased by 164%), 
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CPT-ϭɴ ;decreased by 43%) (Fig. A2.2a), mitochondrial biogenesis such PGC-1ɲ
(decreased by 66%), TFAM (increased by 34%) (Fig. A2.2b), mitochondrial function 
such as ATP-5d (increased by 164%), SDH-b (decreased by 37%) (Fig. A2.2c) and 
skeletal muscle development such as myogenin (decreased by 99.9%) (Fig. A2.2d). 
These data suggest that induced-histone acetylation by the broad spectrum HDIs is 
associated with alterations at the gene transcriptional level with SCR increasing the 
expression of more metabolic and mitochondrial genes than TSA (Table 2.3).  
 
 
Table 2.3: Effect of SCR and TSA on metabolic and mitochondrial gene expression 
in vitro 
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Figure 2.5: Effect of A) SCR and B) TSA on the expression of metabolic and 
mitochondrial genes. Genes involved in lipid metabolism (e.g. CPT-ϭɴ͕,^>͕WWZ-ɲ͕
PPAR-ɷ Θ ^-1), mitochondrial biogenesis (e.g. PGC-ϭɲ͕ TFAM), mitochondrial 
function (e.g. SDH-b, ATP-5d, COX-7a) and skeletal muscle development (e.g. 
myogenin) are on Y-axis and hours post HDI treatment (0, 1, 2, 4, 8, 16 & 24 hrs) are 
on X-axis. Gene expression levels are calculated as percentage of VEH (VEH=100%) 
and represented as colours with VEH falling in the 75-125% range of neutral colour 
and increasing red or green colour densities representing the decrease or increase 
in gene expression percentage respectively. 
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2.3.3  SCR, but not TSA, improved L6 myotube oxidative capacity and 
mitochondrial function  
We next assessed whether increased global histone 3 acetylation at 0.1 and 1 μM of 
SCR and TSA were associated with the regulation of skeletal muscle metabolism 
including mitochondrial function and oxidative capacity in vitro.  The effect of these 
concentrations of SCR & TSA on muscle metabolism was observed by measuring the 
oxygen consumption rate (OCR), an indicator of mitochondrial respiration, using a 
Seahorse XF Analyser. SCR improved muscle oxidative capacity and mitochondrial 
function in L6 myotubes whereas TSA downregulated it. We observed that SCR 
enhanced basal OCR at both 0.1 and 1 μM concentrations by 14% and 18% 
respectively, suggesting that SCR increased cellular aerobic respiration.  
 
To determine the metabolic parameter(s) contributing to the increase in basal 
oxidative metabolism, we also performed mitochondrial function tests on these 
cells. The increase in basal respiration in response to SCR treatment was associated 
with increased ATP turnover by 16% & 20% at 0.1 and 1 μM concentrations 
respectively, without any change in uncoupled respiration, which are the two 
parameters contributing to basal OCR. SCR also increased maximal respiratory 
capacity at both 0.1 and 1 μM concentrations, by 23.5% and 20% respectively. TSA 
did not improve any of these metabolic parameters but reduced (29%) the maximal 
respiratory capacity at 1 μM concentration (Fig. 2.3). These data suggest that the 
broad spectrum HDIs can regulate mitochondrial function with SCR enhancing 
skeletal muscle cell oxidative capacity, mitochondrial function and metabolism in 
vitro. 
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Figure 2.6: (A) Graphical representation of oxygen consumption rate (OCR; 
expressed as pmoles/min) as measured throughout mitochondrial function assays 
in L6 myotubes treated with broad spectrum HDIs. (B) Mean OCR for parameters 
of mitochondrial function, including basal mitochondrial respiration, ATP 
turnover, uncoupled respiration and maximal respiratory capacity in L6 myotubes 
treated with broad spectrum HDIs. OCR is calculated as percentage of VEH 
(VEH=100%). Data is mean ± SEM, *p< 0.05, #p < 0.01, + p< 0.001, HDI concentration 
vs. VEH, n = 6-14). 
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2.4  Discussion 
 
The class IIa HDAC transcriptional repressors are known regulators of skeletal 
muscle development, phenotype and metabolic adaptations in response to exercise 
[96, 141, 146-148, 170]. This family of enzymes can control metabolic gene 
transcription in muscle, heart, liver, and pancreas [253, 268]. More recently, class 
IIa HDACs have been implicated in the regulation of genes involved in glucose 
metabolism in muscle, liver and adipose tissue [113, 170, 254].  Therefore, we 
hypothesized that pharmacological inhibition of class IIa HDACs using HDIs could 
enhance skeletal muscle oxidative metabolism. We and Takigawa-Imamura et al. 
have previously shown that broad spectrum HDIs can enhance glucose uptake and 
glucose metabolism in muscle cells [248, 298]. However, to date, no studies have 
directly examined the effects of HDIs as a therapeutic strategy to improve muscle 
oxidative metabolism. With this in mind, we tested and screened the efficacy of the 
commercially available hydroxamate broad spectrum class I and class II HDIs – SCR 
and TSA, in proof-of-principle experiments, to determine whether HDIs regulate 
metabolic processes in myotubes. Data from this chapter shows that the broad 
spectrum HDI SCR can increase metabolic gene expression, mitochondrial function 
and oxidative metabolism in cultured L6 myotubes. 
 
Classical broad spectrum HDIs are designed to interact with the zinc-containing 
catalytic core, abolish HDAC catalytic activity and thus, result in the enhanced 
acetylation of histone proteins [297]. We observed that both TSA and SCR increased 
global H3 (K9) acetylation in myotubes. This highlights the ability of these HDIs to 
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inhibit HDAC activity and increase acetylation levels of histones. The acetylation of 
histone 3 at lysine residue 9 (H3K9) acts to promote transcriptional initiation and a 
high intensity of H3K9 acetylation around the promoters or transcription start site is 
associated with high expression levels of downstream genes [299-301]. Studies have 
shown that reduced H3 acetylation around the promoters of various metabolic 
genes such as the D-site binding protein (DBP) clock gene in adipocytes, the 
pancreatic and duodenal homeobox factor 1 (Pdx1) in pancreatic islets and the 
GLUT-4 gene in skeletal muscle is associated with their reduced expression that 
could impair glucose metabolism and homeostasis [219, 302-305]. Therefore, 
altered H3 acetylation levels could be associated with impaired metabolism in 
various tissues that contribute to the development of metabolic abnormalities such 
as obesity and type 2 diabetes. Therefore, the enhanced global histone H3 
acetylation response in myotubes further led us to examine the therapeutic 
potential of broad spectrum HDIs to regulate muscle cell metabolic gene expression 
and metabolism. 
 
The increase in H3K9 acetylation, a promoter of transcription, was also associated 
with increased expression of various metabolic and mitochondrial genes by SCR. 
Conversely, TSA demonstrated selective and differential regulation of metabolic 
gene expression. SCR increased gene expression of PGC-ϭɲ, a transcriptional 
coactivator and master switch of both nuclear and mitochondrial-encoded genes of 
oxidative metabolism, mitochondrial biogenesis and mitochondrial function [187]. 
Consistent with this, SCR also improved the gene expression of TFs and enzymes 
involved in mitochondrial biogenesis such as TFAM, PPAR-ɲ͕ŵŝƚŽĐŚŽŶĚƌŝĂůĨƵŶĐƚŝŽŶ
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such as ATP-5d, and lipid oxidation such as PPAR-ɲ͕WWZ-ɷĂŶĚ,^>͘/ŶƚĞrestingly, 
SCR didn’t improve the expression of SCD-1 gene, a central lipogenic enzyme 
catalyzing the synthesis of fatty acids which when inhibited, reduces body fat and 
improves insulin sensitivity and glucose metabolism in vivo [306, 307]. This suggests 
that SCR induced lipid oxidation rather than estrification. Hence, the effect of SCR to 
improve muscle mitochondrial function and metabolism could be mediated via 
enhanced expression of various metabolic and mitochondrial genes. This is similar 
to the data previously shown by Takigawa-Imamura et al. and our group that SCR 
mediated increased glucose metabolism is mediated via upregulation of GLUT-4 
gene expression [248]. However, Takigawa-Imamura et al. showed no effect of SCR 
on expression of genes involved in lipid or glucose metabolism such as PPAR target 
genes, while we observed a correlation between metabolic gene expression 
including PGC-ϭɲ͕WWZɲ͕ɷĂŶĚŵŝƚŽĐŚŽŶĚƌŝĂů ĨƵŶĐƚŝŽŶĂŶĚŵĞƚĂďŽůŝƐŵ following 
SCR treatment. 
 
On the other hand, TSA increased the expression of some metabolic and 
mitochondrial genes such HSL and ATP-5d. Despite an increase in the expression of 
d&Ɛ ƐƵĐŚ WWZ ɲ͕ ɷ ĂŶĚ d&D͕ d^ ƌĞĚƵĐĞĚ ƚŚĞ ĞǆƉƌĞƐƐŝŽŶ ŽĨ the master 
transcriptional coactivator PGC-ϭɲ͕ ƚŚĞ ĞǆƉƌĞƐƐŝŽŶ ŽĨ which contributes to co-
activation and enhancement of the transcriptional activity of above mentioned TFs, 
to regulate the expression of metabolic genes [308-312]. This could be responsible 
for the TSA-mediated reduction in the expression of other genes involved in lipid 
metabolism such as CPT-ϭɴĂŶĚŵŝƚŽĐŚŽŶĚƌŝĂůĨƵŶĐƚŝŽŶƐƵĐŚĂƐ^,-b, that require 
PGC-ϭɲ ĞǆƉƌĞƐƐŝŽŶ [5, 165, 313]. The differential effect of TSA on metabolic and 
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mitochondrial gene expression and the decrease in PGC-ϭɲ ĞǆƉƌĞƐƐŝŽŶ ĐŽƵůĚ ďĞ
responsible for the reduction in mitochondrial function. TSA has been shown to be 
toxic to cells at 1μM concentration, which is the concentration at which TSA 
reduced maximal respiratory capacity of the mitochondria in muscle cells in our 
study [248]. Similar responses to TSA have been observed in other tissues. For 
example, TSA has also been shown to be toxic to pancreatic ɴ-cells in vitro [260]. 
 
Various independent studies have demonstrated a coordinated downregulation of 
various nuclear and mitochondrial-encoded genes of oxidative metabolism is 
associated with impaired oxidative metabolism and mitochondrial function in both 
insulin resistant (prediabetic) and T2D muscle [4, 5]. Most of these metabolic and 
mitochondrial genes, including PGC-ϭɲ, are now known to be regulated by class IIa 
HDACs by repressing the transcriptional activity MEF2 transcription factor via 
deacetylating the histones at the metabolic gene promoter region. This results in 
the silencing of MEF2 target genes [100, 191]. Therefore, the mechanism behind the 
HDI mediated increase in gene expression could be interpreted as its ability to 
inhibit class IIa HDACs activity and consequently resulting in MEF2 mediated 
transcription of the metabolic genes.  
 
Besides targeting histones, HDACs and HATs are also known to regulate the 
acetylation of non-histone proteins such as TFs, which affects their DNA binding 
affinity, transcriptional activation, and interaction with other proteins [88]. 
Acetylation of MEF2 TFs was shown to enhance their DNA binding affinity, 
interaction with other proteins and transcriptional activation [314, 315]. However, 
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both negative and positive effects on TFs have been observed due to their altered 
acetylation status [88]. Similarly, the majority of the enzymes participating in the 
intermediary cellular metabolism such as glycolysis, tricarboxylic acid and urea 
cycles, fatty acid and glycogen metabolism can be reversibly acetylated. Acetylation 
can affect the activity or stability of these metabolic enzymes and the response 
varies widely among the various metabolic enzymes and proteins [239, 240]. Given 
the ability of broad spectrum HDIs to inhibit all HDACs, further studies 
characterizing the role of various HDAC isoforms in regulating the acetylation levels 
of TFs and enzymes/proteins involved in muscle metabolism are warranted.  
 
These observations suggest that differential regulation of gene expression by HDI 
could be a combined or independent effect of regulated acetylation level of 
histones and/or transcription factors. Additionally, the effect of HDIs  on 
metabolism could be independent of histone acetylation mediated gene expression 
and might be due to targeting cytoplasmic proteins involved in metabolism, or a 
combination of both. 
 
Both SCR and TSA were found to decrease myogenin expression, a key regulator of 
myogenesis. But studies have shown a dual role of myogenin in muscle 
development and mature skeletal msucle [316, 317]. During atrophy of fully 
developed skeletal muscle, induced under various pathological conditions including 
diabetes or denervation, the class IIa HDACs are upregulated and redundantly 
regulate skeletal muscle atrophy by upregulating myogenin gene expression 
followed by increased expression of E3 ubiquitin ligases and loss of muscle mass 
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[97, 318, 319]. This indicates the potential of the broad spectrum HDIs to 
ameliorate muscle wasting disorders via inhibition of class IIa HDACs.  
 
Mitochondrial dysfunction and reduced muscle oxidative capacity are associated 
with skeletal muscle metabolic dysregulation in response to caloric excess and are 
risk factors in the pathogenesis of metabolic diseases. Therefore, any therapy to 
resolve skeletal muscle metabolic dysregulation should increase basal skeletal 
muscle energy expenditure, oxidative capacity and mitochondrial function [47]. We 
assessed whether the broad spectrum HDIs - SCR and TSA regulated basal energy 
expenditure by measuring cellular OCR using the Seahorse XF analyser. SCR 
increased basal OCR, a measure of aerobic respiration. We have previously also 
shown that extracellular acidification rate (ECAR), a measure of anaerobic glycolysis 
was also enhanced by SCR [298]. Together, this suggests that SCR can increase basal 
energy expenditure through increased oxidative and nonoxidative metabolism. To 
ascertain the mechanism by which SCR increases oxidative metabolism, we also 
performed mitochondrial function tests on these cells. Basal respiration is 
controlled by two parameters - ATP turnover, which in most cell types 
quantitatively is the largest contributor  and proton leak (or uncoupled respiration) 
[320]. It was interesting to find that the increase in basal respiration was due to 
enhanced ATP turnover, while there was no contributing effect from uncoupled 
respiration. Future studies will be required to charaterize the mechanism resulting 
in higher ATP turnover. SCR also improved the maximal respiratory capacity of 
mitochondria. This indicates an improvement in mitochondrial function, muscle 
oxidative metabolism and energy expenditure by the broad spectrum HDI SCR. TSA 
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neither improved basal respiration nor mitochondrial function. Rather, TSA resulted 
in inhibition of OCR after FCCP addition suggesting that TSA reduced maximal 
respiratory capacity of mitochondria, which is a strong indicator of potential 
mitochondrial dysfunction [320]. 
 
SCR and TSA exhibit inhibitory activity towards both class I and class II HDACs. SCR 
inhibits both classes with similar potency, whereas TSA exhibits lower potency 
towards class IIa HDACs. Thus, we cannot conclude that the SCR and TSA’s effects 
on gene expression and metabolism are mediated through inhibition of class IIa 
HDACs [291]. Indeed, there is good rationale for inhibiting both classes of HDACs, as 
the class IIa HDACs are thought to lack intrinsic HDAC activity, but instead recruite 
class I HDAC (HDAC3) as part of a multi-protein repressive complex for this function 
[110]. It has been proposed that classical broad spectrum HDIs could impair class IIa 
activity by dissociating this HDAC3 repressive complex from class IIa HDACs [291].  
The abarrent response of TSA on mitochondrial function and metabolic gene 
expression can also be attributed to its higher potency against class I HDACs at low 
nanomolar concentrations and lower against class IIa HDACs [90, 321]. However, 
there is a possibility of the involvement of other HDAC isoforms and thus their 
inhibition via broad spectrum HDI in regulating muscle metabolic parameters. 
Further studies are needed to characterise the role of the various HDAC isoforms on 
the acetylation of various histone and non-histone proteins in muscle metabolism 
and mitochondrial function to delineate the mechanism behind the potential of 
broad spectrum HDI in regulating metabolic gene expression and muscle 
metabolism. Taken together, these results suggest that SCR to regulate metabolic 
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gene expression and enhance muscle metabolism and the ability of TSA to impair 
mitochondrial function. Also, toxic side effects along with costly and highly 
inefficient production preclude TSA from being used clinically [91, 297]. 
 
In conclusion, results from the present study suggest HDACi is an effective strategy 
to regulate muscle metabolic gene expression and metabolism in vitro. We have 
shown that the broad spectrum HDI SCR can enhance skeletal muscle cell 
metabolism via improved metabolic gene expression, mitochondrial function & 
oxidative capacity in vitro. SCR is a robust HDI that possesses relatively low toxicity 
in vitro [322]. Hence it can be used in proof-of-principle experiments, to determine 
whether HDIs can improve muscle metabolic parameters in vivo. As impaired 
muscle metabolism contributes to the development of insulin resistance in 
metabolic diseases such as obesity and type 2 diabetes, these data indicate that 
further experiments targeting class IIa HDACs as a therapeutic strategy for the 
treatment of muscle insulin resistance in diet-induced obesity and type 2 diabetes 
are needed. Therefore, Chapter 3 will further investigate the therapeutic efficacy of 
inhibiting HDACs by the broad spectrum HDI SCR on various skeletal muscle and 
whole body metabolic parameters in diet-induced obesity in vivo. 
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CHAPTER THREE 
The effect of the broad spectrum HDAC inhibitor Scriptaid on 
skeletal muscle and whole body metabolism in vivo 
 
3.1   Intoduction 
 
Class IIa HDACs are transcriptional repressors with established roles in muscle 
development, differentiation, remodelling and metabolism [128, 141, 144, 147]. 
They regulate the phenotypic adaptation of skeletal muscle in response to exercise 
[7, 96].  Emerging evidence has shown that class IIa HDACs repress metabolic and 
mitochondrial gene expression in metabolic tissues and increase hepatic glucose 
production [96, 191, 242, 253, 323]. Hence, they are associated with the 
development of various metabolic diseases such as obesity and type 2 diabetes 
[254]. Given this, we hypothesized that HDAC inhibition could improve metabolism 
and have therapeutic potential for metabolic diseases. In the previous chapter, we 
tested commercially available broad spectrum HDIs for their efficacy in regulating 
muscle metabolic parameters in vitro. Based on our in vitro screening, the broad 
spectrum HDI SCR induced the largest improvement in skeletal muscle metabolism 
via improved metabolic gene expression, mitochondrial function, and oxidative 
capacity in vitro. 
 
Therefore, SCR was selected to test the effect of broad spectrum HDAC inhibition 
(HDACi) on various skeletal muscle and whole body metabolic parameters in vivo. 
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Obesity is the common underlying cause of insulin resistance. Obesity is associated 
with the excess adipose tissue mediated increased flux of free fatty acids to the 
circulation (or impaired adipose tissue lipolysis), muscle mitochondrial dysfunction 
and impaired muscle fat oxidative capacity [25, 28]. This results in the net 
accumulation of fatty acids as lipids such as TAGs, DAGs and ceramides in various 
non-adipose tissues including muscle and liver. Lipid metabolites such DAGs and 
ceramides could interfere with insulin signalling and impair insulin-mediated 
glucose metabolism by these tissues [25, 28]. Hence, they act as potential 
mediators of skeletal muscle insulin resistance in obesity. Therefore, this study will 
assess whether the broad spectrum HDI identified in Chapter 2 could act as an 
effective exercise mimetic to enhance skeletal muscle metabolic adaptations, and 
normalize whole body metabolism in response to high fat feeding induced insulin 
resistance and metabolic dysfunction in vivo. Therefore, the aim of this study was to 
investigate the effect of broad spectrum HDI SCR on  
a) skeletal muscle metabolic parameters such as histone acetylation, metabolic 
and mitochondrial gene expression, lipid levels and glucose metabolism in 
diet-induced obese C57Bl6 mice;  
b) whole body metabolic parameters such as the time to fatigue during 
incremental exercise performance, body composition, energy expenditure 
and whole body insulin action and glucose metabolism in diet-induced obese 
C57Bl6 mice. 
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3.2   Methods 
 
3.2.1  Animal Experiments 
Male C57Bl6 mice (7/8 weeks old) were obtained from the Animal Resource Centre 
(WA) and were housed in the Metabolic Research Unit (MRU) Animal Facility. All 
mice were housed in a temperature (24°C) and humidity controlled environment 
with a 12:12-h light/dark cycle, with food and water provided ad libitum for the 
duration of the study. All mice were grouped 4 mice per cage. Studies were 
conducted in accordance with the guidelines of the Deakin University Animal Ethics 
Committee (AEC) and its Animal Welfare Committee (AWC) approved all 
experiments. All Deakin research conducted is subject to the Australian Code for the 
Responsible Conduct of Research. Studies commenced after a 2 week acclimation 
period following the arrival of the mice at the MRU animal facility. 
 
3.2.2  Dose determination of SCR for in vivo histone acetylation 
The dose response of SCR towards global histone (H3) acetylation was determined 
by administering the C57Bl6 mice (total 27 mice) with an acute intraperitoneal (i.p.) 
injection of SCR (Santa Cruz Biotechnology, California), at a concentration of either 
1, 3 or 10 mg.kg-1 (SCR stocks were prepared as 0.2mg/ml, 0.6mg/ml and 1mg/ml in 
DMSO further diluted with PBS for 1, 3 or 10 mg.kg-1 doses respectively). Mice were 
sacrificed at either 0, 1, 2, 4, 6, 8, 12, 18 and 24 hours post injection. The soleus 
(oxidative fiber) and extensor digitorum longus muscle (EDL) skeletal muscles along 
with other tissues such as liver, heart, pancreas and brain were collected, frozen in 
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liquid nitrogen and stored at -80°C until analysis. These tissues were analysed for 
global H3 acetylation by immunoblotting to determine the time course chromatin 
remodelling effect of SCR on global histone (H3) acetylation in various metabolic 
tissues. The concentration of SCR that increased H3 acetylation in soleus and EDL 
skeletal muscle, in the absence of an increase in H3 acetylation in other tissues such 
as liver or heart, was used for subsequent in vivo experiments. 
 
3.2.3  Diet induced obesity (DIO) studies with SCR  
For DIO studies, C57Bl6 mice (9 weeks old, 48 mice per cohort) were divided into 
two dietary groups and placed on either a high fat diet (HFD, 43% of total calculated 
energy is from lipids, SF04-001 23% Fat Semi Pure Rodent Diet, Specialty Feeds, 
Western Australia) or standard rodent diet (SRD, Barastoc, Ridley AgriProducts) 
(n=24 per diet group) after the acclimation period for a total of 12-18 weeks. Mice 
were grouped such that initial average body weights (BW) of both the diet groups 
was similar.  Mice were housed four per cage for the first 8-12 weeks. Body weight 
and food intake were measured throughout the diet twice per week. Energy intakes 
were calculated on the basis of digestible energy from each diet- 13.25 MJ/Kg from 
SRD and 19 MJ/Kg from HFD.  
 
After 9-13 weeks of HFD period, mice in each diet group were further sub-divided 
into two treatment groups, based on average body weight, fasting blood glucose 
level and fat mass. Mice received daily single i.p. injection of SCR (1mg.kg-1 i.e. dose 
selected from the dose response in vivo study) or vehicle (VEH) DMSO in the 
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afternoon (four groups, n=10 per group) until sacrificed. All mice were housed two 
per cage during the period of SCR treatment. Following 2 weeks of SCR injections, 
various metabolic experiments such as 24hr energy expenditure by indirect 
calorimetry, incremental exercise test, insulin tolerance test (ITT), glucose tolerance 
test (GTT) were performed with an interval of four days between each experiment. 
Body composition by EchoMRI scan was every 4-5 days throughout the treatment 
period. 
 
Mice were fasted for 4 hrs before being sacrificed. Blood was drawn by cardiac 
puncture and collected into tubes containing heparin followed by centrifugation at 
4°C at 10,000 RPM for 10 minutes and plasma collection. Tissues such as soleus 
muscle, extensor digitorum longus muscle (EDL), quadriceps femoris muscle, liver 
(weighed), epididymal fat (weighed), brown fat, heart, and brain were collected, 
snapfrozen in liquid nitrogen and stored at -80°C until analysis. 
 
3.2.4  Indirect calorimtery 
Indirect calorimetry was performed using the Fusion Metabolic system, AccuScan 
Instruments, USA that uses open circuit calorimetry. The Metabolic System 
consisted of a Metabolic Analyzer, Oxygen Analyzer, Carbon Dioxide Analyzer, a 
multi channel Flow Controller and air-tight Cages. This system measures the amount 
of air entering each cage by a mass flow meter in the Flow Controller and uses 
zirconia and infrared sensors to monitor the air entering and leaving each cage for 
oxygen (O2) and carbon dioxide (CO2) content, respectively, inside respiratory cages  
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in which individual mice were housed. The metabolic experiments were set as per 
the manufacturer’s guide before placing the mice in individual air tight cages and 
monitoring in the metabolic chambers for 24 hours with ad-libitum access to water 
and their respective diets. To minimize the effect of environmental variations in the 
initial hours of recording, mice were monitored for >26 hrs and the final 24hrs of 
data only was considered for calculations. Parameters such as VO2 (Oxygen 
consumption rate), VCO2 (carbon dioxide production rate) and respiratory 
quotient [RQ/respiratory exchange ratio (RER) or substrate utilization i.e. VCO2 / 
VO2] were measured every minute. The VO2 (mL/kg/min), RQ and calculated energy 
expenditure (EE in Kcal/hr) data were averaged for each hour and expressed as 
hourly and average for light (12hrs), dark (12hrs) and complete 24hrs. Glucose and 
lipid oxidation (GOX and LOX) are computed from the formulas below that include 
VO2, VCO2, derived by Patrick C. Even et al. 2012 [324]. 
GOX (g/kg) = (4.55 X VO2) – (3.21 X VCO2) 
LOX (g/kg) = (1.67 X VO2) – (1.67 X VCO2) 
 
3.2.5  Incremental exercise test  
An incremental exercise test was performed on an Accuscan treadmill (AccuScan 
Instruments, USA). All mice were familiarized with the treadmill by making them run 
for a ~30 seconds two days before performing the actual exercise test. Mice were 
subjected to run on a motorised treadmill at a speed of 8 meters per minute (Mpm) 
at 0% grade with an increase in speed of 2Mpm every 2 minutes. At 20Mpm, the 
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grade was increased by 5% every 2 minutes. A timed exercise test was performed 
on each mouse until exhaustion which was defined as time to fatigue. Data is 
represented in seconds.  
 
3.2.6  EchoMRI Scans 
Body composition was determined by the EchoMRI™ Whole Body Composition 
Analyzer (Singapore). As per manufacturer’s guide, scans were performed by 
placing mice into a probe with a cylindrical plastic insert added to limit their 
movement in a quantitative magnetic resonance (QMR) system that measures 
whole body fat mass, lean tissue mass, free water, and total body water, within 1 
minute without the need for anesthesia or sedation. A recommended system test 
was done once a day prior to measurement scans with a canola oil test sample 
serving as a standard for the system test. Fat mass and lean mass data is 
represented in grams and percentage of body weight. 
 
3.2.7  Fasting blood glucose spot, intraperitoneal glucose tolerance test (ipGTT), 
plasma insulin ELISA and intraperitoneal insulin tolerance test (ipITT) 
Fasting blood glucose levels were determined in unanesthetized mice fasted 
overnight (16hrs O/N) by tail bleeding followed by spotting on a glucometer (Accu-
Chek Performa, Roche Diagnostics). For ipGTT, after 4 hrs fasting mice were injected 
intraperitoneally with 2g glucose per kg animal lean Mass (Glucose intravenous 
infusion, PharmaLab, 50% solution made up of 25g glucose in 50 ml water). Blood 
glucose levels were determined by bleeding the tail and measuring on a glucometer 
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at 0, 15, 30, 45, 60 and 90 minutes after glucose administration. Blood samples 
were collected in tubes containing ~10μl EDTA (16mM EDTA in 0.9% saline) at 0, 15, 
30 and 60 minutes time points. After centrifugation at 4°C at 10,000 RPM for 10 
minutes, plasma was collected and stored at -80°C for insulin measurement. The 
measurement of plasma insulin concentration was done using Mouse Insulin ELISA 
kit (ALPCO Diagnostics). Briefly, 5μl of standards, controls and samples combined 
with 75μl of conjugate were incubated for 2 hrs at RT with shaking at 700-900 rpm. 
This was followed by washing 6 times before incubation with 100μl of TMB 
substrate for 30 minutes at RT with shaking at 700-900 rpm. 100μl of stop solution 
was added and absorbance was measured at 450nm. The ipITT was performed by 
fasting mice for 4 hrs and injecting them with 0.5 Units of human recombinant 
insulin (Humulin) per kg animal lean mass. Blood glucose was measured at 0, 20, 40, 
60, 90 and 120 minutes by tail bleeding on a glucometer.  
 
3.2.8  Protein extraction and analysis by immunoblotting 
Tissues were minced on dry ice and homogenised in ~200-230 μl cold lysis buffer 
(details in section 2.2.3) and centrifuged at 10000 RPM for 10 minutes at 4°C to 
remove insoluble cellular debris. The extracted supernatants were used for protein 
quantification using the bicinchoninic acid (BCA) total protein kit as per 
manufacturer’s instructions (Pierce). 50 micrograms (for acetylated H3-K9)/ 20 
micrograms (for mitochondrial OXPHOS complexes) of protein lysates were 
denatured in 4X SDS reducing buffer by incubating at 37°C and 100°C respectively 
for 5 min and resolved by SDS-PAGE (120-140 V, ~45 min) on a 12.5% (w/v) 
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polyacrylamide gel and transferred to a polyvinylidene membrane as previously 
described in section 2.2.4. Membranes were exposed to the primary antibodies for 
acetylated H3 (K9) (Sigma-Aldrich) (1 in 500 dilution), mitochondrial OXPHOS 
complexes (MitoSciences) (1 in 1000 dilution) and ɲ-Tubulin (Sigma-Aldrich) (1 in 
1000 dilution) diluted in 5 mL of 1xTBST and 0.2% Sodium azide (NaN3) overnight at 
4°C. Followed by probing with the appropriate anti-species horseradish peroxidase 
(HRP) conjugated secondary antibodies, bands were visualized by ECL 
Chemiluminescent Substrate Reagent Kit (Invitrogen) on ChemiDoc™ XRS+ imaging 
systems (Biorad) and quanitified by Image lab software (Biorad).  
 
3.2.8.1  Protein carbonyls immunoblotting 
Protein carbonyls, used as a biomarker for protein oxidation, were detected using 
the protein carbonyls western blot detection kit (COSMO BIO co. ltd). 18 
micrograms of protein lysates were denatured in 4X SDS reducing buffer by 
incubating at 100°C respectively for 5 min and resolved by SDS-PAGE on a 8 % (w/v) 
polyacrylamide gel and transferred to a polyvinylidene membrane as previously 
described in section 2.4. Oxidized BSA, soluble in SDS-PAGE sample buffer was 
loaded (10 μl) as a positive control. For DNPH (2,4-Dinitrophenylhydrazine) 
derivatization, the transferred PVDF membrane was immersed in 100% Methanol 
for 1 minute followed by washing the membrane in 20% methanol - 80% TBS (10 
mM Tris-HCl, pH 7.4, 0.14 M NaCl) for 5 minutes. The membrane was washed in 2 N 
HCl for 5 minutes before incubation with 1XDNPH solution (10X DNPH solution 
diluted in 2NHCL) for exactly 5 minutes. The membrane was washed twice in 2 N 
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HCl, 100% methanol and TBS before blocking in 5% Skim milk/TBST (10 mM Tris-HCl, 
pH 7.4, 0.14 M NaCl, 0.1% Tween-20) for 1 hour at room temperature with constant 
agitation. The membrane was incubated with rabbit anti-DNP antibody diluted 
1:2,000 (5 μl) in 10 ml 5% Skim milk/TBST for 1 hour at room temperature.  This was 
followed by washing the membrane three times in TBST for 5 minutes each time 
before exposure to anti-Rabbit HRP-conjugated secondary antibody diluted 1 in 
10,000 in 5% Skim milk/TBST for 1 hour at room temperature. The membrane was 
then washed three times in TBST for 5 minutes each time. Bands were visualized by 
ECL Chemiluminescent Substrate Reagent Kit (Invitrogen) on ChemiDoc™ XRS+ 
imaging systems (Biorad) and quantified by Image lab software (Biorad). 
 
3.2.9  Lipidomics 
10-20 mg of tissues - soleus muscle, EDL muscle and liver were homogenised in 200-
250 μl of PBS, frozen down in liquid nitrogen and sent to Baker IDI Heart and 
Diabetes Institute. All lipidomics studies i.e. analysis of TAGs, DAGs and ceramides 
in these tissues were carried out by Dr Darren Henstridge, Senior Research Officer 
at Cellular & Molecular Metabolism Laboratory, Baker IDI Heart and Diabetes 
Institute. 
 
3.2.10  Quantitation of gene expression by SYBR Green Real-time PCR 
Total RNA from the tissues (soleus, EDL, liver and hypothalamic region of brain) was 
extracted by homogenizing ~20-30 milligrams of tissue in 1 ml of Trizol followed by 
incubation at RT for 5 min. 200 μl of chloroform was added to the homogenate, 
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shaken for 15 seconds and incubated for 1 min at RT before centrifuging at 12,000g 
for 10 min at 4 °C. The aqueous phase (400-500 μl) was transferred to a fresh tube 
and mixed with an equal volume of 70% ethanol and further purified with RNeasy 
columns (the RNeasy® Mini Kit, Qiagen) to remove genomic DNA as mentioned in 
section 2.2.6. Total RNA was reverse-transcribed into cDNA, using the SuperScript™ 
III transcription system (Invitrogen) and quantified by OliGreen assay (Quant-iTTM 
OliGreen® ssDNA Assay Kit; Invitrogen) following the manufacturer’s instructions as 
mentioned in section 2.2.7. Quantitative real-time PCR was performed on cDNA 
using MX3005P™ Multiplex Quantitative PCR (QPCR) system (Stratagene) as 
mentioned in section 2.2.8. The gene expression levels were normalised to cDNA 
concentration and data represented as the percentage of VEH (SRD fed mice) where 
the VEH is expressed as 100%. The metabolic and mitochondrial genes analysed in 
vivo and their functions are summarized in appendix Table A3.1. The primer sets 
employed during the real-time PCR studies are listed in Table 3.1. 
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Table 3.1: Real-time PCR mouse primer sequences 
Mouse CPT-1 ɴ Forward Primer 5'- TCG CAG GAG AAA ACA CCA TGT -3’ 
 
Reverse Primer 5'- AAC AGT GCT TGG CGG ATG TG -3’ 
 
Mouse ATP-5d Forward Primer 5'- ACA CAG AAG ACG GCA CCA -3’ 
 
Reverse Primer 5'– GCA CAG AGG AGT CGG CAT TC -3’ 
Mouse SDH-b Forward Primer 5'- TGG TGG AAC GGA GAC AAG -3’ 
 
Reverse Primer 5'- CAG CGG TAG ACA GAG AAG G -3’ 
 
Mouse GLUT-4 Forward Primer 5'- CCA GCC TAC GCC ACC ATA G -3’ 
 
Reverse Primer 5'- TTC CAG CAG CAG CAG AGC -3’ 
 
Mouse PDK-4 Forward Primer 5'- TGT GAT GTG GTA GCA GTA GTC -3’ 
 
Reverse Primer 5'- ATG TGG TGA AGG TGT GAA GG -3’ 
Mouse PGC-ϭɲ Forward Primer 5'- CCC TGC CAT TGT TAA GAC C -3’ 
 
Reverse Primer 5'- TGC TGC TGT TCC TGT TTT C -3’ 
 
Mouse PEPCK Forward Primer 5'- ACT GTT GGC TGG CTC TCA CTG -3’ 
 
Reverse Primer 5'- GGG AAC CTG GCG TTG AAT GC -3’ 
 
Mouse G6Pase Forward Primer 5'- ACG CCT TCT ATG TCC TCT TTC CC -3’ 
  
Reverse Primer 5'- TGT TGC TGT AGT AGT CGG TGT CC -3’ 
 
Mouse SCD-1 Forward Primer 5'- CAA CAC CAT GGC GTT CCA -3’ 
 
Reverse Primer 5'- GGT GGG CGC GGT GAT -3’ 
 
Mouse FAS Forward Primer 5'- TCG GGT GTG GTG GGT TTG G -3’ 
  
Reverse Primer 5'- GCG TGA GAT GTG TTG CTG AGG -3’ 
 
Mouse NPY Forward Primer 5'- CCG CTC TGC GAC ACT ACA T -3’ 
  
Reverse Primer 5'- TGT CTC AGG GCT GGA TCT CT -3’ 
 
Mouse AgRP Forward Primer 5'- GCG GAG GTG CTA GAT CCA -3’ 
 
Reverse Primer 5'- AGG ACT CGT GCA GCC TTA -3’ 
Mouse POMC Forward Primer 5'- CAG GTC CTG GAG TCC GAC -3’ 
 
Reverse Primer 5'- CAT GAA GCC ACC GTA ACG -3’ 
All primers were designed in-house using the Beacon Primer Designer program 
software and synthesised by Gene Works (Adelaide, Australia). Some primers were 
already optimized before and were already in use in the laboratory. Primer pairs 
that were specifically designed and ordered for this study were optimized for their 
efficiency before use (Appendix Fig A3.1) 
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3.2.11  Glucose uptake assay in isolated EDL skeletal muscle 
Base buffer was prepared by adding Krebs Daily Buffer (consists of 0.162 ml 4.5% 
NaCl, 0.006 ml 5.75% KCl, 0.005 ml 6.1% CaCl2, 0.002 ml 10.55% KH2PO4, 0.002 ml 
19.1% MgSO4.7H2O. 0.16 ml 1.3% NaHCO3, 0.663 ml H2O in 1 ml with pH7.4) to 1 
mg/ml 0.1% BSA and 1.35 mg/ml 8 mM mannitol. Gas with 95% O2 / 5% CO2 was 
added for 20 min and buffer was divided into 3 equal portions. EDL tissues were 
carefully removed from the anaesthetised mouse and placed in 1 ml of Pre-
incubation buffer (consisting of 1 ml base buffer with 2 mM pyruvate) for 30 min. 
Buffer was removed with a pipette and tissues were incubated for 20 min in 1 ml of 
Incubation buffer (consisting of 1 ml base buffer with 10 μM 2-Deoxy-D-glucose). 
For insulin stimulation, 10 μM of insulin stock was prepared by adding 17 μL stock 
Humulin (Eli Lily) to 983 μL water. 1 μL/ml of 10μM insulin stock was added for a 
final concentration of 10 nM. After incubation, buffer was removed and 1 ml of 
reaction buffer (consisting of 1 ml base buffer with 10 μM 2-Deoxy-D-glucose, 0.5 
μCi/ml 2-Deoxy-D-[1-3H]glucose (GE Healthcare TRK383) and 0.2 μCi/ml D-[1-
14C]Mannitol (GE Healthcare CFA238)] was added for incubation for exactly 10 min. 
Tissues were removed from the tube and rapidly dipped in ice-cold saline or PBS 
followed by blotting on tissue before snap freezing in liquid N2 or freeze clamp. 
Tubes were placed in 2 ml plastic tubes and tissues were stored at -70ºC. For the 
analysis, tendons were cut off and tissues were weighed to .01 of a mg. The samples 
were homogenized in 800 ul of ice cold PBS using a polytron homogenizer and 
homogenate was transferred to a 20 ml scintialltion vial. 5 ml Ultima Gold was 
added and radioactivity was counted for 5 min using dual channels (3H, 14C). 
 103 
 
3.2.12  Glucose production assay  
 FAO cells, a rat hepatoma cell line, were grown in RPMI-1640 media (Gibco) 
supplemented with 10% FBS and 1% Penicillin/Streptomycin. FAO hepatocytes 
were seeded in a 48-well plate at a density of 150 K cells/well in 200ul of growth 
media (as mentioned in section 2.2.1 B). Hepatocytes were treated for 24 hrs with 
0 μM (control), 0.1μM, 1μM and 10 μM concentrations of broad spectrum HDI SCR 
in GP1 media (glucose and serum- free RPMI media supplemented with 2mM Na 
Pyruvate, 20 mM Na L-Lactate and 0.1% (w/v) BSA) in the presence or absence of 
0.1nM insulin. To measure the glucose produced by the cells, 40μl of media 
collected from each well and 40μl of glucose standards were combined with 250μl 
of Assay Buffer consisting of 0.12M NaH2PO4.2H2O pH 7.0, 1mg/mL phenol, 
0.5mg/mL 4-aminoantipyrine, 1.6units/mL peroxidise and 10units/mL glucose 
oxidase. This was incubated for 25min at 37°C after which absorbance was 
measured at 490nm. Cells were lysed in 100μl 0.03% SDS and protein was 
quantified using a BCA Protein Assay kit (Pierce). All treatment conditions were 
analysed as six replicates, over three independent experiments and data was 
pooled to give average values for each treatment. Glucose production is expressed 
as percentage of glucose produced by control cells i.e 100% under basal conditions. 
 
3.2.13  Statistical analysis 
Data is reported as mean ± standard error of the mean. In some experiments, data 
is represented as the percentage of VEH where VEH is represented as 100%. 
Statistical analysis was performed using the software package SPSS (PASW Statistics 
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18) and Minitab. Normal distribution of data across the groups was assessed using 
the Kolmogorov-Smirnov test (KS-test). Analysis of variance between the groups (or 
testing for mean differences between groups) for normally distributed data was 
performed using appropriate parametric tests such as independent samples t-test 
(including Levene’s Test for Equality of Variance), one way ANOVA with appropriate 
post hoc test, two way ANOVA and two way ANOVA with repeated measurements 
with a Tukey Post hoc test. Analysis of variance between the groups (or testing for 
mean differences between the groups) for data not normally distributed was 
performed by using appropriate nonparametric tests such as independent samples 
Kruskal-Wallis Test and Mann-Whitney U test. The p-value less than 0.05 denoted 
the presence of a statistically significant difference. 
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3.3  Results 
 
3.3.1  SCR (1mg/kg dose) increased histone acetylation in soleus & EDL muscle in 
vivo 
 
First, we tested the effects of different doses of SCR towards global H3 acetylation 
in various tissues in vivo. C57Bl6 mice were administered with an acute 
intraperitoneal (i.p.) injection of 1, 3 or 10 mg.kg-1 dose of SCR before sacrificing at 
either 0, 1, 2, 4, 6, 8, 12, 18 and 24 hours. We observed that amongst the three 
doses, the lowest dose (1 mg.kg-1) of SCR increased global H3 acetylation in soleus 
and EDL skeletal muscles. Global H3 acetylation was not markedly increased in 
other tissues such as heart, brain, liver and pancreas (Fig. 3.1). 3 or 10 mg.kg-1 dose 
of SCR showed similar results (Appendix Fig. A3.2). This indicates that the broad 
spectrum HDI SCR can increase global histone acetylation levels in skeletal muscle. 
From these data, 1 mg.kg-1 dose of SCR was chosen to test its efficacy on 
metabolism in subsequent in vivo experiments. 
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Figure 3.1: Representative immunoblots demonstrating the time-dependent 
effects of 1 mg.kg-1 SCR on global Histone 3-lysine 9 (K9 H3) acetylation in various 
tissues in C57Bl6 mice. 
 
 
3.3.2  SCR increased metabolic gene expression in EDL muscle of diet induced 
obese mice 
We next assessed the muscle specific effects of chronic SCR treatment 
(1mg/kg/day) in response to SRD and HFD feeding in C57Bl6 mice. Firstly, the 
expression of various metabolic genes in EDL (a glycolytic muscle composed 
primarily of fast white fibers) and soleus muscle (an oxidative muscle composed 
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primarily of slow red fibers) of mice fed by SRD and HFD were determined. In EDL 
muscle, HFD fed mice had lower PGC-ϭɲĞǆƉƌĞƐƐŝŽŶĐŽŵƉĂƌĞĚǁŝƚŚ SRD fed mice 
(main diet effect). In the context of GLUT-4 gene expression, VEH treated HFD fed 
mice had lower GLUT-4 gene expression compared with SRD fed mice receiving 
VEH. A main effect for SCR treatment was observed in EDL muscle for a number of 
genes. SCR increased the expression of various metabolic genes such as PGC-ϭɲ͕
GLUT-4, PDK-4, CPT-ϭɴ, SDH-b, and ATP-5d in EDL muscle compared with VEH 
treated mice (main SCR treatment effect). A significant diet and treatment 
interaction was also observed for a number of genes in EDL muscle. HFD SCR mice 
had higher expression of GLUT-4, SDH-b, and ATP-5d genes compared with HFD VEH 
mice in the EDL muscle (main SCR treatment effect on HF diet, Fig. 3.2 A).  
 
In soleus muscle, HFD fed mice had differential expression of metabolic genes (such 
as decreased GLUT-4 and CPT-ϭɴĂŶĚ increased PDK-4 and SDH-b) compared with 
SRD fed mice (main diet effect). No effect of SCR treatment was observed on the 
expression of any of the metabolic genes examined in soleus muscle. A trend was 
observed for increased GLUT-4 gene expression with SCR treatment in SRD fed mice 
(Fig. 3.2 B). This suggests that chronic SCR treatment increased metabolic gene 
expression in EDL muscle, but had no effect in soleus muscle. 
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Figure 3.2: Metabolic gene expression in A) EDL muscle, and B) soleus muscle of 
SRD and HFD fed C57Bl6 mice treated with VEH or SCR. Data is mean ± SEM, 
D=Diet effect with p< 0.05 for SRD vs. HFD, T= SCR treatment effect with p< 0.05, 
*p< 0.05 for HFD SCR vs. HFD VEH, †p< 0.05 for HFD VEH vs. SRD VEH, n = 10 per 
treatment group, 2-Way ANOVA. 
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3.3.3  SCR lowered lipid levels in Soleus muscle in C57Bl6 mice 
Lipidomic analyses of total triglycerides (TAGs), diglycerides (DAGs) and ceramide 
levels were performed on the EDL and soleus muscles of SRD and HFD fed mice 
treated with VEH or SCR. In EDL, HFD fed mice had lower levels of ceramides 
compared with SRD fed mice (main diet effect). No effect of SCR treatment was 
observed on total lipid levels in EDL muscle (Fig. 3.3 A).  
In soleus muscle, HFD mice had higher total TAG levels compared with SRD fed mice 
(main diet effect). A main effect for SCR treatment showed that SCR lowered TAG, 
DAG and ceramide (trend) levels in mice compared with VEH treated mice (main 
SCR treatment effect, Fig. 3.3 B). Together, this data indicates that SCR lowered 
total lipid levels in oxidative soleus muscle. 
 
3.3.4  SCR normalises skeletal muscle glucose uptake ex vivo in DIO mice  
We further examined the the effect of SCR on insulin stimulated glucose uptake in 
muscle ex vivo. In SRD fed mice, in the presence of insulin, glucose uptake was 
increased by skeletal muscle in both VEH and SCR receiving mice compared with 
basal glucose uptake. In case of HFD fed mice, there was no increase in insulin 
stimulated glucose uptake over basal in VEH treated mice. However, the increase in 
insulin-stimulated glucose uptake in comparison with basal was observed with the 
SCR treatment in HFD fed mice (Fig. 3.4). 
 110 
 
        
  
Figure 3.3: TAG, DAG and Ceramide levels in A) EDL muscle, and B) soleus muscle 
of SRD and HFD fed C57Bl6 mice treated with VEH or SCR. Data is mean ± SEM, 
D=Diet effect with p< 0.05 for SRD vs. HFD, T= SCR treatment effect with p< 0.05 for 
VEH vs. SCR, n = 10 per treatment group, 2-Way ANOVA. 
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Figure 3.4: Ex vivo insulin-stimulated skeletal muscle glucose uptake in response 
to SCR. Data is mean ± SEM, * p< 0.05 for Insulin vs. Basal. 
 
3.3.5  SCR lowered OXPHOS complex II subunit levels in the soleus muscle of SRD 
fed mice with no effect on protein oxidation levels in C57Bl6 mice 
 
Pathological metabolic changes are associated with altered OXPHOS protein levels, 
mediated by the altered or improper assembly or expression of the 5 mitochondrial 
OXPHOS complexes, and thus altered protein levels of various subunits forming 
these complexes. Hence, we determined subunit protein levels of the 5 
mitochondrial OXPHOS complexes in EDL and soleus muscle in response to HFD 
feeding and SCR treatment. Quantitative analyses of OXPHOS complex subunits 
showed no change in their protein levels in EDL muscle following SCR treatment. In 
EDL muscle, HFD mice had higher protein levels of complex 3 (core 2 subunit) and 
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ĐŽŵƉůĞǆϱ;&ϭɲ subunit) compared with SRD fed mice (main diet effect , Fig. 3.5.1 
A). In soleus muscle, HFD feed mice had higher protein levels of ĐŽŵƉůĞǆ ϱ ;&ϭɲ
subunit) and a trend for increased complex 2 (Ip 30kDa subunit) compared with SRD 
fed mice (main diet effect, Fig. 3.5.1 B). SCR decreased complex 2 (Ip 30kDa subunit) 
protein levels in the soleus muscle of SRD fed mice in comparison with VEH (Fig. 
3.5.1 B). 
 
We also examined protein oxidation levels, which are reflective of cellular redox 
state, in response to HFD feeding and SCR treatment. Protein carbonyl content, a 
biomarker of protein oxidation formed due to the protein modification induced as a 
result of oxidation by ROS, was assessed in EDL and soleus muscles of SRD and HFD 
fed mice treated with VEH or SCR. No effect of SCR was observed on protein 
carbonyl content in EDL muscle of any diet group compared with VEH (Fig. 3.5.2 A). 
However, in soleus muscle, SCR treatment exhibited a trend to increase protein 
carbonyl levels in comparison with VEH (Fig. 3.5.2 B). This suggests that SCR had no 
effect on the protein carbonyl content and protein oxidation levels in vivo. 
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Figure 3.5.1: Mitochondrial OXPHOS complex subunit protein levels in A) EDL 
muscle, and B) soleus muscle of SRD and HFD fed C57Bl6 mice treated with VEH or 
SCR. Data is mean ± SEM, D=Diet effect with p< 0.05 for SRD vs. HFD, * p< 0.05 for 
SRD SCR vs. SRD VEH, n = 10 per treatment group, 2-Way ANOVA. 
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Figure 3.5.2: Protein carbonyl levels in A) EDL muscle, and B) soleus muscle of SRD 
and HFD fed C57Bl6 mice treated with VEH or SCR. Data is mean ± SEM, n = 10 per 
treatment group, 2-Way ANOVA. 
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3.3.6  SCR increased incremental exercise performance in C57Bl6 mice 
To examine whether SCR affects exercise performance of SRD and HFD fed mice, a 
forced treadmill incremental exercise test to exhaustion was performed. SCR did 
not alter the incremental exercise performance within each diet group. But, a main 
effect for SCR treatment was observed, showing that mice treated with SCR ran for 
a longer period of time compared with VEH treated mice (Fig. 3.6). Hence, the data 
suggests that SCR improved the time to fatigue during an incremental exercise 
performance in vivo. 
 
 
 
 
Figure 3.6: Time to fatigue during an incremental exercise test in SRD and HFD fed 
C57Bl6 mice treated with VEH or SCR. Data is mean ± SEM, T= SCR treatment effect 
with p< 0.05 for VEH vs. SCR, n = 6 per treatment group, 2-Way ANOVA. 
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3.3.7  SCR had no effect on body weight, body composition, food intake, energy 
intake and neuropeptide expression in C57Bl6 mice 
 
We next examined the effect of SCR on whole body metabolism and energy 
homeostasis. Body weight data showed a main effect for diet on body weight of 
mice, with HFD mice having higher body weights than the SRD fed mice. The main 
diet effect was also observed in food intake data. SCR had no effect on body weight, 
food intake and energy intake of SRD fed and HFD fed mice (Fig. 3.7.1). We also 
determined the impact of SCR on the adiposity in SRD and HFD fed mice. HFD fed 
mice had higher fat mass and lower lean mass (as grams or percentage of body 
weight) compared with SRD fed mice (main diet effect). SCR had no effect on fat 
mass or lean mass compared with VEH treated mice (as grams in Fig. 3.7.2 A & B or 
as percentage of body weight in appendix Fig A3.3) in any of the diet groups 
throughout the treatment period.  We further determined the effect of SCR on the 
expression of neuropeptides responsible for regulating feeding behaviour and body-
weight homeostasis. SCR had no effect on neuropeptide expression in mice 
compared with VEH in the fasted state (Fig. 3.7.3). 
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Figure 3.7.1: A) Body weight, B) food intake and C) digestible energy of SRD and 
HFD fed C57Bl6 mice treated with VEH or SCR. Data is mean ± SEM, D=Diet effect 
with p< 0.05 for SRD vs. HFD, n = 10 per treatment group, 2-Way ANOVA. 
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Figure 3.7.2: Body Composition- A) Fat mass (grams), B) Lean mass (grams) of SRD 
and HFD fed C57Bl6 mice treated with VEH or SCR. Data is mean ± SEM, D=Diet 
effect with p< 0.05 for SRD vs. HFD, n = 10 per treatment group, 2-Way ANOVA. 
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Figure 3.7.3: Neuropeptide expression in the brain of SRD and HFD fed C57Bl6 
mice treated with VEH or SCR. Data is mean ± SEM, n = 10 per treatment group, 2-
Way ANOVA. 
 
 
3.3.8  SCR increased oxygen consumption rate, glucose and lipid oxidation and 
energy expenditure in C57Bl6 mice 
 
We next investigated the impact of SCR on whole body energy metabolism. Indirect 
calorimetry was performed to evaluate the impact of SCR on oxygen consumption 
rate (VO2), substrate utilization (RQ/RER), substrate oxidation including glucose or 
lipid oxidation, and energy expenditure (EE) over 24 hours. 
Mice fed HFD had lower VO2 than mice fed on SRD (main diet effect, Fig. 3.8.1 A & 
B). The average VO2 data for 12 hrs showed that HFD mice had lower VO2 during the 
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dark period (main diet effect, Fig. 3.8.1 C). A main effect for SCR treatment showed 
that SCR increased VO2 when compared with VEH treated mice in both hourly and 
average 24 hrs data (main SCR treatment effect, Fig. 3.8.1 A & B). Increased VO2 in 
response to SCR treatment was observed during the light period (Fig. 3.8.1 C). 
 
Substrate utilization (RQ) hourly and average over 24 hrs data showed a main effect 
for diet, where HFD fed mice had a RQ of 0.79-0.83 compared with the RQ of 0.89-
0.96 in SRD fed mice (Fig. 3.8.2 A & B). This main effect for diet indicated that mice 
on HFD were proportionally oxidizing more lipids than carbohydrates when 
compared with SRD mice. A main effect for SCR treatment was also observed on RQ 
values. Hourly RQ data demonstrated that mice treated with SCR had lower RQ in 
comparison with VEH treated mice (main SCR treatment effect, Fig. 3.8.2 A). This 
indicated that SCR treatment resulted in a shift towards greater lipid oxidation. A 
main effect for SCR treatment was observed in SRD fed mice. SCR decreased RQ 
when compared with VEH in SRD fed mice, which indicated that SRD fed mice were 
proportionally oxidizing more lipids than carbohydrates following SCR treatment. 
 
We further examined the effect of SCR on substrate oxidation. Mice on HFD were 
found to oxidize more glucose and lipids during both light and dark periods 
compared with mice on SRD (main diet effect) (Fig. 3.8.3 A & C). SCR treatment 
increased total glucose oxidation (GOX) in mice compared with VEH receiving mice 
(main SCR treatment effect, Fig. 3.8.3 A). A main SCR effect to increase GOX was 
observed during the light cycle (Fig. 3.8.3 B). SCR also increased lipid oxidation 
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during the light period in mice compared with VEH (main SCR treatment effect, Fig. 
3.8.3 D). 
 
The hourly data for EE indicated that the HFD mice had lower EE compared with 
SRD fed mice (main diet effect, Fig. 3.8.4 A). However, a main effect for SCR 
treatment was observed during the hourly data as well as the average for 24 hrs, 
light and dark period EE data (Fig. 3.8.4 A, B & C). There was an increase in the EE of 
mice receiving SCR treatment compared with the VEH treated mice (main SCR 
treatment effect). Total activity count data showed that HFD mice had lowered total 
counts compared with SRD fed mice (main diet effect). No effect for SCR was 
observed on total activity counts for mice in either diet group (Fig. 3.8.5). 
 
Together this data showed a main effect for SCR treatment on energy metabolism 
of mice and suggests that mice treated with SCR had higher oxygen consumption 
rate, substrate utilization, glucose and lipid oxidation and energy expenditure. 
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Figure 3.8.1: Oxygen consumption rate (VO2) of SRD and HFD fed C57Bl6 mice 
treated with VEH or SCR. A) Hourly average VO2 for 24 hours B) Average VO2  over 
24 hours and C) Average VO2 for light & dark period (12hrs). Data is mean ± SEM, 
D=Diet effect with p< 0.05 for SRD vs. HFD, T= SCR treatment effect with p< 0.05 for 
VEH vs. SCR, n = 10 per treatment group, 2-Way ANOVA. 
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Figure 3.8.2: Respiratory Quotient (RQ) of SRD and HFD fed C57Bl6 mice treated 
with VEH or SCR. A) Hourly average RQ for 24 hours B) Average RQ over 24 hours 
and C) Average RQ for light & dark period (12hrs). Data is mean ± SEM, D=Diet 
effect with p< 0.05 for SRD vs. HFD, T= SCR treatment effect with p< 0.05 for VEH vs. 
SCR, * p< 0.05 for SRD VEH vs. SRD SCR, n = 10 per treatment group, 2-Way ANOVA. 
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Figure 3.8.3: Glucose and lipid oxidation of SRD and HFD fed C57Bl6 mice treated 
with VEH or SCR. A) Total glucose oxidation over 24 hours, B) Total Glucose 
oxidation for light & dark period (12hrs), C) Total lipid oxidation over 24 hours and 
D) Total lipid oxidation for light & dark period (12hrs). Data is mean ± SEM, D=Diet 
effect with p< 0.05 for SRD vs. HFD, T= SCR treatment effect with p< 0.05 for VEH vs. 
SCR, n = 10 per treatment group, 2-Way ANOVA. 
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Figure 3.8.4: Energy Expenditure (EE) of SRD and HFD fed C57Bl6 mice treated 
with VEH or SCR. A) Hourly average EE for 24 hours B) Average EE over 24 hours 
and C) Average EE for light & dark period (12hrs). Data is mean ± SEM, D=Diet 
effect with p< 0.05 for SRD vs. HFD, T= SCR treatment effect with p< 0.05 for VEH vs. 
SCR, n = 10 per treatment group, 2-Way ANOVA. 
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Figure 3.8.5: Total activity counts for SRD and HFD fed C57Bl6 mice treated with 
VEH or SCR. Data is mean ± SEM, D=Diet effect with p< 0.05 for SRD vs. HFD, n = 10 
per treatment group, 2-Way ANOVA. 
 
 
3.3.9  SCR had no effect on glucose tolerance or blood insulin levels, but impaired 
insulin tolerance 
 
Glucose and insulin tolerance tests were performed to investigate the effect of SCR 
on glucose homeostasis and insulin action. Two way ANOVA with repeated 
measurements on Glucose tolerance test (GTT) and its area under the curve (AUC) 
showed a main effect for diet on blood glucose levels. HFD fed mice had higher 
blood glucose levels (at 30, 45, 60 and 90 minutes time points) compared with SRD 
fed mice (main diet effect, Fig. 3.9 A & B).  
 
SCR had no effect on glucose tolerance of mice in any of the diet groups compared 
with VEH. Two way ANOVA with repeated measurements on plasma insulin levels 
(at various time points post glucose administration) and its AUC showed a main 
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effect for diet with HFD fed mice having higher plasma insulin levels compared with 
SRD fed mice (Fig. 3.9 C & D).  SCR had no effect on plasma insulin levels. 
 
A main effect for SCR treatment was observed in insulin tolerance (Fig. 3.9 E). Two 
way ANOVA with repeated measurements on insulin tolerance test (ITT) 
demonstrated that mice treated with SCR had higher blood glucose levels than VEH 
treated mice (main SCR treatment effect, Fig. 3.9 E). However, the SCR effect was 
not significant when area under the curve for ITT was calculated (Fig. 3.9 F). 
Together, these data suggest that SCR had no effect on glucose tolerance, but 
impairs the ability of insulin to suppress blood glucose levels. 
 
3.3.10  SCR had no effect on the expression of metabolic genes in the liver in vivo 
Given that we showed enhanced skeletal muscle metabolism and that the liver also 
plays a key role in glucose homeostasis and whole body insulin action. We assessed 
the effect of SCR treatment on the expression of metabolic genes in the liver of 
mice fed on SRD and HFD. The liver of HFD fed mice had increased expression of the 
G6Pase and FASN genes (main diet effect, Fig. 3.10). However, no alterations in the 
expression of gluconeogenic genes (such as PEPCK and G6Pase) and lipogenic genes 
(such as SCD-1 and FASN) in the liver were observed following SCR treatment (Fig. 
3.10). This suggests that SCR had no effect on the expression of gluconeogenic and 
lipogenic genes in liver. 
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Figure 3.9: Blood glucose levels and plasma insulin levels following intraperitoneal 
glucose tolerance test (ipGTT) and intraperitoneal insulin tolerance test (ipITT) in 
SRD and HFD fed C57Bl6 mice treated with VEH or SCR. A) ipGTT curve, B) Area 
under the curve (AUC) graph for ipGTT , C) plasma insulin levels curve after glucose 
load, D) Area under the curve (AUC) graph for plasma insulin levels, E) ipITT curve, 
and F) Area under the curve (AUC) graph for ipITT, Data is mean ± SEM, D=Diet 
effect with p< 0.05 for SRD vs. HFD, T= SCR treatment effect with p< 0.05 for VEH vs. 
SCR, n = 10 per treatment group, 2-Way ANOVA. 
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Figure 3.10: Gluconeogenic and lipogenic gene expression in the liver of SRD and 
HFD fed C57Bl6 mice treated with VEH or SCR. Data is mean ± SEM, D=Diet effect 
with p< 0.05 for SRD vs. HFD, n = 10 per treatment group, 2-Way ANOVA. 
 
 
 
3.3.11  SCR had no effect on total lipid levels in the liver of C57Bl6 mice 
Lipidomic analyses of total triglyceride (TAG), diglyceride (DAG) and ceramide levels 
were performed in the liver of SRD and HFD fed mice treated with SCR. A main 
effect for diet was observed, with the liver HFD fed mice having higher total DAGs, 
TAGs and lower total ceramides than SRD fed mice (Fig. 3.11). However, SCR 
showed no effect on these lipid levels in the liver except for a trend to decrease 
total liver ceramides when compared with VEH (Fig. 3.11). This indicates that SCR 
had no effect on total liver lipid levels in vivo. 
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Figure 3.11: A) TAG, B) DAG, and C) Ceramide levels in in the liver of SRD and HFD 
fed C57Bl6 mice treated with VEH or SCR. Data is mean ± SEM, D=Diet effect with 
p< 0.05 for SRD vs. HFD, T, p value= trend for SCR treatment effect with p> 0.05 for 
VEH vs. SCR, n = 10 per treatment group, 2-Way ANOVA. 
 
 
3.3.12  SCR impaired the ability of insulin to suppress hepatic glucose production  
Next, we assessed the direct effect of SCR on basal hepatic glucose production and 
on the ability of insulin to suppress hepatic glucose production in FAO cells. 24 
hours of SCR exposure at 0.1μM, 1μM and 10 μM concentrations did not affect 
basal glucose production in FAO cells. However, in the presence of insulin, there 
was 56% decrease in hepatic glucose production in the control cells which was 
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reduced by SCR at 10 μM concentration [by 23.4%, p=0.014, 10 μM SCR (+Insulin) vs 
0 μM Control (+Insulin), Fig. 3.12] in FAO cells. This suggests that SCR impairs the 
ability of insulin to suppress glucose production by hepatocytes and contributes to 
increased hepatic glucose production in the presence of insulin. 
 
 
 
 
 
Figure 3.12: Hepatic glucose production under basal and insulin stimulated 
conditions in FAO cells treated with 0 (control) or 0.1 μM or 1μM or 10 μM SCR. 
On the X-axis are the 0 μM (control), 0.1μM, 1μM and 10 μM concentrations of SCR 
in the absence (basal) or presence of insulin. Y-axis shows glucose production, 
expressed as percentage of glucose produced by basal control cells which is set as 
100%. Data is mean ± SEM, +ƉфϬ͘ϬϱĨŽƌŽŶƚƌŽů;വ/ŶƐƵůŝŶͿǀƐŽŶƚƌŽů;н/ŶƐƵůŝŶͿ͕ΎƉф
0.05, SCR concentration (+Insulin) vs. Control (+Insulin), n = 18. 
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3.4  Discussion 
 
Results from proof-of-principle studies performed in Chapter 2 demonstrated that 
HDAC inhibition (HDACi) is an effective strategy to improve skeletal muscle 
metabolism in vitro, showing it has the potential to mimic phenotypic adaptations 
of skeletal muscle in response to exercise. This provided a good rationale for the 
hypothesis that the broad spectrum HDI SCR could have potential to regulate 
various skeletal muscle and whole body metabolic parameters in vivo and 
potentially treat metabolic diseases. Therefore, this study was aimed at 
investigating whether SCR was an effective exercise mimetic that regulates skeletal 
muscle metabolic adaptations and whole body metabolism in diet-induced obesity. 
Key findings from this study demonstrated that the SCR enhanced skeletal muscle 
metabolism by improving HFD-mediated impairments in skeletal muscle metabolic 
gene expression, decreasing muscle lipid levels, and restoring insulin action on 
muscle glucose uptake. Furthermore, SCR has the ability to improve exercise 
performance and energy metabolism. However, it also impaired glucose 
homeostasis in vivo by inhibiting the ability of insulin to suppress blood glucose 
levels. This was associated with the ability of SCR to impair the ability of insulin to 
suppress hepatic glucose production in hepatocytes. 
 
We examined the ability of SCR to regulate skeletal muscle metabolic parameters in 
vivo. The ability of SCR to regulate global H3 acetylation in vivo, a proxy measure of 
HDI activity and its associated effects on metabolic gene expression and metabolism 
in skeletal muscle were assessed. We observed that SCR, a classical HDI, increased 
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global H3 (K9) acetylation in EDL and soleus muscle. Acetylation at this site is 
associated with initiation of transcription [299-301]. Consistent with this, in EDL 
muscle, we observed that SCR treatment increased PGC-ϭɲ gene expression, a 
transcriptional coactivator and master switch of both metabolic and mitochondrial 
genes of oxidative metabolism, mitochondrial biogenesis and mitochondrial 
function. Accordingly, SCR increased the expression of genes involved in 
mitochondrial function, such as SDH-b and ATP-5d, in EDL muscle. In particular, SCR 
increased expression of these genes in response to high fat feeding in vivo. 
Interestingly, SCR increased PDK-4 gene expression in EDL muscle. Studies have 
shown coordinated upregulation of PDK-4 gene along with PGC-ϭɲ gene expression 
[325]. PDK-4, a negative regulator of glucose oxidation, inhibits pyruvate 
dehydrogenase complex (PDC) activity that is required for pyruvate conversion to 
acetyl-CoA, a precursor required for substrate oxidation and energy production by 
mitochondria. Therefore, an increase in PDK-4 gene expression is associated with 
the switch from glucose oxidation to lipid oxidation that maintains the continuous 
flow of acetyl-CoA from fatty acid oxidation and energy production in mitochondria 
[326]. This suggests that SCR has the ability to enhance lipid oxidation. This is 
consistent with our in vitro results in Chapter 2, where SCR induced the expression 
of genes involved in lipid oxidation rather than lipid esterification. SCR showed 
similar responses in vivo by increasing the expression of genes such as CPT-ϭɴ, a 
rate-limiting enzyme of lipid metabolism, in EDL muscle [327]. 
 
EDL is a glycolytic muscle composed primarily of fast white fibers [328]. Hence, 
SCR’s effect on metabolic gene expression in EDL muscle suggests that it has the 
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potential to increase oxidative gene expression that could enhance the oxidative 
capacity of EDL glycolytic muscle. Muscle specific PGC-ϭɲ expression in transgenic 
mice has been shown to induce transformation of skeletal muscle fibers from 
glycolytic into more oxidative type [189]. This suggests that SCR mediated increases 
in PGC-ϭɲ expression in EDL glycolytic muscle might promote skeletal muscle 
remodelling towards a more oxidative phenotype. Most metabolic and 
mitochondrial genes, including PGC-ϭɲ, are known to be regulated by the class IIa 
HDACs:MEF2 regulatory pathway [191]. These enzymes repress the transcriptional 
activity of the MEF2 TF by deacetylating the histones surrounding MEF2 binding 
regions [20]. This deacetylase activity is conferred by the HDAC3 (class I HDAC) 
corepressor complex, which associates with the class IIa HDAC catalytic deacetylase 
domain, Thus, class IIa HDACs lack intrinsic deacetylase activity and only act as 
scaffolds to recruit enzymatically active HDAC3 co-repressor complex to their 
targeted MEF2 TFs. This eventually results in silencing of MEF2 target metabolic 
genes [110]. Hence, as SCR equally inhibits the deacetylase domain of both class I 
and II HDACs, it could therefore inhibit the class IIa HDAC catalytic deacetylase 
domain and association with the HDAC3 repressor complex and simultaneously 
inhibiting HDAC3 deacetylase activity. This consequently could have resulted, in 
part, in MEF2 mediated transcription of the metabolic genes. 
 
Despite an increase in H3 acetylation and metabolic gene expression, SCR did not 
significantly alter total lipid levels in EDL muscle. Although, we have observed that 
SCR treatment tended to decrease total lipid levels in EDL muscle. Hence, this could 
be a type II statistical error, which might have missed significant lipid data and 
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showed false negative results. We could possibly avoid this false type II error by 
increasing the animal numbers or treatment duration to increase the statistical 
power of the study. On the other hand, an increase in H3 acetylation in soleus 
muscle, an oxidative muscle, was not associated with increased in expression of 
metabolic and mitochondrial genes. The gene expression levels were assessed from 
animal tissues culled 24 hrs after the last SCR dose. It is possible that due to the 
transient nature of gene expression levels, an increase in metabolic gene expression 
level was not detected in soleus samples. Despite this, SCR lowered total lipid levels 
and thus has the potential to increase lipid oxidation in soleus muscle, which is an 
oxidative type I muscle. This suggests that the effect of chronic SCR treatment on 
lipid oxidation could be independent of H3 acetylation and metabolic gene 
transcription. Furthermore, SCR could be acting at the post-transcriptional level 
such as metabolic protein translation, protein/enzyme stability and/or activity 
required for lipid oxidation. Similar results have been demonstrated by Takigawa et. 
al. where they have shown that prolonged exposure to SCR had no effect on the 
transcription of genes involved in glucose or lipid metabolism but still increased 
GLUT-4 protein expression. They did not check expression of proteins involved in 
lipid metabolism [248]. The notion that HDI could regulate non-histone protein 
function and stability is supported by evidence that these are now known to be 
HDAC targets [88]. Histone acetylation has recently been shown to regulate the 
activity and/or stability of the majority of the enzymes participating in intermediary 
cellular metabolism, including fatty acid metabolism [239]. SCR is a hydroxamate 
HDI having hydroxamic acid as a zinc chelating agent that has a strong affinity for 
zinc ion [292]. Owing to strength of this hydroxamate–metal ion interaction, SCR is 
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non-selective and could affect a number of non-HDAC targets, such as several other 
Zn2+-dependent metallo-enzymes involved in lipid metabolism [292]. For example, 
Zn2+ is important for the activity of the enzyme UDP-3-O-(R-3-hydroxymyristoyl)-
GlcNAc deacetylase (LpxC), which is involved in lipid biosynthesis. Hence, it is 
possible that SCR might be chelating Zn2+ in these kinds of similar metallo-enzymes 
to regulate their activity and thus affect lipid metabolism [329, 330]. Nonetheless, 
these results suggest that SCR enhances muscle metabolic and mitochondrial gene 
expression, oxidative metabolism, and lowers total lipid levels in skeletal muscle. 
 
Impaired muscle oxidative capacity has been proposed to increase intramyocellular 
lipid (IMCL). Various muscle lipid metabolites interfere with insulin signaling and 
contribute to skeletal muscle insulin resistance in obesity and T2D, which impairs 
muscle glucose uptake in response to insulin in diabetic patients [24, 25]. Skeletal 
muscle is a key site for the majority of glucose disposal under insulin-stimulated 
conditions [3]. Hence, we next examined whether the SCR mediated reduction in 
muscle lipids enhanced muscle glucose uptake and insulin sensitivity under high fat 
feeding conditions. We observed that SCR increased GLUT-4 gene expression in EDL 
muscle, which was associated with increased insulin-stimulated glucose uptake in 
muscle under high fat feeding conditions. This is in agreement with the ability of 
SCR to increase muscle GLUT-4 gene expression and GLUT-4 translocation to the 
plasma membrane resulting in improved basal and insulin-stimulated glucose 
uptake in muscle cells [131, 248, 298]. These results suggest that SCR has the 
potential to improve muscle insulin sensitivity and glucose metabolism in obesity. 
Altogether this data indicates that SCR treatment could be an effective therapeutic 
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strategy to improve metabolic gene expression, lipid metabolism, insulin action and 
glucose metabolism in skeletal muscle in metabolic diseases. 
 
The functional consequences of SCR-mediated increases in skeletal muscle 
metabolic gene expression were examined, in part, by measuring time to fatigue 
during a forced treadmill incremental exercise test. SCR treatment increased the 
incremental exercise performance, which suggests that SCR augments endurance 
and decreases fatigability in vivo. The increase in in vivo endurance could be, in 
part, the result of increased metabolic and mitochondrial gene expression including 
PGC-ϭɲ in skeletal muscle in vivo. The transcriptional coactivator PGC-ϭɲ is 
responsible for increasing mitochondrial biogenesis, mitochondrial function, 
oxidative fibre type remodelling and substrate oxidation that results in increased 
muscle oxidative capacity [181, 188]. This is consistent with our in vitro results 
(Chapter 2), in which SCR increased muscle metabolic gene expression, basal 
respiration and energy expenditure by increased ATP turnover, resulting in 
increased mitochondrial function and skeletal muscle oxidative capacity. SCR 
increased in vivo PGC-ϭɲ ŐĞŶĞ ĞǆƉƌĞƐƐŝŽŶ ŝŶ > ŐůǇĐŽůǇƚŝĐ ƚǇƉĞ // muscle, which 
could have resulted in increased oxidative fibre type remodelling and oxidative 
capacity. It is also possible that SCR, in part by inhibiting HDACs, could have resulted 
in increased activity of MEF2 TF which is required at the promoter region of a 
number of metabolic genes and hence contribute to the regulation of oxidative 
metabolism [167, 191]. Pothoff et al. showed that increased activation of MEF TF 
mimicked exercise effect in vivo by increasing muscle oxidative remodelling, 
oxidative capacity, mitochondrial content, and also augmented endurance by 
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increasing exercise performance in vivo [96]. From our data examining muscle 
metabolic parameters, we can conclude that SCR is able to mimic as well as improve 
specific aspects of exercise adaptations in skeletal muscle. 
 
To further elucidate the potential of SCR as an effective exercise mimetic, we 
examined its effect on whole body energy metabolism. SCR increased energy 
expenditure during both the light and dark periods. The increased EE was associated 
with increased oxygen consumption during the light period. We also observed that 
increased EE by SCR was not associated with any changes in physical activity.  SCR 
reduced the respiratory exchange ratio indicating that following SCR treatment 
mice started proportionally oxidizing more lipids than carbohydrates in vivo. 
Increased oxygen consumption was also associated with increased substrate 
(glucose and lipids) oxidation during the light period, when mice are mostly inactive 
and consume less food. This suggests that SCR might have improved basal 
metabolic rate in the post-absorptive state. These data suggest that SCR has the 
potential to increase whole body energy metabolism. 
 
Despite increasing EE, substrate oxidation and muscle metabolism, SCR did not 
reduce body weight and had no effect on food or energy intake. The possible 
interpretations of these counter-intuitive findings could be as follows. Though there 
was an increase in energy expenditure, this change was subtle and thus, did not 
alter body weight in the short time period of treatment. The improvements in EE 
were observed after 2 weeks of SCR treatment. By increasing the treatment 
duration, we could possibly see significant body weight changes. We did not 
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measure energy absorption in these experiments. Hence, it is possible that SCR 
could regulate energy absorption and contribute to the maintenance of body 
weight. This is consistent with our results of body composition. SCR had no effect on 
fat or lean mass in vivo. We observed no changes in the expression of 
neuropeptides in the arcuate nucleus of hypothalamic region of brain, responsible 
for regulating feeding behaviour, body weight and energy intake, and thus 
maintaining of energy homeostasis, following SCR treatment [271]. Further detailed 
studies are required to elucidate the impact of broad spectrum HDI SCR on the 
hypothalamus to regulate feeding behaviour and body weight homeostasis. 
 
Evidence suggests that impaired glucose and lipid metabolism in skeletal muscle 
contributes to impaired whole body insulin action, systemic glucose disposal and 
thus glucose homeostasis in metabolic diseases [3, 23, 25, 331]. Therefore, we next 
examined SCR’s effects on whole body glucose and insulin tolerance in vivo. Despite 
increasing muscle metabolic parameters and whole body energy expenditure, SCR 
had no effect on glucose tolerance, but worsened the ability of insulin to suppress 
blood glucose levels during an insulin tolerance test. Thus, SCR impaired whole body 
insulin action and glucose homeostasis. In addition to skeletal muscle, various other 
organs such as the liver also contribute to the regulation of whole-body glucose 
homeostasis. In the liver, insulin suppresses endogenous glucose production and 
promotes glucose uptake for glycogen synthesis and storage [332]. Hence, we next 
examined SCR’s effect on hepatocyte glucose production under basal and insulin 
stimulated conditions. This was done in cultured hepatocytes to assess the direct 
effect of SCR on hepatic glucose production (HGP) in the absence of any SCR 
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mediated improvements in muscle metabolic profile and energy metabolism and 
thus, avoiding cross-tissue effects on HGP. SCR impaired the ability of insulin to 
suppress HGP in vitro. These findings suggest that impaired suppression of glucose 
production by insulin could have contributed to impaired whole body glucose and 
insulin tolerance in SCR treated diet-induced obese mice.  
 
These data suggest that SCR might be regulating molecular pathways such as 
glycogenolysis and gluconeogenesis that contribute to HGP. Recently, it has been 
shown that class IIa HDACs recruit HDAC3 (HDAC1) to deacetylate the 
gluconeogenic FOXO-1 TF that results in increased FOXO transcriptional activity, 
expression of gluconeogenic genes and increased gluconeogenesis [254]. Other 
studies have shown that involvement of class I HDACs (HDAC1 and 2) to enhance 
gluconeogenic TF activity and gluconeogenesis [333]. Paradoxically, despite being 
able to inhibit HDACs, SCR’s increased HGP. This indicates that HDACs might be, in 
part, important in suppression of gluconeogenesis and hence HGP. This speculation 
could be supported by various other published studies suggesting that HDAC3 
deacetylase activity is important for the suppression of gluconeogenic TF activity, 
and hence gluconeogenic gene transcription [333-337]. However, we did not 
observe any changes in gluconeogenic gene expression in the liver in vivo. These 
analyses were performed 24 hours after the last SCR dose, in liver tissue extracted 
from fasted mice and under non-insulin stimulated conditions. In addition to 
gluconeogenesis, it is also possible that SCR might regulate HGP by inducing 
glycogenolysis. Further studies are needed to fully elucidate the effect of SCR on 
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insulin action in liver and mechanisms such as gluconeogenesis that contribute to 
regulate glucose output from the liver.  
 
Based on our in vivo and in vitro data, we have shown that HDACi is an effective 
strategy to regulate muscle metabolic parameters. The broad spectrum HDI SCR 
could be a promising therapeutic drug to increase muscle metabolism, endurance 
and whole body energy metabolism in metabolic diseases such as obesity and T2D. 
Many pharmacological agents, currently available or newly developed as anti-
diabetic drugs, target various tissues such as liver, pancreas, adipose tissue and the 
gastrointestinal tract to lower blood glucose levels and improve insulin sensistivity. 
However no drugs directly target skeletal muscle metabolism and insulin resistance 
in metabolic diseases such as T2D [338, 339].  Hence, SCR could have therapeutic 
implications to directly and potently regulate muscle metabolism in metabolic 
disorders. In the context of the side effects exhibited by SCR on whole body insulin 
action and HGP, we can’t ignore that even all the current anti-diabetic therapies 
have certain limitations associated with them [338].  However, anti-diabetic 
medications are sometimes recommended as an adjunct to diet and exercise or as a 
combination therapy of hypoglycemic drugs and insulin sensitizers. Metformin, a 
common anti-diabetic drug mostly prescribed to obese patients to improve insulin 
sensitivity, lowers blood glucose levels, reduces glucose output from the liver, 
increases fatty acid oxidation and is associated with few side effects such as weight 
gain [340, 341]. Therefore, SCR as an adjunct to Metformin therapy could have the 
combined potential to improve muscle metabolism and reduce hepatic glucose 
production in type 2 diabetes patients. In future studies, it will be of interest to 
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investigate the combined potential of Metformin and SCR as a therapeutic 
intervention to treat metabolic diseases such as T2D. Similarly, SCR could be 
combined with other drugs such as thiazolidinediones (TZDs) and incretin-based 
therapies such as glucagon-like peptide 1 (GLP-1) analogues to increase insulin 
suppression of endogenous glucose production and improve body weight [341]. 
 
In conclusion, the key findings from this study demonstrated that HDACi is an 
effective strategy to regulate muscle metabolic parameters in vivo. The broad 
spectrum HDI SCR could act as an effective exercise mimetic to enhance skeletal 
muscle metabolism by decreasing muscle lipid levels and improving HFD mediated 
impairments in skeletal muscle insulin action in vivo. SCR has the ability to improve 
whole body endurance and energy metabolism. But SCR impaired glucose 
homeostasis in vivo by impairing insulin’s ability to suppress blood glucose levels. 
This was associated with the ability of SCR to impair suppression of glucose 
production by insulin in hepatocytes. Although there are concerns with off-target 
effects of broad spectrum HDACi, these drugs may prove useful to normalize 
skeletal muscle metabolism in metabolic diseases, and have the potential as an add-
on therapy to current anti-diabetic medications. The challenge will be to ensure 
sufficient HDAC3 activity that is required for the normal physiological function of 
other tissues such as liver and heart. Therefore, specific inhibition of class IIa 
HDACs, that we propose to be the mediators of skeletal muscle metabolic 
adaptations in response to exercise, might represent a more specific approach to 
normalize skeletal muscle metabolism and treat metabolic diseases by avoiding off-
target effects. This data provides the impetus to develop more specific class IIa HDIs 
 143 
 
and to determine their specificity and efficacy to regulate skeletal muscle 
metabolism along with whole body energy and glucose metabolism with minimal 
side effects. 
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CHAPTER FOUR 
The effect of class IIa specific HDAC inhibitors on metabolic 
parameters in vitro 
 
4.1 Introduction 
 
Class IIa HDAC chromatin remodelling enzymes act as transcriptional repressors and 
regulate the adaptive response of skeletal muscle to exercise [96, 172]. Growing 
evidence also suggests that class IIa HDACs are present in almost all metabolically 
active tissues. Hence, they could regulate the expression of a broader set of genes 
involved in various metabolic processes such as glucose metabolism and insulin 
action in skeletal muscle [169, 298], substrate oxidation and energy production in 
the heart [191], hepatic glucose production [254], pancreatic ɴ-cell development 
[268], and  GLUT-4 gene expression in adipocytes [113]. Therefore, we hypothesized 
that pharmacological inhibition of class IIa HDAC by HDI could be an effective 
exercise mimetic to enhance skeletal muscle metabolism and will have therapeutic 
potential to enhance muscle insulin sensitivity in metabolic diseases such as obesity 
and T2D. 
 
In Chapter 3, we tested the efficacy of the broad spectrum HDI SCR to regulate 
muscle and whole body metabolism in vivo. Based on the results from Chapter 3, 
we found that SCR effectively normalized skeletal muscle metabolic parameters in 
response to high fat feeding. It also enhanced endurance and whole body energy 
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metabolism in vivo. However, it worsened whole body glucose homeostasis and 
impaired insulin suppression of glucose production in hepatocytes. This could 
possibly be explained on the basis that the broad spectrum HDI SCR has a 
hydroxamic acid ZBG which is a strong chelating agent [292]. Therefore, SCR 
potentially inhibits all zinc-containing HDAC isoforms and regulates various non-
HDAC targets.  Consequently, isoform non-selectivity could induce non-specific 
cellular responses and undesirable side effects in clinical applications. 
 
Studies have reported that inhibition of class I HDACs, in particular HDAC3, has 
negative effects on liver and heart metabolism, resulting in increased lipid 
accumulation, and cardiac and liver hypertrophy [208, 288]. Inactivation of HDAC3 
deacetylase activity also affected normal circadian regulation of metabolic genes in 
vivo [290]. Various studies suggest that HDAC3 deacetylase activity could be 
important for the suppression of gluconeogenic TF activity and hence gluconeogenic 
gene transcription [333-335]. Therefore, HDAC3 inhibition could contribute to 
increased hepatic glucose output. This is in agreement with our findings from 
Chapter 3, where SCR increased HGP and impaired whole body insulin action and 
glucose homeostasis. Therefore, broad spectrum inhibition could be beneficial on 
skeletal muscle metabolism, but the off target effects associated with them 
precludes their potential use as therapeutic agents. Based on our findings and 
published literature on HDAC biology, we hypothesized that specific inhibition of 
class IIa HDACs could be a more specific exercise mimetic to normalize skeletal 
muscle metabolism by ameliorating the negative effects associated with broad 
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spectrum HDI. Hence, it could be a promising strategy to improve whole body 
metabolism and insulin action to treat obesity and T2D. 
 
Increasing knowledge about HDI structure suggests that various modifications can 
be performed to each of the three- cap, linker and ZBG (chelator) regions of the 
canonical HDI structure to modulate class or isoform selectivity. For example, ZBGs 
can be modified with hydroxamic acid (NHOH), or carboxylic acid (COOH). The linker 
region can exist as a long aromatic linker, or a short aliphatic linker, while the 
capping region can contain a fluorine (-F) atom in the benzene ring, or a methyl (-
CH3) group in the pyrrole ring [342]. Mai et al. have synthesized and biochemically 
characterized new compounds that they showed to be highly selective against the 
class IIa HDACs [293, 343]. On the basis of the proposed structures of class IIa 
specific HDIs by Mai. et.al., we have collaborated with Dr Fred Pfeffer and 
Cassandra Flemming (School of Life & Environmental Science, Deakin University) 
and have performed further chemical manipulations on the HDI structure to 
produce new derivatives of class IIa selective HDIs (Fig 4.1). The four compounds 
used in this study were MRU 062, MRU 059, MRU 047 and MRU 066 and were novel 
class IIa HDI analogues (Fig 4.1). The purpose of this study was to characterize the 
ability of these class IIa HDI analogues to regulate muscle metabolic parameters in 
vitro. Amongst them, MRU 047 is the precursor compound and a key intermediate 
for the synthesis of MRU 062, the structure which has been shown to be class IIa 
selective by Mai. et. al. [293]. MRU 062, already published as MC1568, has been 
analysed by Nebbioso et al. and has been shown to inhibit class IIa HDACs in skeletal 
muscle and heart [281]. Further chemical modifications have also been performed, 
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such as the removal of the cap region from the structure of these two compounds, 
producing MRU 066 and MRU 059, which are novel analogues of MRU 062 and MRU 
047, respectively. Therefore the aim of this study was to determine whether a class 
IIa specific HDI regulates skeletal muscle metabolic gene expression, mitochondrial 
function and metabolism in L6 myotubes and to establish what key components of 
the canonical cap-linker-chelator HDI structure are important for this response. 
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Figure 4.1: Four novel class IIa HDIs analogues used in vitro 
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4.2  Methods 
 
4.2.1 L6 myoblasts culture and differentiation 
L6 myoblasts were grown, seeded and differentiated as described in section 2.2.1.  
 
4.2.2  Cell culture treatment with novel class IIa HDI analogues for histone 
acetylation (Immunoblotting) 
 
Cells for this experiment were cultured in 6-well plates described in section 2.2.1. 
Concentrations of the novel class IIa HDI analogues that can induce global histone 
(H3) acetylation was determined by treating 5 days post differentiated myotubes 
for 1 hour with 0, 0.1 and 1 μM concentrations of one of the following four novel 
class IIa HDI analogues named as MRU 062, MRU 059, MRU 047 and MRU 066. HDIs 
stocks were prepared as 1mM concentration in PBS + 10% DMSO (VEH). All 
treatments were made to a constant volume in VEH and differentiation media for 
each dose. 
  
4.2.3  Protein extraction for immunoblotting studies 
Cells were harvested immediately after HDIs treatment for extracting protein 
lysates as described in section 2.2.3. The total protein concentration in the lysates 
was determined using the bicinchoninic acid (BCA) total protein kit as per 
manufacturer’s instructions (Pierce). 
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4.2.4  Immunoblotting  
Fifty micrograms of protein lysates were denatured in 4X loading buffer and 
separated using SDS PAGE as described in section 2.2.4. The membranes were 
exposed to the primary antibodies for acetylated H3 (K9) and ɲ-Tubulin and then 
exposed to appropriate anti-species horseradish peroxidase (HRP) conjugated 
secondary antibodies. Protein bands were detected using chemiluminescence-
based immunodetection and visualized on a Chemidoc XRS System and Analysis 
Software. Bands were quantified using Bio-Rad Quantity One 1-D Image Analysis 
Software. Data was normalized to the VEH. 
 
4.2.5  Cell culture treatment for time course gene expression analysis 
To investigate the time course effect of novel class IIa HDI analogues on metabolic 
and mitochondrial gene expression, cells were seeded in 6-well plates as mentioned 
in section 2.2.1. Five days post differentiated myotubes were incubated with 1 μM 
concentration of one of the following four novel class IIa HDI analogues - MRU 062, 
MRU 059, MRU 047 and MRU 066 or VEH for 1 hour. HDIs stocks were prepared as 
1mM concentration in PBS + 10% DMSO.  
 
4.2.6  RNA extraction and real-time PCR 
Total mRNA was extracted at the various time points post HDI treatment as 
described in section 2.2.6. Total mRNA was reverse transcribed to cDNA and gene 
expression levels were quantified using real time PCR as described in section 2.2.7 
and 2.2.8, respectively. The gene expression levels of each sample were analysed in 
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duplicate and the average gene expression for each sample was normalised to its 
cDNA concentration and represented as the percentage of the VEH. The metabolic 
and mitochondrial genes analysed in vitro and their functions are listed in appendix 
table A1. The primer sets employed during the real-time PCR studies are listed in 
table 2. 
 
4.2.7  Cellular bioenergetics and mitochondrial function assays (Seahorse XF-24 
analyser) 
 
Cellular bioenergetics and mitochondrial function analyses were performed using 
the Seahorse XF24 Extracellular Flux Analyser as mentioned in section 2.2.9. Briefly, 
L6 myoblasts were seeded into 24 well Seahorse V7 plates at a density of 25K 
cells/well followed by differentiation on next day. After 3 days of differentiation, 
myotubes were treated twice per day for 1 hour with 0 μM, 0.1 μM, and 1 μM of 
novel class IIa HDI analogues - MRU 062, MRU 059, MRU 047 and MRU 066 for 2 
days. HDIs stocks were prepared as 1mM concentration in PBS + 10% DMSO. The 
assay was performed on 6th day of differentiation and the effect of each HDI 
treatment on OCR during various mitochondrial parameters was recorded. All 
treatment conditions were analysed as seven or fourteen replicates, over at least 
one or two independent experiments and data was pooled to give average values 
for each treatment. 
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4.2.8  IC50 determination 
IC50 values for MRU 062 (MC1568), MRU 047, MRU 059, MRU 066  and control 
HDAC inhibitors [TSA or suberoylanilide hydroxamic acid (SAHA)] were determined 
using fluorogenic, acetylated peptide substrates for class I and II HDACs and 
recombinant HDAC3 (class I), HDAC4 (class IIa) and HDAC6 (class IIb) and were 
performed by BPS Bioscience. Enzymatic reactions were performed in duplicate at 
370C for 30 min. The reaction contained HDAC assay buffer, 5μg BSA, class specific 
HDAC substrate, recombinant HDAC enzyme and HDAC inhibitor. The reactions 
were terminated with the adĚŝƚŝŽŶŽĨϱϬʅůŽĨϮǆ,ĞǀĞůŽƉĞƌ^ŽůƵƚŝŽŶďĞĨŽƌĞ
being incubated at room temperature for 15 min. Fluorescence intensity was 
measured at an excitation of 360 nm and an emission of 460 nm using a Biotek 
Synergy microplate reader. To determine IC50 values, the fluorescent intensity data 
were analyzed using the computer software, Graphpad Prism. In the absence of the 
compound, the fluorescent intensity (Ft) in each data set was defined as 100% 
activity. In the absence of HDAC, the fluorescent intensity (Fb) in each data set was 
defined as 0% activity. The percent activity in the presence of each compound was 
calculated according to the following equation: %activity = (F-Fb)/(Ft-Fb), where F= 
the fluorescent intensity in the presence of the compound. The values of % activity 
versus a series of compound concentrations were then plotted using non-linear 
regression analysis of Sigmoidal dose-response curve generated with the equation 
Y=B+(T-B)/1+10((LogEC50-X)×Hill Slope), where Y=percent activity, B=minimum percent 
activity, T=maximum percent activity, X= logarithm of compound and Hill 
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Slope=slope factor or Hill coefficient. The IC50 value was determined by the 
concentration inhibitng a half-maximal percent activity. 
 
4.2.9  Statistical analysis 
All values are reported as mean ± standard error of the mean. Some data is 
represented as the percentage of VEH (VEH=100%). Statistical analysis was 
performed using software package SPSS (PASW Statistics 18) as mentioned in 
2.2.11. 
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4.3  Results 
 
4.3.1  Novel class IIa HDI analogues increased global H3 (K9) acetylation in L6 
myotubes 
HDIs inhibit HDAC enzymatic activity and regulate histone acetylation levels.  Hence, 
we determined whether the novel HDIs, predicted to be highly selective against 
class IIa HDACs, could regulate the patterns of histone acetylation. We assessed the 
responses to different concentrations of four novel class IIa HDI analogues- MRU 
062, MRU 059, MRU 047 and MRU 066 on acetylation of lysine 9 on histone 3 (K9 
H3) in vitro. All novel class IIa HDI analogues, except MRU 066, increased histone 
acetylaytion following 1 hr of exposure at various concentrations in L6 myotubes. 
MRU 062 and MRU 059 significantly increased the global acetylation of H3 (K9) at 
0.1 μM and 1 μM, by 24.6% and 17.3%, respectively. MRU 047 significantly 
increased H3 acetylation at both 0.1 μM and 1 μM, by 18.9% and 31.6% 
respectively. MRU 066 decreased H3 acetylation by 16.8% at 0.1 μM (Fig. 4.2).  This 
suggests that out of the four novel class IIa HDI analogues, MRU 062, 059 and 047 
increased acetylation level of histones. 
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Figure 4.2: (A) Representative immunoblots of Histone 3-lysine 9 (K9 H3) 
acetylation at 0, 0.1 and 1 μM concentrations of novel class IIa HDI analogues- 
MRU 062, MRU 059, MRU 047 and MRU 066 in L6 myotubes. (B) Acetylated lysine 
9-histone 3 (K9 H3) protein abundance in L6 myotubes treated with 0, 0.1 and 1 
μM concentrations of of novel class IIa HDI analogues. Data was normalized to VEH 
(0 μM) and reported as mean ± SEM, statistically significant at *p< 0.05, #p < 0.01, 
+p< 0.001, HDI concentration vs. control, n= 4-8 per group.  
 
4.3.2  Novel class IIa HDI analogues had differential effects on metabolic and 
mitochondrial gene expression  
 
Changes in the global histone 3 acetylation levels are associated with transcriptional 
regulation [86]. Therefore, we assessed whether the increase in histone (H3 K9) 
acetylation following HDI treatment was associated with the regulation of gene 
expression in vitro. L6 myotubes were treated with 1μM of the four novel class IIa 
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HDI analogues for 1 hour followed by metabolic and mitochondrial gene expression 
analysis at various time points over 24 hours. All four novel class IIa HDI analogues 
regulated metabolic and mitochondrial gene expression differentially as 
summarized in the heat maps (Fig. 4.3). MRU 059 increased the expression of 
various genes involved in lipid metabolism, mitochondrial biogenesis and 
mitochondrial function. MRU 047 and MRU 066 had differential effects on 
metabolic and mitochondrial gene expression, whereas MRU 062 downregulated 
the expression of the majority of the metabolic genes (Table 4.1).  
 
Full details are given in appendix Fig A4.1. Over the time course, the peak change 
compared to VEH (100%) demonstrated that MRU 059 had differential effects on 
the expression of genes involved in lipid metabolism such as SCD-1 (increased by 
184%) and PPAR-ɲ;decreased by 59.5%) (Fig. A4.1a), mitochondrial biogenesis such 
as TFAM (increased by 40%) (Fig. A4.1b), mitochondrial function such as COX-7a 
(increased by 45.5%) (Fig. A4.1c) and skeletal muscle development such as 
myogenin (increased by 31%) (Fig. A4.1d). MRU 047 regulated the expression of 
genes involved in lipid metabolism such as PPAR-ɷ ;increased by 122%), HSL 
(decreased by 24%) and PPAR-ɲ ;decreased by 79%) (Fig. A4.1a), mitochondrial 
biogenesis such as PGC-1ɲ ;decreased by 31%) (Fig. 4.1b) and did not have any 
effect on the expression of genes involved in mitochondrial function such as COX-
7a, SDH-b or ATP-5d (Fig. A4.1c) and decreased the skeletal muscle development 
gene expression such as myogenin (by 76%) (Fig. A4.1d). MRU 066 also had 
differential effects on the expression of genes involved in lipid metabolism such as 
PPAR- ɷ;increased by 144%), SCD-1 (increased by 281%), HSL (decreased by 40%) 
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and PPAR-ɲ;decreased by 68%) (Fig. A4.1a), mitochondrial biogenesis such as TFAM 
(decreased by 44%) (Fig. A4.1b), mitochondrial function such as COX-7a (decreased 
by 36%), SDH-b (decreased by 36% at 8 hrs while increased by 57% at 24 hrs) (Fig. 
A4.1c), and skeletal muscle development such as myogenin (decreased by 83.5%) 
(Fig. A4.1d). MRU 062 decreased the expression of the majority of metabolic and 
mitochondrial genes (decreased CPT1-ɴ -84%, HSL -73.5%, PPAR-ɲ -91%, PPAR-ɷ -
95%, PGC-1ɲ -83%, TFAM -75%, SDH-b -81%, COX-7a -75%, ATP-5d -80% and 
myogenin -90.5%) (Fig. A4.1a, A4.1b, A4.1c, A4.1d). 
 
These data suggest that the novel class IIa HDI analogues induced transcriptional 
alterations, with MRU 059 increasing the expression of a greater number of 
metabolic and mitochondrial genes than MRU 047 and MRU 066, while MRU 062 
decreasing the expression of most of the genes assessed (Table 4.1).  
 
Table 4.1: Effect of novel class IIa HDI analogues on the expression of metabolic 
and mitochondrial genes in vitro 
 
CPT-1ɴ HSL SCD-1 PPAR- ɷ PPAR-ɲ PGC-1ɲ TFAM SDH-b ATP-5d COX-7a Myogenin
MRU 059
MRU 047
MRU 066
MRU 062
HDIs
Genes
Lipid metabolism
Mitochondrial
biogenesis
Mitochondrial
function
Skeletal 
Muscle 
Development
: Increase,       : Decrease, : No effect
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Figure 4.3: Effect of novel class IIa HDI analogues- MRU 062, MRU 059, MRU 047 
and MRU 066 on the expression of metabolic and mitochondrial genes. Genes 
involved in lipid metabolism (e.g. CPT-1ɴ, HSL, PPAR-ɲ͕ WWZ-ɷ Θ ^-1), 
mitochondrial biogenesis (e.g. PGC-ϭɲ͕d&DͿ͕ŵŝƚŽĐŚŽŶĚƌŝĂů ĨƵŶĐƚŝŽŶ;Ğ͘Ő͘^,-b, 
ATP-5d, COX-7a) and skeletal muscle development (e.g. myogenin) are on Y-axis and 
hours post HDI treatment (2, 4, 8, 16 & 24 hrs) are on X-axis. Gene expression levels 
are calculated as percentage of VEH (VEH=100%) and represented as colours with 
VEH falling in the 75-125% range of neutral colour and increasing red or green 
colour densities representing the decrease or increase in gene expression 
percentage respectively. 
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4.3.3  MRU 062 improved oxidative capacity and mitochondrial function in L6 
myotubes 
 
We further determined whether the novel class IIa HDI analogues could alter 
myotube mitochondrial function and oxidative capacity in vitro. The effects of novel 
class IIa HDI analogues on muscle metabolism were assessed by measuring the OCR 
during various parameters of mitochondrial function using the Seahorse XF 
Analyser. Similar to the patterns of regulated histone acetylation, all of the novel 
class IIa HDI analogues, except MRU 066, increased atleast one parameter of 
mitochondrial function in L6 myotubes (Fig. 4.4). We observed that MRU 062 
enhanced (by 49.5%) basal respiration at 1 μM concentration, which was associated 
with increased (by 48.6%) ATP turnover at the same concentration, without any 
change in uncoupled respiration, which are the two parameters contributing to 
basal OCR. MRU 062 also increased maximal respiratory capacity at both 0.1 (by 
32.6%) and 1 μM (by 71%) concentrations. MRU 059 and MRU 047 increased the 
maximal respiratory capacity at 1 μM concentration (by 40.5% & 28.2%, 
respectively). MRU 066 did not enhnace any of these metabolic parameters (Fig. 
4.4). These data suggest that some novel class IIa HDI analogues can regulate 
muscle cell mitochondrial function, with MRU 062 having the greatest effect on 
mitochondrial function and oxidative capacity. 
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Figure 4.4: (A) Graphical representation of oxygen consumption rate (OCR; 
expressed as pmoles/min) as measured throughout mitochondrial function assays 
in L6 myotubes treated with novel class IIa HDI analogues- MRU 062, MRU 059, 
MRU 047 and MRU 066. (B) Mean OCR for parameters of mitochondrial function, 
including basal respiration, ATP turnover, uncoupled respiration and maximal 
respiratory capacity in L6 myotubes treated with novel class IIa HDI analogues. 
OCR is calculated as percentage of VEH (VEH =100%). Data is mean ± SEM, *p< 0.05, 
#p < 0.01, + p< 0.001, HDI concentration vs. VEH, n = 6-7). 
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4.3.4  MRU 062 (a published class IIa specific HDI as MC1568), MRU 047, MRU 066 
and MRU 059 are not specific against class IIa HDAC members 
 
MRU 062 has been published by Mai et. al. as a class IIa specific HDI [293]. Nebbioso 
et al. has shown that MRU 062 (MC1568) inhibits class IIa HDACs in skeletal muscle 
and heart [281]. On the basis of the proposed structure of MRU 062 and its 
precursor MRU 047, we further chemically manipulated their cap, linker and ZBG 
regions to develop their analogues - MRU 066 and MRU 059 respectively. Despite 
an increase in global histone acetylation and improvements in muscle metabolism 
via enhanced mitochondrial function and oxidative capacity, MRU 062 (MC1568) 
downregulated the expression of various metabolic and mitochondrial genes in 
muscle in vitro.  This raised questions about its mechanism of action. Hence, we 
were further interested to determine the IC50 values (i.e. the concentration 
inhibiting a half-maximal percent activity of the various HDACs) of the four novel 
class IIa HDI analogues against the different HDAC isoforms from the various classes 
particularly towards class IIa HDACs. All four class IIa HDI analogues- MRU 062, MRU 
047, MRU 066 and MRU 059 showed no inhibition against class IIa HDAC members 
as summarized in Table 4.2. 
 
In detail, TSA or SAHA was used as a positive control HDIs, which inhibited the 
activity of HDAC3 (class I HDAC, IC50 = 0.028μM), HDAC 4 and 5 (class IIa HDACs, 
IC50 = 3μM and 1 μM respectively) and HDAC 6 (class IIb HDAC, IC50 = 0.027μM) 
(Fig. 4.5 E-H). MRU 062 did not inhibit HDAC 3 activity. MRU 062 showed no 
inhibition against class IIa HDAC members - HDAC 4 and 5. Rather, it weakly 
inhibited HDAC 6 activity (IC50 = 1.9μM) (Fig. 4.5 A-D). This data showed that MRU 
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062 or MC 1568, a published class IIa specific HDI, is not specific against class IIa 
HDAC members. Similar results were obtained with MRU 047, MRU 066 and MRU 
059 indicating that they showed no inhibition against any HDAC isoform, including 
class IIa HDACs (Appendix Fig A.2). 
 
Table 4.2: Mean IC50 (μM) values of the novel class IIa HDI analogues against 
various HDAC isoforms *N.I.:  No inhibition is less than 20% inhibition in the 
compound range studied. 
 
 Compounds IC50 μM* 
HDAC3 HDAC4 HDAC5 HDAC6 
Class IIa HDI 
analogues 
MRU047 >100 N.I. N.I. N.I. 
MRU059 N.I. N.I. N.I. N.I. 
MRU062 N.I. N.I. N.I. 1.9 
MRU066 N.I. N.I. N.I. N.I. 
Control broad 
spectrum HDIs 
SAHA 0.028 — — 0.027 
TSA — 3 1 — 
 
 
 
 
 
Figure 4.5: IC50 values of MRU 062 OR MC1568 against various HDAC isoforms. A-
D are the IC50 of MC1568 against HDAC3 (class I HDAC), HDAC 4 and 5 (class IIa 
HDACs) and HDAC 6 (class IIb HDAC). E-H are the IC50 values of Control HDAC 
inhibitors - TSA or SAHA. On x axis of each graph is the HDI concentration & on y –
axis is the % activity of the individual HDACs.  
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4.4  Discussion 
 
Evidence in the literature suggests that the class IIa HDACs contribute to exercise-
mediated phenotypic adaptations in muscle. Key findings from chapter 3 
demonstrated that inhibition of HDACs using the broad spectrum HDI SCR could 
improve muscle metabolism and whole body energy expenditure, but compromised 
whole body glucose homesotasis. Based on previous findings on HDAC biology, we 
hypothesized that specific inhibition of class IIa HDACs by using class IIa specific 
HDIs could more effectively normalize whole body metabolism by ameliorating the 
negative effects associated by broad spectrum HDI. Hence, it could be a promising 
strategy to treat obesity and T2D. With this in mind, we screened four novel class IIa 
HDI analagues- MRU 062 (or published MC1568), MRU 047, MRU 066 and MRU 059 
in this study for their efficacy to regulate regulate metabolic processes in cultured 
myotubes. Data from this chapter shows that despite regulating muscle metabolic 
gene expression, mitochondrial function and oxidative metabolism in L6 myotubes, 
MRU 062, a published class IIa specific HDI and all other analogues were not 
selective against class IIa HDAC members. 
 
We observed that MRU 062, MRU 047 and MRU 059 increased global H3 (K9) 
acetylation whereas MRU 066 decreased the same in myotubes. In response to 
regulated histone acetylation levels, the ability of these HDIs to regulate basal 
energy expenditure, mitochondrial parameters and metabolic gene expression was 
assessed. It was found that MRU 047 and MRU 059 increased the maximal 
respiratory capacity of mitochondria without affecting basal respiration. This was 
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associated with their ability to differentially regulate the expression of various 
metabolic and mitochondrial genes such as PPAR-ɲ͕ WWZ-ɷ͕ W'-ϭɲ ĂŶĚ d&D. 
MRU 066 did not affect basal respiration and mitochondrial function, but still had 
variable effects on metabolic and mitochondrial gene expression, which was 
independent of global H3 (K9) acetylation. MRU 062 showed the maximum increase 
in mitochondrial function and oxidative capacity amongst all HDI analogues. It 
increased basal respiration which seemed to be contributed by an increase in ATP 
turnover, without any effect on uncoupled respiration. It also enhanced the 
maximal respiratory capacity of mitochondria. Despite this, MRU 062 
downregulated the expression of various metabolic and mitochondrial genes in 
myotubes. This data is compatible with the data published by Nebbioso et. al [281]. 
They have shown that MC1568 (MRU 062) inhibited MEF2 acetylation, which 
consequently blocked MEF2 transcriptional activity and the expression of MEF2 
targeted genes involved in myogenesis [281]. MEF2 transcriptional activity is 
required to regulate the expression of various metabolic and mitochondrial genes 
and acetylation of MEF2 TF has been shown to increase its transcriptional activity 
[167, 191, 314]. Following this study, this group has also shown that MC1568 has 
the potential to antagonize the effects of the anti-diabetic drug rosiglitazone by 
ŝŶƚĞƌĨĞƌŝŶŐǁŝƚŚWWZɶ signalling-mediated differentiation pathways, mostly in the 
heart and adipose tissue [344]. 
 
MC1568 had been shown to be highly selective against class IIa HDACs (IC50 = 
0.22μM) by Mai. et. al. [293, 343]. On the other hand, Nebbioso et. al. showed 
MC1568 to be class II selective HDI rather than specific class IIa HDI as MC1568 
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inhibited HDAC6 (class IIb HDAC) activity along with HDAC4 & 5 (class IIa HDACs) in 
vitro. They also showed that despite inhibiting class IIa HDACs activity, MC1568 
stabilizes the HDAC3-HDAC4-MEF2 inhibitory complex. Another paper by 
Annamaria Scognamiglio et. al. [139] showed that this compound downregulates 
HDAC4 protein expression via ubiquitin E3 ligase RANBP2 mediated degradation by 
proteasomal pathways. MC1568 has been shown to enhance Pax4 transcription 
factor expression and consequently pancreatic ɴĂŶĚɷĐĞůůŵĂƐƐ but had no effect 
on the inhibition of cell growth or cell death/apoptosis in pancreatic cancer cell 
lines and normal human pancreatic ductal epithelial cells [268, 345]. Still, it is hard 
to postulate whether these effects by MC1568 are in response to the specific 
inhibition of any sub-type of class II HDACs, IIa or IIb HDACs, or due to its effect on 
any other non-HDAC target. 
 
Interestingly, our IC50 data revealed that MC1568 showed no inhibition against 
class IIa HDACs, rather it had only weak specificity against class IIb HDACs (HDAC 6). 
This suggests that the ability of these HDI analogues to regulate global H3 
acetylation doesn’t necessarily involve their ability to dissociate HDAC3 corepressor 
complex from class IIa HDACs and in turn, inhibit class I HDAC (HDAC3) conferred 
deactylase activity to class IIa HDACs, which lack intrinsic HDAC activity. This could 
be a result of inhibiting other HDAC isoforms such as HDAC6. This indicates that the 
physiological effects shown by MC1568 in the above mentioned studies, along with 
the regulated metabolic gene expression and mitochondrial function in our study, 
could be independent of the class IIa HDACs/MEF2 signalling pathway and could 
involve other HDAC isoforms such as HDAC6. Further studies are warranted to fully 
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delineate the specificity of MC1568, which is from the class of 
(aryloxopropenyl)pyrrolyl hydroxyamides, towards different HDAC isoforms and to 
fully elucidate the role of other HDACs apart from class IIa in the regulation of 
muscle metabolic processes [293]. 
 
The potency and selectivity of HDIs can be interpreted on the basis of canonical HDI 
structure comprising of the cap-linker-chelator (ZBG) pharmacophore model. 
Classical HDIs are generally broad spectrum and non selective [291]. Further class/ 
isoform selectivity could be achieved by modifying each of the three regions – cap, 
linker and chelator (ZBG). Emerging evidence suggests that subtle differences in 
HDAC isoform active sites can be exploited to design selective HDIs [342]. 
 
The ability of the capping region to interact differently with the amino acid residues 
present at the rim region of the active site cavity in various HDACs has allowed the 
development of class-selective HDIs. This region acts as a scaffold to establish the 
appropriate three-dimensional conformation for chelator presentation [346]. 
Therefore, the lack of a capping group in the case of MRU 059 and MRU 066 could 
contribute to loss of inhibitory activity. 
 
Unlike the class II HDACs active site structure, a bulky cyclic peptide moiety at the 
capping group is preffered by class I HDACs [346-348]. Molecules with a large 
aromatic capping groups also display class I selectivity, but were also found to 
inhibit class II HDAC (such as HDAC6). Insertion of a halogen group such as chlorine, 
fluorine and bromine in the aromatic ring (halogenated aryl) of the capping group 
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confers class II selectivity [293]. The type and the position of the halogen group 
insertion in the aromatic benzene ring play a crucial role in determining class 
selectivity. For example, chlorine or fluorine insertion at position C3 (meta) of the 
benzene ring were highly selective against class IIa HDACs seen in the case of 
(aryloxopropenyl)pyrrolyl hydroxyamides synthesized by Mai. et. al. [293]. 
Modification of the linker by changing its length and groups further influenced class 
selectivity. For example, both TSA (pan HDI) and SK-7041 (class I HDI) have similar 
zinc binding and cap groups, but have a different linker region. SK-7041 possesses 
an amide bond and phenyl ring in the linker compared with the alkyl linker of TSA 
[342]. Insertion of an aromatic pyrrole in the linker chain of the 
(aryloxopropenyl)pyrrolyl hydroxyamides increased the preference for class IIa 
HDACs. Reduced class IIa selectivity in these compounds suggests that the structure 
of ZBG plays an important role in selectivity towards class II HDACs. 
 
Chemoproteomic binding profiling of HDIs to study the relationship between 
inhibitor structure and activity against various molecular targets has revealed that 
hydroxamic acid based HDIs (hydroxamate inhibitors) that have hydroxamic acid or 
hydroxamates as the zinc or metal binding group, generally form strong 
electrostatic interactions with the zinc in the HDAC active site. Hence, 
hydroxamates are a strong chelating metal-binding group. Additionally, owing to 
the strength of the hydroxamate–metal ion interaction, most hydroxamate HDIs are 
nonselective and have limitations associated with off target effects. They have the 
ability to potently affect a number of non-HDAC targets that share a similar 
chemical ligand space as HDACs such as several other Zn2+ -dependent metallo-
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enzymes, that are not components of HDAC complexes [292]. Besides, hydroxamate 
groups are highly potent against class I and class IIb HDACs (HDAC6 and HDAC10) 
and exhibit low affinity for class IIa HDACs [291]. This is consistent with our IC50 
results for MRU 062 and its analogue MRU 066. 
 
Another example of the role of the ZBG in modulating class selectivity is shown by 
substituting the epoxyketone ZBG of the Chlamydocin HDI, which is class I selective 
because of a cyclic tetrapeptide capping group, with a simple carbonyl group- 
“hydroxymethylketone” group as a zinc ligand and enhancing its selectivity towards 
class IIa HDACs [349]. On the other hand, replacing this ZBG with others such as a 
sulfhydryl group, hydroxamic acid (cyclic tetrapeptide hydroxamic acids/CHAPs) and 
N-formyl hydroxylamine (retrohydroxamate) in the same cyclic tetrapeptide 
structure results in a loss of class selectivity, and acquires broad selectivity [350-
352]. Sulphur containing ZBG such as thiols, disulfides and thioesters have been 
found to be as potent as hydroxamate HDIs and partially resolve their limitations of 
being non-selective. But, they have the limitation of binding with other sulphur 
containing amino acids once they get activated biologically [350, 353]. Carboxylic 
acid ZBGs, as in case of MRU 047 and its analogue MRU 059, have been found to be 
a weak chelating group compared with hydroxamates [354]. Whereas, benzamide 
ZBGs have been shown shown to exhibit class I selectivity [342]. Therefore, each 
cap, linker and chelator moiety showing similar selectivity towards a particular class 
of HDAC can be used to develop potentially selective HDIs. For example, the MS-275 
HDI is composed of a benzamide ZBG and an aromatic linker, both of which 
contribute to class I selectivity [342]. Likewise, the hydroxamic acid APHA (aroyl 
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pyrrolyl hydroxamide, class II selective) and SK-7041 (class I selective) HDIs differ in 
their aromatic linkers and phenyl capping group, while otherwise maintaining a 
similar structure [354]. This results in the different class selectivities. These data 
suggest that small structural differences in each of the cap, linker and ZBGs 
individually contribute to profound class and isoform selectivity. Therefore, 
understanding the interplay between these regions and production of the various 
combinations of modifications at each of these regions could have the potential to 
develop robust class IIa selective HDIs. 
 
Some natural products such as cyclostellettamines, the macrocyclic bispyridinium 
salts, are potent HDIs despite lacking the canonical cap-linker-chelator (ZBG) HDI 
structure. Their two acyclic (Open-Chain) derivatives - “bispyridinium dienes”- 
showed no inhibition against HDAC2 and HDAC3 isoforms of class I HDACs. But a 
slight difference of alkyl chain length (i.e. one methylene carbon on the C3-alkyl 
chain) of one pyridinium ring rendered these two derivatives to display unique 
profiles, with one derivative selective against HDAC1 and other derivative highly 
selective against HDAC4 (class IIa HDAC) [355]. 
 
As mentioned previously, a tyrosine residue surrounding the Zn2+ ion in the HDAC 
catalytic domain is responsible for the catalytic proficiency in all HDACs [104]. 
However, this tyrosine residue is substituted with a histidine residue in the catalytic 
domain of class IIa enzymes and accounts for their diminished intrinsic deacetylase 
activity. This substitution also renders class IIa HDACs a wide catalytic cleft that 
enables them to accommodate bulkier molecules compared with other HDACs [106, 
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108, 109]. Mechanistic insights using X-ray crystallography of the class IIa HDAC 
structure have led to the design of the trifluoromethylketone (TFMK) inhibitors, 
which inhibit class IIa HDACs (HDAC4) in the nanomolar range. It is postulated that 
binding of this inhibitor results in inappropriate conformation of the structural zinc 
binding domain, such that it breaks the association with the HDAC3 repressor 
complex [106, 108, 354]. Later, a series of diphenylmethylene hydroxamic acids 
were reported to be novel class IIa selective HDIs having IC50s in the micromolar 
range [356].  
 
Recently, bulky trifluoromethyloxadiazole (TFMO) compounds have been published 
as novel and highly selective HDIs against class IIa HDACs, with minimal detectable 
off-target interactions [357]. It was also shown that replacement of TMFO by a 
hydroxamate group resulted in off target activities. TFMO is a metal-binding group 
that directly binds to the active site zinc via weak electrostatic interactions due to 
the greater distance between TFMO and the zinc of the HDAC active site, compared 
with canonical metal-chelating geometries observed with classical HDIs such as 
hydroxamates. Hence, TFMO are a nonchelating zinc-binding group (ZBG) [357]. 
Despite this different metal-binding character, the bulky structure of TMFO forms a 
U-shaped conformation with the zinc that allows it to exploit the large volume of 
the class IIa HDAC active site, unlikely to be accommodated by class I HDACs and 
hence confers class IIa HDAC selective inhibition [357]. TMFO were non-cytotoxic 
and specifically inhibited class IIa HDACs at nanomolar concentrations, without 
affecting class I HDACs and thus, H3K9 acetylation, as HDAC activity by class IIa 
HDACs is acquired via class I HDAC [357]. Though TMFO didn’t inhibit HDAC3 and 
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the proteomic study could not detect the association of HDAC3 with class IIa HDACs 
while coeluting class IIa HDACs from TMFO affinity resin, it is necessary to further 
elucidate the effect of these novel HDIs on the association of the class IIa HDAC-
HDAC3 corepressor complex [357]. HDAC3 has been shown to maintain deacetylase 
activity by deacetylating the MEF2 TF and MEF2 targeted gene promoters and 
stabilize the MEF2-class IIa HDAC-HDAC3 repressor complex even in the presence of 
HDI inhibiting class IIa HDACs[281] . 
 
Class IIa HDACs are now known to be not functional deacetylases but rather to act 
as scaffolds to recruit the enzymatically active SMRT/N-CoR-HDAC3 complex to 
their targeted TFs such as MEF2 [110].  Therefore, the strategy to develop class IIa 
selective HDIs shouldn’t only target their HDAC activity associated with the zinc 
active site of class IIa HDACs, as current HDIs have targeted. Rather, it should be 
combined with the target to inhibit class IIa HDAC-HDAC3 association in the class IIa 
HDAC structural zinc binding domain, the proper folding of which is required for the 
association of class IIa HDACs with the active deacetylases such as HDAC3. Besides, 
HDAC3-NCoR complex deacetylase activity is important for normal physiological 
functions in other tissues such as liver and heart. However, class IIa HDACs are also 
known to repress MEF2 independent of their deactylase activity, exerted by its C- 
terminal domain (HDAC-independent mechanism) and this occurs through their N-
terminal domain mediated interactions with other corepressors. With this strategy, 
new compounds have been tested that bind MEF2 at the class IIa HDAC binding site. 
N-(2-aminophenyl)-N’-phenyloctanediamide, commercially available as BML-210, 
and its analogues have been shown to directly bind MEF2, inhibit HDAC4:MEF2 
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interaction and thus block class IIa HDAC recruitment to MEF2 targetted gene 
promoters in vitro. This study showed that BML-210 and its derivitives don’t target 
the class IIa HDAC active site, but rather target the protein–protein interactions 
between these HDACs and its functional partners such as MEF2 TFs [93]. Previous 
studies have shown that BML-210 is a benzamide derivative or analogue of the pan 
hydroxamate HDI SAHA (N1-hydroxy-N8-phenyl-octanediamide), both having 
similar structure except for the replacement of the hydroxamate ZBG by an 
aminobenzamide ZBG in BML-210. Although the hydroxamate ZBG is more potent 
than aminobenzamides, and aminobenzamide ZBGs have very low potency for class 
I HDACs (HDAC1 and 2), but aminobenzamide ZBGs still have an unexpected degree 
of selectivity for the HDAC3-NCoR complex [292]. 
 
Therefore, we postulate that the most promising strategy will be to develop novel 
molecules inhibiting class IIa HDACs function by specifically blocking their 
interaction with MEF2, without affecting HDAC3 corepressor function. In this way, 
we would be able to preclude the deacetylation of MEF2 by HDAC3, side effects 
associated with HDAC3 inhibition and last but not the least, class IIa HDAC N-
terminal mediated repression. Therefore, this class of HDIs would present a novel 
strategy to enhance muscle metabolism and treat insulin resistance in metabolic 
diseases such as obesity and type 2 diabetes. 
 
In conclusion, results from the present study suggest that a published class IIa 
specific HDI MC1568 (MRU 062) and other class II HDI analogues are not selective 
against class IIa HDAC members. Modification of the cap, linker and zing binding 
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regions favouring affinity and potency for class IIa HDACs could possibly lead to the 
development of robust class IIa selective HDIs. The strategy behind developing this 
class of selective HDIs should target dissociation of the class IIa HDACs and MEF2, so 
as to preclude off target effects resulting from non-selective HDAC inhibition. 
Further studies are required to effectively develop and test class IIa selective HDIs 
ǁŝƚŚŝŵƉƌŽǀĞĚƐƉĞĐŝĮĐŝƚǇthat could act as a therapeutic strategy for the treatment 
of metabolic diseases such as obesity and type 2 diabetes. 
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CHAPTER FIVE 
Conclusions and Future Directions 
 
Skeletal muscle insulin resistance contributes to the pathogenesis of metabolic 
diseases such as obesity and type 2 diabetes (T2D) [358]. It is associated with 
reduced metabolic and mitochondrial gene expression, impaired mitochondrial 
function and oxidative metabolism in skeletal muscle [4, 5].  Hence, increasing 
metabolic and mitochondrial gene expression that enhances oxidative capacity and 
energy expenditure of skeletal muscle could be an effective therapeutic strategy to 
treat metabolic diseases. Class IIa HDACs have emerged as epigenetic regulators 
that remodel chromatin structure and contribute to transcriptional repression 
[128]. These enzymes have established roles in regulating muscle development, 
differentiation and remodelling [141, 144, 147]. Class IIa HDACs potently repress 
the transcriptional activity of MEF2 to mediate metabolic and mitochondrial gene 
expression. This happens as class IIa HDACs are recruited by MEF2 that is bound to 
metabolic gene promoters and in turn, alter chromatin confirmation by 
deacetylating the histones surrounding the MEF2 binding region and inactivate 
metabolic transcription [20, 128, 191]. In response to exercise, the class IIa HDACs 
are exported out of the nucleus, which removes their transcriptional repressive 
function on MEF2, and allows histone acetylation and exercise-induced metabolic 
and mitochondrial gene expression in skeletal muscle [169, 170, 172]. Hence, we 
hypothesized that pharmacological inhibition of class IIa HDACs by HDAC inhibitors 
(HDIs) could potentially enhance skeletal muscle metabolic gene expression and 
metabolism, and could have therapeutic potential to enhance muscle insulin 
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sensitivity in metabolic diseases such as T2D. The major aim of this project was to 
determine whether HDIs mimic aspects of exercise and have therapeutic potential 
to treat skeletal muscle insulin resistance in metabolic diseases such as obesity and 
T2D.  
 
Over the last decade, the pharmacological applications of classical HDIs to treat 
cancer, inflammatory and cognitive disorders have been thoroughly documented 
[103, 214, 218, 276, 278]. These classical HDIs are designed to target the zinc 
containing catalytic deacetylase domain conserved in all HDAC isoforms. Hence, 
they are broad spectrum and non-selective [291, 292]. Very little is known about 
the therapeutic efficacy of these HDIs to treat metabolic diseases such as obesity 
and T2D. With this strategy in mind, the purpose of Chapter 2, was to establish an 
effective HDACi strategy by screening for broad spectrum HDIs that regulate 
skeletal muscle gene expression, mitochondrial function and metabolism in vitro. In 
this study we screened some well known hydoxamate broad spectrum HDIs - SCR 
and TSA, that have a five-carbon linker surrounded by a bulky cap region on one 
side and hydroxamic acid ZBG on the other side, for their potential to regulate 
metabolic parameters in L6 myotubes [292]. Both HDIs induced global histone H3 
acetylation at lysine residue 9 that is considered to precede transcriptional 
initiation. Consistent with this, SCR increased the expression of PGC-ϭɲ, a 
transcriptional coactivator and master switch of both nuclear and mitochondrial-
encoded genes of oxidative metabolism, mitochondrial biogenesis and 
mitochondrial function in L6 myotubes [187]. This was associated with increased 
gene expression of various TFs and enzymes involved in mitochondrial biogenesis, 
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mitochondrial function and lipid oxidation by SCR in myotubes. Accordingly, SCR 
enhanced basal respiration and thus basal energy expenditure in myotubes. 
Detailed analysis of mitochondrial function showed that increased ATP turnover 
was the key regulator of increased basal respiration, without any contributing effect 
from uncoupled respiration. SCR also increased the maximal respiratory capacity of 
mitochondria.  
 
Despite inducing H3 acetylation, TSA had differential effects on metabolic gene 
expression. It increased the expression of a number of metabolic genes and TFs, and 
decreased PGC-ϭɲ ŐĞŶĞ ĞǆƉƌĞƐƐŝŽŶ. TSA neither improved basal respiration, nor 
mitochondrial function. It reduced the maximal respiratory capacity of 
mitochondria, which is a strong indicator of potential mitochondrial dysfunction. 
This could be attributed to the cytotoxic nature of TSA, which has previously been 
ŽďƐĞƌǀĞĚ ŝŶŵǇŽƚƵďĞƐĂŶĚƉĂŶĐƌĞĂƚŝĐɴ-cells [248, 260]. Besides, costly and highly 
inefficient production precludes TSA from being used clinically [91]. Hence, in vitro 
screening from Chapter 2 identified that the broad spectrum HDI SCR can improve 
metabolic gene expression mediated mitochondrial function, oxidative metabolism 
and basal energy expenditure in skeletal muscle in vitro. This data is particularly 
important because skeletal muscle metabolic dysregulation is associated with 
mitochondrial dysfunction and reduced muscle oxidative capacity. Strong evidence 
suggests that these two factors are contributing risk factors to the pathogenesis of 
insulin resistance in metabolic diseases such as obesity and T2D [43, 56, 358]. 
Hence, from this proof-of-principle study, we have identified SCR as a broad 
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spectrum HDI that can regulate muscle mitochondrial and oxidative capacity in 
vitro. 
 
SCR exhibits inhibitory potency towards both class I and class II HDACs zinc 
containing catalytic deacetylase domains [292]. Hence, SCR effects are not 
mediated entirely through class IIa HDACi. Class IIa HDACs lack intrinsic HDAC 
activity and recruit the HDAC3 (class I HDAC) co-repressor complex via their 
catalytic domain for deacetylase function [110]. This is a good rationale to inhibit 
both the classes. Thus, classical broad spectrum HDIs impair class IIa activity by 
dissociating them from the HDAC3 repressive complex in addition to inhibiting class 
I (HDAC3) deacetylase activity [291]. SCR has hydroxamic acid as its ZBD, which is a 
strong chelating agent. Hence SCR could potentially inhibit all zinc-containing HDAC 
isoforms and non HDAC targets and could exhibit non-selective effects [292]. 
Besides deacetylating histones, HDACs are known to target various TFs and 
cytoplasmic enzymes that in turn could be regulated by HDIs. Studies have shown 
that similar hydroxamic acid based HDI can regulate acetylation of various enzymes 
participating in intermediary cellular metabolism and in turn, their activity and 
stability [239]. While the targets and the mechanism behind broad spectrum HDI 
mediated effects are unclear, growing evidence suggests that various HDIs are now 
clinically approved for their therapeutic effects in various diseases. The results in 
Chapter 2 have shown promising results with broad spectrum HDI SCR. This 
provided a strong rationale to investigate further the in vivo therapeutic efficacy of 
the broad spectrum HDI SCR on skeletal muscle and whole body metabolism in 
response to high fat feeding-induced insulin resistance and metabolic dysfunction. 
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Therefore, the aim of Chapter 3 was to investigate whether the broad spectrum HDI 
SCR acts as an effective exercise mimetic and regulates skeletal muscle metabolic 
adaptations and normalizes whole body metabolism in diet-induced obesity. 
 
The key findings from Chapter 3 showed that SCR increased the expression of 
various metabolic and mitochondrial genes in skeletal muscle in vivo. SCR increased 
the expression of genes involved in oxidative phophorylation (OXPHOS genes) in 
response to high fat feeding conditions. This was associated with an effect of SCR 
treatment to increase muscle PGC-ϭɲĞǆƉƌĞƐƐŝŽŶ͘^ŝŵŝůĂƌůǇ͕ƐƚƵĚŝĞƐŚĂǀĞƐŚŽǁŶƚŚĂƚ
reduced PGC-ϭɲ ĞǆƉƌĞƐƐŝŽŶ ĂŶĚ ŝƚƐ ĚĞƉĞŶĚĞŶƚ ŵŝƚŽĐŚŽŶĚƌŝĂů ŐĞŶĞ ĞǆƉƌĞƐƐŝŽŶ
program, in muscle cell exposed to saturated fatty acid palmitate, was reversed 
with a similar class of HDI treatment [249]. Coordinated downregulation of PGC-ϭɲ
and its targeted OXPHOS and metabolic gene expression is though to contribute to 
mitochondrial dysfunction and impaired oxidative metabolism of skeletal muscle in 
insulin resistant and T2D patients [4, 5, 57]. Hence, our in vitro and in vivo results 
suggest that SCR could increase muscle metabolic gene expression, mitochondrial 
function and oxidative capacity with the potential to improve skeletal muscle 
function in metabolic diseases.  
 
Considerable evidence indicates that impaired muscle mitochondrial gene 
expression and function is associated with abnormalities in skeletal muscle lipid 
metabolism in insulin resistance states. A combination of abnormal skeletal muscle 
lipid metabolism and elevated circulating lipids due to high fat feeding result in 
elevated lipid levels in muscle [24, 25, 35]. This increases ROS production by 
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mitochondria resulting in oxidative damage, which further worsens mitochondrial 
dysfunction and oxidative capacity of skeletal muscle [46, 47].  In addition, lipid 
metabolites such as DAGs and ceramides interfere with insulin signaling and 
contribute to skeletal muscle insulin resistance in obesity and T2D [24, 36]. In 
Chapter 2, SCR increased the expression of genes involved in lipid oxidation but did 
not improve the expression of the SCD-1 gene, encoding a central lipogenic enzyme 
catalyzing the synthesis of fatty acids [306, 307]. This suggests that SCR induced 
lipid oxidation rather than estrification in vitro. This was consistent with the results 
of Chapter 3, where SCR increased PDK-4 gene expression in muscle, which is a 
negative regulator of glucose oxidation and its increased expression is associated 
with the switch from glucose oxidation to lipid oxidation for energy production in 
mitochondria [326]. This again indicates that SCR has the ability to favour lipid 
oxidation. We also observed that SCR lowered total lipid levels in skeletal muscle in 
vivo. Together these data indicate that SCR has the potential to increase muscle’s 
efficiency to utilize lipids and reduce lipid levels, which could prevent mitochondria 
from oxidative damage and dysfunction and normalize insulin action in muscle. 
Skeletal muscle plays an important role in maintaining whole body metabolic 
homeostasis because it has large mass and high oxidative capacity for substrates 
[25]. Hence, impaired metabolism in this tissue contributes to the early 
pathogenesis of metabolic diseases such as obesity and Type 2 diabetes. Together, 
these data provide evidence that the broad spectrum HDI SCR has the potential to 
increase metabolic gene expression, oxidative capacity, energy expenditure and 
reduce lipid accumulation in skeletal muscle that could be an important therapeutic 
intervention to improve muscle metabolism in metabolic diseases. 
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Mitochondrial dysfunction and lipid accumulation-mediated interference in insulin 
action also contributes to decreased insulin-stimulated glucose uptake in skeletal 
muscle [24, 358]. Consistent with our previous findings, SCR increased GLUT-4 gene 
expression and increased insulin-stimulated glucose uptake in skeletal muscle in 
response to high fat feeding. Similar results have shown previously that the broad 
spectrum HDI SCR enhanced GLUT-4 gene expression and GLUT-4 translocation to 
the plasma membrane resulting in improved basal and insulin-stimulated glucose 
uptake in muscle cells [131, 248]. Skeletal muscle clears ~80% of glucose in 
response to insulin and contributes to the maintenance of whole body glucose 
homeostasis. Thus, insulin resistance in skeletal muscle contributes to impaired 
glucose metabolism in T2D. High fat feeding results in muscle insulin resistance and 
impairs insulin-stimulated glucose uptake by skeletal muscle [25]. Hence, this data 
is important because of the ability of SCR to lower muscle lipid levels that is 
associated with improved high fat feeding-impaired skeletal muscle insulin action 
and insulin-stimulated glucose uptake, and thus has the potential to ameliorate 
skeletal muscle insulin resistance in metabolic diseases.  
 
This study also showed that SCR increased incremental exercise performance, which 
suggests that SCR augments endurance and decreases fatigability. Exercise is known 
to mediate beneficial effects, in part, by triggering class IIa HDAC nuclear export 
which removes their repressive effect from MEF2 TFs and results in the metabolic 
adaptations of skeletal muscle [7]. Pothoff et al. showed forced class IIa HDAC 
expression suppresses skeletal muscle oxidative adaptations (i.e. towards oxidative 
fibre type remodelling) in response to exercise training. Increased activation of MEF 
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TF mimicked exercise effect in vivo by increaseing muscle oxidative remodelling and 
oxidative capacity, and also augmented endurance by increasing exercise 
performance in vivo [96]. Hence, these data strongly suggest that SCR has not only 
increased exercise performance but mimicked exercise adaptations in skeletal 
muscle, which could be a therapeuctic intervention to treat metabolic diseases. 
 
In addition to regulating muscle metabolic parameters, SCR treatment increased 
energy expenditure (EE) in vivo. This was not associated with any changes in 
physical activity in vivo, but was associated with increased oxygen consumption and 
oxidation of glucose and lipid in vivo. These improvements were observed in the 
light period, when mice are mostly inactive and consume less food. These results 
suggest that SCR potentially increased basal metabolic rate. SCR reduced the 
respiratory exchange ratio indicating that SCR treatment shifted substrate oxidation 
towards lipids. Whole body disordered lipid metabolism results in the ectopic 
accumulation of lipids in various tissues such as the muscle and liver, an important 
risk factor that causes insulin resistance and T2D [28, 359]. Hence, the EE data 
suggests that SCR treatment is an effective therapy to increase whole body lipid 
oxidation, increase substrate utilization and thus increase whole body energy 
expenditure in metabolic diseases. Despite improving the above mentioned 
parameters, SCR had no effect on body weight in vivo, which could have been 
expected to reduce given the increase in EE. This was associated with no changes in 
food intake or expression of neuropeptides responsible for regulating feeding 
behaviour and body weight. This could possibly be due to the subtle improvement 
in energy metabolism, which followed 2 weeks of SCR treatment. Hence, we 
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speculate that these subtle changes could affect body weight by increasing the 
treatment duration. Further studies can also fully investigate the impact of SCR 
treatment on mechanisms regulated by the hypothalamus, which is responsible for 
regulating feeding behaviour and body weight homeostasis. Most of the significant 
data of study in Chapter 3 was a result of main SCR treatment effect. With the 
exception of the effect of SCR treatment to increase mitochondrial OXPHOS gene 
expression (SDH-b & ATP-5d), GLUT-4 gene expression and glucose uptake in 
skeletal muscle of HFD fed mice, no effect of SCR treatment was observed in either 
diet group (SCR treatment*diet interaction). Increasing animal numbers or 
treatment duration will assist in increasing the statistical power of future studies. 
This could be particularly related to the experiments such as metabolic gene 
expression in EDL muscle, lipid levels in soleus muscle, incremental exercise test and 
whole body energy metabolism via calorimetry where the main effect of SCR 
treatment was observed but its effect in either diet group was missed. Besides, 
Increasing animal numbers or treatment duration could also increase the statistical 
power of the experiments such as metabolic gene expression (GLUT-4) in soleus 
muscle, lipid (ceramides) levels in liver, lipid levels in EDL muscle, body weight etc. 
where a trend for the effect of SCR treatment was observed which was not 
statiscally significant. Indeed, it is possible that much of our data could be classified 
as a type II statistical error. 
 
The literature has shown that increased lipid levels in various tissues inhibit insulin-
stimulated glucose uptake in both healthy and type 2 diabetic subjects [24, 34, 331]. 
Conversely, increased lipid oxidation, decreased total lipid levels and EE is 
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associated with improved glucose tolerance and insulin action [41, 250, 360]. But 
our study demonstrated that despite improving these parameters, SCR had no 
effect on glucose tolerance. Rather, it impaired whole body insulin action. SCR 
increased glucose production by hepatocytes in response to insulin. This could 
suggest that impaired suppression of glucose production by insulin could have 
contributed to impaired whole body glucose and insulin tolerance in SCR treated 
diet-induced obese mice. This indicates that SCR has the potential to impair whole 
body insulin action and glucose homeostasis in the postabsorptive state. These 
results suggest that HDACs might be important in the suppression of hepatic 
glucose production (HGP). Various studies suggest that HDAC3 activity might be 
required for suppression of gluconeogensis and hence, its inhibition could 
contribute to elevated HGP [333-335]. Future animal studies could focus on 
investigating the effect of SCR on mechanisms such as gluconeogenesis that 
contribute to the regulation of glucose output from liver. Together these data 
suggest that SCR has the potential to improve muscle metabolism, endurance and 
whole body energy expenditure but could impair whole body insulin action and 
glucose homeostasis. 
 
The key findings from Chapters 2 and 3 showed that SCR has the potential to 
regulate muscle specific metabolic parameters. This is supported by Takigawa et. 
al., who also showed that SCR mediated effects on glucose metabolism were not 
observed in undifferentiated myoblasts or adipocytes, and were only specific to 
differentiated myotubes [248]. Hence, we have proposed and developed a novel 
therapy by using broad spectrum HDI SCR to directly and potently regulate muscle 
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metabolism that could potentially combat muscle insulin resistance in metabolic 
diseases such as obesity and T2D. This is particularly promising, as no current anti-
diabetic drugs directly target skeletal muscle metabolism and insulin resistance in 
T2D. Many pharmacological agents, currently available as anti-diabetic drugs, target 
various tissues such as liver, pancreas, adipose tissue and the gastrointestinal tract 
to lower blood glucose levels in diabetes. These drugs are associated with certain 
limitations [338]. In addition, novel emerging anti-diabetic therapies also being 
developed to target the function of pancreas, kidney, lipid accumulation in liver, 
reduce caloric intake and increase satiety in obesity etc. But none of them are more 
advantageous than already available options [339]. Metformin is the most 
commonly used anti-diabetic drug and insulin sensitizer that lowers blood glucose 
levels, reduces glucose output from liver, and has few side effects such as weight 
gain [340, 341]. Therefore, to achieve therapeutic efficiency, an add-on therapy of 
SCR to Metformin could have the potential to improve muscle metabolism and 
reduce hepatic glucose production in T2D. It will be of interest to further investigate 
the combined potential of Metformin and SCR regime as therapeutic agents to treat 
metabolic diseases such as T2D. 
 
In the context of side effects exhibited by SCR, we can’t ignore that all of the current 
anti-diabetic therapies have certain limitations associated with them [338]. The off-
target effects associated with broad spectrum HDACi, such as HDAC3 inhibition, 
suggest that the achievement of class selective and target specific inhibition could 
be the key to minimize off-target effects while using HDI therapeutics to treat 
metabolic diseases. Therefore, specific inhibition of class IIa HDACs, that we 
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propose to be the mediators of skeletal muscle metabolic adaptations in response 
to exercise, might represent new tools to normalize skeletal muscle metabolism in 
metabolic diseases and minimise off-target effects. These data provide the impetus 
to develop novel class IIa specific HDIs and to determine their specificity and 
efficacy to regulate skeletal muscle metabolism along with whole body energy and 
glucose metabolism with minimal side effects. Emerging studies suggest that 
various modifications can be done to each of the three- cap, linker and ZBG 
(chelator) regions of the canonical HDI structure to modulate class or isoform 
selectivity [342, 354]. Mai et al. have synthesized and biochemically characterized 
new compounds that they showed to be highly selective against the class IIa HDACs 
[293]. On the basis of the proposed structures of class IIa specific HDIs by Mai. 
et.al., we have performed further chemical manipulations on those HDI structure to 
produce new class IIa HDIs derivatives. Hence, the purpose of Chapter 4 was to 
determine whether novel class IIa HDIs analogues, having modulated canonical cap-
linker-chelator HDI structure, could regulate skeletal muscle gene expression, 
mitochondrial function and metabolism in vitro. The four compounds used in this 
study were MRU 062, MRU 059, MRU 047 and MRU 066 and were referred to as 
novel class IIa HDIs analogues (Fig 4.1). We characterized the effects of these class 
IIa HDIs analogues on muscle metabolic parameters in vitro.  Amongst them the 
structure of MRU 062 has been shown to be class IIa selective by Mai. et. al [293].  
MRU 062, already published as MC1568, has been analysed by Nebbioso et al. and 
has shown to inhibit class IIa HDACs in skeletal muscle and heart [281].   
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We observed that all novel class IIa HDI analogues regulated H3 acetylation levels 
and had selective and differential effects on mitochondrial function and various 
metabolic and mitochondrial gene expression in vitro. The main compound amongst 
class IIa HDI analogues used in this study, MC1568, induced the largest 
improvement in muscle mitochondrial function and oxidative capacity in vitro. 
However, it downregulated the expression of various metabolic and mitochondrial 
genes in vitro. Similar responses have been published by Nebbioso et. al. Firstly, 
they showed that MC1568 is a class II selective HDI rather than class IIa specific HDI, 
as published by Mai. et. al [281, 293]. Secondly, despite inhibiting class IIa HDACs 
activity in in vitro assays, MC 1568 stabilized the HDAC3-HDAC4-MEF2 inhibitory 
complex and resulted in MEF2 TF deacetylation by HDAC3 and blocked MEF 
transcriptional activity in myogenesis [281]. MEF2 transcriptional activity is required 
for the expression of various metabolic and mitochondrial genes and acetylation of 
MEF2 TF increases its transcriptional activity [167, 191, 314, 315]. MC1568 can 
potentially anatagonize the effects of the anti-diabetic drug rosiglitazone by 
ŝŶƚĞƌĨĞƌŝŶŐǁŝƚŚ ƚŚĞWWZɶƐŝŐŶĂůůŝŶŐ-mediated differentiation pathways, mostly in 
the heart and adipose tissue [344]. Surprisingly, our IC50 data revealed that 
MC1568 is not class IIa specific HDI, rather it is a class IIb (HDAC6) specific but weak 
HDI. This suggests that the physiological effects shown by MC1568 in the above 
mentioned studies along with the regulated metabolic gene expression and 
mitochondrial function in our study could be independent of class IIa HDACs/MEF2 
signalling pathway and could involve the role of other HDAC isoforms such as 
HDAC6. Hence, it is difficult to postulate whether the MC1568 effects are in 
response to the specific inhibition of any subtype of HDACs, or whether they are 
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completely unrelated to HDACs and mediated via non-HDAC targets. Further studies 
are warranted to fully delineate MC1568 specificity towards different HDAC 
isoforms and to elucidate the role of other HDACs, apart from the class IIa family, in 
the regulation of muscle metabolic processes. 
 
Hence, this generates the need to develop more class IIa specific HDIs and to 
determine their therapeutic effects in muscle metabolism. Emerging knowledge 
about the HDI structure suggests that subtle modifications in each of the three – 
cap, linker and chelator (ZBG) regions can be exploited to attain class/isoform 
selectivity. Despite this, very little is understood about the structure-activity 
relationship that is associated with class IIa selectivity. The tyrosine residue 
surrounding the Zn2+ ion in the HDAC catalytic domain is responsible for the 
catalytic proficiency in all HDACs. However, this tyrosine residue is substituted by a 
histidine residue in the catalytic domain of class IIa enzymes and accounts for their 
diminished intrinsic deacetylase activity. This substitution renders class IIa HDACs a 
wide catalytic domain that enables them to accommodate bulkier molecules 
compared with other HDACs [106]. Recently, bulky trifluoromethyloxadiazole 
(TFMO) compounds, which exploit the large volume of the class IIa HDAC active site, 
have been published as novel and promising HDIs highly selective against class IIa 
HDACs, with minimal detectable off-target interactions. These compounds have 
TFMO that binds to the zinc ion in the class IIa HDAC catalytic domain, and 
circumvent the non-selective and off target limitations associated with 
hydroxamate HDIs [357]. Based on these recent findings, a thorough investigation 
into the class IIa structure-activity relationships to identify structural features that 
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are critical and govern selectivity for class IIa HDAC enzymes should be performed. 
This will help to develop more potent class IIa specific HDIs that can be tested as 
antidiabetic agents. 
 
Class IIa HDACs recruit the enzymatically active SMRT/N-CoR-HDAC3 complex to 
deacetylate the histones surrounding metabolic promoter regions to which MEF2 
binds and also to deacetylate and inactivate MEF2 TFs. HDAC3 has also been shown 
to maintain deacetylase activity and stabilize the MEF2-class IIa HDAC-HDAC3 
repressor complex even in the presence of class II specific HDI inhibiting class IIa 
HDACs [128, 281]. HDAC3-NCoR complex deacetylase activity is important for 
normal physiological functions in other tissues such as the liver and heart [208, 288, 
289]. However, class IIa HDACs are also known to exert a repressive effect on MEF2 
TF independent of a deactylase mechanism and this occurs through their N-terminal 
domain that mediates interactions with other corepressors [112, 113, 118]. On the 
basis of all the above mentioned reasons, we postulate that the most promising 
strategy will be to develop novel inhibitors designed to impair class IIa HDACs 
function by specifically blocking their interaction with MEF2 TFs, without affecting 
HDAC3 corepressor function. This will preclude the deacetylation of MEF2 TF and 
surrounding histones by HDAC3, side effects associated with HDAC3 inhibition and 
class IIa HDAC N-terminal mediated repression. Besides, these kinds of selective 
HDIs, which will be designed to inhibit specifically MEF2: class IIa HDACs interaction, 
might be more promising compounds to precisely target MEF2 transcriptional 
activity in skeletal muscle away from liver, since both class IIa HDACs and MEF2 TFs 
are abundantly expressed in skeletal muscle unlike the liver, which lacks MEF2 TFs 
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[93, 99]. Therefore, this type of class IIa specific HDIs would present a novel and 
potent strategy to enhance muscle metabolism and treat insulin resistance in 
metabolic diseases such as obesity and type 2 diabetes. 
 
In conclusion, from these studies, we have supported our hypothesis that HDAC 
inhibitors (HDIs) could potentially be used to enhance skeletal muscle metabolism 
and mitochondrial function and could represent a novel therapeutic intervention to 
enhance muscle insulin sensitivity in metabolic diseases such as obesity and T2D. 
Exercise coupled with diet is a cornerstone of the non-pharmacological and safe 
treatment of obesity and T2D [14]. Regular exercise induces beneficial and multiple 
adaptations in the various metabolic tissues that could treat metabolic diseases [6, 
14, 188]. Exercise-mediated adaptations can normalize skeletal muscle insulin 
resistance. Increased susceptibility of the contemporary human population towards 
a sedentary lifestyle and poor adherence to regular exercise regimes demands 
alternative approaches that could in part mimic aspects of exercise adaptations in 
skeletal muscle to treat muscle metabolic disorders, particularly in weak and aging 
diabetic patients [21]. Hence, this research is of significant importance because of 
the therapeutic ability of HDIs to mimic aspects of exercise and treat skeletal 
muscle insulin resistance in metabolic diseases such as obesity and T2D. Broad 
spectrum HDIs could therapeutically enhance skeletal muscle metabolic 
parameters, endurance and whole body energy metabolism. But because of their 
non-selective nature, there are certain side effects associated with their use. They 
could worsen whole body glucose homeostasis. Hence, these off-targets could be 
minimized by specific inhibition of class II a HDACs, that we propose, to some 
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extent, to be the mediators of the skeletal muscle exercise adaptations. Further 
research will determine the development and identification of potential HDIs that 
specifically inhibit class IIa HDAC activity, particularly their interaction with MEF2 
TFs. Hence, class IIa specific HDIs could be a more promising strategy to reverse 
insulin resistance and treat obesity and T2D. This research could ultimately assist in 
combating the diabetes epidemic and attenuating the social and economic burden 
that this disease has on Australia’s health system.  
 
 
 
 
 
 
 
 
 
 
 
 
 190 
 
APPENDIX  
Table A2.1: Metabolic and mitochondrial genes analysed in vitro 
Genes Function 
CPT-1ɴ 
( Carnitine 
palmitoyl 
transferase 1) 
A part of  a muscle-specific mitochondrial 
enzyme family called carnitine acyltransferases 
and is the rate-limiting enzyme in the fatty acid (a 
type of lipid) metabolism that mediates the 
transport of long-chain fatty acids across the 
mitochondrial membranes for ɴ-oxidation    
HSL (hormone 
sensitive 
lipase) 
A lipolytic enzyme that hydrolyzes a variety 
of esters/cleaves fatty acyl esters of various 
compounds, including cholesterol, steroids, 
retinoic acid and glycerol (TAGs and DAGs) 
 
SCD-1 
(Stearoyl-
coenzyme A 
desaturase 1) 
A microsomal rate-limiting lipogenic enzyme that 
catalyzes the synthesis of monounsaturated fatty 
acids (MUFAs), that in turn produce complex 
lipids such as TAGs, DAGs, wax esters, cholesteryl 
esters and membrane phospholipids 
 
WWZɷ
(Peroxisome 
proliferator-
activated 
receptor delta) 
Ligand-activated transcription factor that is a 
member of the nuclear-hormone receptor (NR) 
superfamily and enhances mitochondrial fatty 
ĂĐŝĚ;ůŝƉŝĚͿƚƌĂŶƐƉŽƌƚĂŶĚɴ-oxidation (FAO) in 
skeletal muscle, adipose tissue, liver etc. 
 
PPAR- ɲ
(Peroxisome 
proliferator-
activated 
receptor alpha) 
 
Ligand-activated transcription factor that is a 
member of the nuclear-hormone receptor (NR) 
superfamily and regulates mitochondrial fatty 
acid (lipid) transport anĚɴ-oxidation (FAO) and 
energy metabolism and coordinates 
mitochondrial biogenesis 
 
PGC-ϭɲ
(Peroxisome 
proliferator 
activator 
ƌĞĐĞƉƚŽƌɶ
coactivator 1) 
Transcriptional coactivator that regulates 
mitochondrial biogenesis, muscle remodeling 
towards an oxidative fiber-type composition, 
metabolic and mitochondrial function (i.e. FAO 
by coactivating PPARs) and cellular energy 
metabolism 
 
TFAM  
(Mitochondrial 
transcription 
factor A) 
A key factor for mitochondrial transcription, 
mitochondrial genome (mtDNA ) replication 
(mitochondrial biogenesis) and maintenance of 
its copy number and mitochondrial function 
Lipid 
Metabolism 
Mitochondrial 
Biogenesis
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SDH-b 
(Succinate 
dehydrogenase 
complex, 
subunit B or 
Electron 
Transport 
Chain Complex 
II) 
Inner mitochondrial membrane bound enzyme 
that participates in both the citric acid cycle and 
the electron transport chain and regulates 
mitochondrial function 
ATP-5d (ATP 
synthase, delta 
subunit or 
Electron 
Transport 
Chain Complex 
V) 
Mitochondrial enzyme that catalyzes ATP 
synthesis during oxidative phosphorylation by 
utilizing the protons electrochemical gradient 
across the inner membrane  
 
COX -7a 
(cytochrome c 
oxidase or 
Electron 
Transport 
Chain Complex 
IV) 
Heart/muscle isoform transmembrane 
mitochondrial protein complex that participates 
in the respiratory electron transport chain of 
mitochondria and regulates mitochondrial 
function 
 
Myogenin MyoD family of basic-helix-loop-helix (bHLH) 
transcription fators required for skeletal muscle 
development (myogenesis) and repair 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mitochondrial 
Function 
Skeletal 
Muscle 
Development 
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Figure A2.1: Optimization of rat PCR primers. Rat stock cDNA was serially diluted 
(eg. Undiluted, 1/2, 1/4, 1/8, 1/16, 1/32) and ran in duplicate. The total reaction 
ǀŽůƵŵĞŽĨϮϱʅůĐŽŶƐŝƐƚĞĚŽĨϭϮ͘ϱʅůZKyŵĂƐƚĞƌŵŝǆ͕Ϯ͘ϱʅůĞĂĐŚŽĨϭʅDĨŽƌǁĂƌĚ
ĂŶĚ ƌĞǀĞƌƐĞ ƉƌŝŵĞƌ ĨŽƌ ŽŶĞ ŐĞŶĞ͕ ϱ͘ϱ ʅů E&t ĂŶĚ Ϯ ʅů ŽĨ ƐĞƌŝĂůůǇ ĚŝůƵƚĞĚ ĐE
template. Primer efficiency was tested by using the same set up procedure of SYBR 
Green and thermocycler conditions used for quantifying gene expression. During 
the set up of the PCR cycle, serially diluted samples were labelled as standards 
(indicated in plate sample values). Each serially diluted duplicate was highlighted as 
2-fold dilution (indicated in initial template quantity). The qPCR thermocycler 
conditions were 10 min at 95°C for 1 cycle and then 30 sec at 95°C followed by 1 
min at 60°C for 40 cycles. Analysis was performed using the two most important 
features of result profile- the “Standard Curve” and the “Dissociation Curve”. 
Primers with the efficiency of 100% ± 10 with r2 value ideally around 0.995-1 in 
standard curve and showing a single peak, hence amplifying a single product, in 
dissociation curve were selected. Besides, Ct values were also checked to ensure 
the level of expression of target genes in the sample. 
 
 
A) Rat CPT-ϭɴƉƌŝŵĞƌŽƉƚŝŵŝǌĂƚŝŽŶ 
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B) Rat HSL primer optimization 
 
 
C) Rat PGC-ϭɲƉƌŝŵĞƌŽƉƚŝŵŝǌĂƚŝŽŶ 
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D) ZĂƚWWZɷ;ĚĞůƚĂͿƉƌŝŵĞƌŽƉƚŝŵŝǌĂƚŝŽŶ 
 
 
E) Rat SCD 1 primer optimization 
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F) Rat TFAM 1 primer optimization 
 
 
G) Rat SDH-b primer optimization 
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H) Rat ATP-5d primer optimization 
 
 
I) Rat COX-7a primer optimization 
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Figure A2.2: The effect of broad spectrum HDIs- SCR & TSA on metabolic and 
mitochondrial gene expression in vitro. 
   
 
   
 
 
Figure A2.2a: Effect of SCR and TSA on the expression of genes involved in lipid 
metabolism. Gene expression levels are calculated as percentage of VEH (VEH = 
100%). Data is mean ± SEM, *p< 0.05, #p < 0.01, + p< 0.001, HDI vs. VEH at each time 
point, n = 4 per time point. 
 198 
 
  
 
Figure A2.2b: Effects of SCR and TSA on the expression of genes involved in 
mitochondrial biogenesis. Gene expression levels are calculated as percentage of 
VEH (VEH = 100%). Data is mean ± SEM, *p< 0.05, #p < 0.01, + p< 0.001, HDI vs. VEH 
at each time point, n = 4 per time point. 
 
 
  
 
 
Figure A2.2c: Effects of SCR and TSA on the expression of genes that regulate 
mitochondrial function. Gene expression levels are calculated as percentage of VEH 
(VEH = 100%). Data is mean ± SEM, *p< 0.05, #p < 0.01, + p< 0.001, HDI vs. VEH at 
each time point, n = 4 per time point. 
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Figure A2.2d: Effects of SCR and TSA on the expression of the myogenin gene. 
Gene expression levels are calculated as percentage of VEH (VEH = 100%). Data are 
mean ± SEM, *p< 0.05, #p < 0.01, + p< 0.001, HDI vs. VEH at each time point, n = 4 
per time point. 
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Table A3.1: Metabolic and mitochondrial genes analysed in vivo 
 
Tissues Genes Function 
Soleus and 
EDL skeletal 
muscle 
CPT-1ɴ  
( Carnitine 
palmitoyltransferase 1) 
A part of  a muscle-specific 
mitochondrial enzyme family called 
carnitine acyltransferases and is the 
rate-limiting enzyme in the fatty acid 
(a type of lipid) metabolism that 
mediates the transport of long-chain 
fatty acids across the mitochondrial 
membrĂŶĞƐĨŽƌɴ-oxidation  
 
SDH-b  
(Succinate dehydrogenase 
complex, subunit B or 
Electron Transport Chain 
Complex II) 
Inner mitochondrial membrane 
bound enzyme that participates in 
both the citric acid cycle and the 
electron transport chain and 
regulates mitochondrial function 
 
ATP-5d  
(ATP synthase, delta 
subunit or Electron 
Transport Chain 
 Complex V) 
Mitochondrial enzyme that catalyzes 
ATP synthesis during oxidative 
phosphorylation by utilizing the 
protons electrochemical gradient 
across the inner membrane  
 
Glucose transporter type 4 
(GLUT 4) 
Insulin-regulated glucose transporter 
that is responsible for insulin-
meadiated glucose transport into 
the cell found in skeletal muscle, 
heart, and adipose tissues 
 
Pyruvate dehydrogenase 
Kinase, isozyme 4 (PDK 4) 
 
Enzyme that inhibits pyruvate 
dehydrogenase complex, a key 
regulatory enzyme in glucose 
oxidation that catalyzes the 
conversion of pyruvate to acetyl-CoA 
in mitochondria 
 
PGC-ϭɲ(Peroxisome 
proliferator activator 
ƌĞĐĞƉƚŽƌɶĐŽĂĐƚŝǀĂƚŽƌϭͿ 
Transcriptional coactivator that 
regulates mitochondrial biogenesis, 
muscle remodeling towards an 
oxidative fiber-type composition, 
metabolic and mitochondrial 
function (i.e. FAO by coactivating 
PPARs) and cellular energy 
metabolism 
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Liver 
Phosphoenolpyruvate 
carboxykinase (PEPCK) 
A rate controlling gluconeogenic 
enzyme involved in de novo 
synthesis of glucose (i.e. 
gluconeogenesis) and hepatic 
glucose production by catalyzing the 
conversion of oxaloacetate (OAA) to 
phosphoenolpyruvate (PEP) 
 
 
 
Glucose 6-phosphatase 
(G6Pase) 
An enzyme involved  in 
gluconeogenesis that hydrolyzes 
glucose-6-phosphate to release  
phosphate group and free glucose 
 
SCD-1 (Stearoyl-coenzyme 
A desaturase 1) 
A microsomal rate-limiting lipogenic 
enzyme that catalyzes the synthesis 
of monounsaturated fatty acids 
(MUFAs), that in turn produce 
complex lipids such as TAGs, DAGs, 
wax esters, cholesteryl esters and 
membrane phospholipids 
 
Fatty acid synthase (FAS) Lipogenic enzyme that catalyzes  
synthesis of long-chain saturated 
fatty acid - palmitate from acetyl-
CoA and malonyl-CoA, in the 
presence of NADPH 
 
Brain 
Neuropeptide Y (NPY)  
and  
Agouti-related 
peptide (AgRP) 
Neuropeptide secreted by the 
hypothalamic arcuate nucleus 
responsible for regulating feeding 
behaviour and body-weight 
homeostasis by stimulating feeding 
(Appetite stimulant neuropeptide) 
 
Pro-opiomelanocortin 
(POMC) 
Neuropeptide secreted by the 
hypothalamic arcuate nucleus 
responsible for regulating feeding 
behaviour and body-weight 
homeostasis by inhibiting feeding 
(Appetite suppressant neuropeptide) 
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Figure A3.1: Optimization of mouse PCR primers  
Mouse cDNA (muscle, liver and brain) were serially diluted (eg. Undiluted, 1/2, 1/4, 
1/8, 1/16, 1/32) and ran in duplicate. dŚĞƚŽƚĂůƌĞĂĐƚŝŽŶǀŽůƵŵĞŽĨϮϱʅůĐŽŶƐŝƐƚĞd of 
ϭϮ͘ϱʅůZKyŵĂƐƚĞƌŵŝǆ͕Ϯ͘ϱʅůĞĂĐŚŽĨϭʅD ĨŽƌǁĂƌĚĂŶĚ ƌĞǀĞƌƐĞƉƌŝŵĞƌ ĨŽƌŽŶĞ
ŐĞŶĞ͕ϱ͘ϱʅůE&tĂŶĚϮʅůŽĨƐĞƌŝĂůůǇĚŝůƵƚĞĚĐEƚĞŵƉůĂƚĞ͘ Primer efficiency was 
tested by using the same set up procedure of SYBR Green and thermocycler 
conditions used for quantifying gene expression as previously described in Figure 
A2.1. 
 
A) Mouse CPT-ϭɴƉƌŝŵĞƌŽƉƚŝŵŝǌĂƚŝŽŶ 
 
 
B) Mouse SCD-1 primer optimization 
 203 
 
 
C) Mouse FAS primer optimization 
 
 
D) Mouse NPY primer optimization 
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E) Mouse AgRP primer optimization 
 
 
F) Mouse POMC primer optimization 
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Soleus 
muscle
3 mg.kg-1 SCR 10 mg.kg-1 SCR
0       1      2      4     6     8     12    18    24 0       1      2      4       6      8    12    18    24
EDL
muscle
0       1     2       4      6      8    12    18    24 0      1    2       4      6     8     12    18    24
Heart
0       1      2      4       6       8     12   18    24 0      1       2      4     6      8     12    18     24
Liver
0      1      2      4       6      8    12    18    24 0      1      2     4       6     8     12    18    24
Pancreas
Brain
0      1      2      4      6      8     12     18    24 0      1      2     4      6      8     12    18    24
0      1     2       4      6      8     12   18    240      1      2     4      6      8     12    18    24
Tubulin
Acetylated- K9  
H3
Time (hrs)
Tubulin
Acetylated- K9  
H3
Time (hrs)
Tubulin
Acetylated-K9  
H3
Time (hrs)
Acetylated-K9 
H3
Time (hrs)
Tubulin
Acetylated-K9  
H3
Time (hrs)
Tubulin
Acetylated-K9  
H3
Time (hrs)
Tubulin  
Figure A3.2: Representative immunoblots demonstrating the time-dependent 
effects of 3 and 10 mg.kg-1 dose of SCR on global histone (H3) acetylation in 
various tissues in C57Bl6 mice. 
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Fig A3.3: Body Composition- A) Fat mass (% of body weight), B) Lean mass (% of 
body weight) of SRD and HFD fed C57Bl6 mice treated with VEH or SCR. Data is 
mean ± SEM, D=Diet effect with p< 0.05 for SRD vs. HFD, n = 10 per treatment 
group, 2-Way ANOVA. 
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Figure A4.1: The effect of novel class IIa HDI analogues- MRU 062, MRU 059, MRU 
047 and MRU 066 on metabolic and mitochondrial gene expression in vitro. 
   
 
   
 
 
Figure A4.1a: Effects of novel class IIa HDI analogues- MRU 062, MRU 059, MRU 
047 and MRU 066 on the expression of genes involved in lipid metabolism. Gene 
expression levels are calculated as percentage of VEH (VEH = 100%). Data is mean ± 
SEM, *p< 0.05, #p < 0.01, + p< 0.001, HDI vs. VEH at each time point, n = 4 per time 
point. 
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Figure A4.1b: Effects of novel class IIa HDI analogues- MRU 062, MRU 059, MRU 
047 and MRU 066 on the expression of genes involved in mitochondrial 
biogenesis. Gene expression levels are calculated as percentage of VEH (VEH = 
100%). Data is mean ± SEM, *p< 0.05, #p < 0.01, + p< 0.001, HDI vs. VEH at each time 
point, n = 4 per time point. 
 
 
 
   
 
 
Figure A4.1c: Effects of novel class IIa HDI analogues- MRU 062, MRU 059, MRU 
047 and MRU 066 on the expression of genes that regulate mitochondrial 
function. Gene expression levels are calculated as percentage of VEH (VEH = 100%). 
Data is mean ± SEM, *p< 0.05, #p < 0.01, + p< 0.001, HDI vs. VEH at each time point, 
n = 4 per time point. 
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Figure A4.1d: Effects of novel class IIa HDI analogues- MRU 062, MRU 059, MRU 
047 and MRU 066 on the expression of the myogenin gene. Gene expression levels 
are calculated as percentage of VEH (VEH = 100%). Data is mean ± SEM, *p< 0.05, #p 
< 0.01, + p< 0.001, HDI vs. VEH at each time point, n = 4 per time point. 
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Figure A4.2: IC50 values of MRU 047, MRU 059 and MRU 066 against various 
HDAC isoforms. A-D are the IC50 of MRU 047, E-H are the IC50 values of MRU 059 and 
I-L are the IC50 of MRU 066. On x axis of each graph is the HDI concentration & on y 
–axis is the % activity of the individual HDACs.  
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